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Abstract 
Background: Kainate receptors (KARs) are one of the three classes of ionotropic 
glutamate receptors (iGluRs) expressed primarily in the central nervous system (CNS) 
where they mediate information transfer and neurotransmitter release. Very little is 
known about native KARs and their interacting partners outside the CNS.  
Aim: The aim of this study was to investigate systematically the molecular composition 
and functional properties of KARs in pancreatic endocrine cells and also to investigate 
the role of KARs in the pathogenesis of T1DM. 
Methods: The presence of KAR subunits was investigated in pancreatic clonal β-cells 
(MIN6 and INS-1), α-cells (α-TC) and primary rat islets of Langerhans using RT-PCR 
and immunoblotting. The effect of KAR activation on intracellular calcium 
concentration and insulin secretion in MIN6 was investigated using FURA-2AM 
epifluorescence imaging and Mercodia insulin assay respectively. The effect of 
glutamate, kainate and glutamate transporter inhibitor (dihydrokainic acid) on survival 
and viability of INS-1, α-TC and neuroblastoma cells (SH-SY5Y) was investigated 
using MTT cell viability assay. The presence of autoantibodies against GluR subunits in 
serum of T1DM patients and controls was investigated using ELISA and 
immunoblotting.  
Results: RT-PCR identified mRNAs for GluK2-5 KAR subunits in clonal β-and α-cells 
and all five subunits (GluK1-5) in primary rat islets of Langerhans. The presence of 
these subunits was confirmed using immunoblotting with GluK2/3 and GluK5 
antibodies. In addition, auxiliary KAR subunits Neto 1 and Neto 2 were also identified 
in all cell types. FURA-2AM epifluorescence imaging of cultured MIN6 β-cells showed 
that activation of KARs with kainate induced significant increase in intracellular 
calcium concentration. Kainate also induced increased insulin secretion in MIN6 and 
INS-1 cells. These effects of kainate were blocked by KAR antagonist (NBQX; 30μM) 
but not by an antagonist (GYKI-53655 hydrochloride; 100μM) of other iGluRs. Chronic 
exposure to kainate (0.1-0.5mM), glutamate (0.25-12mM) and dihydrokainic acid 
(0.1mM) cause significantly reduced viability of pancreatic endocrine and neuronal 
cells. ELISA and immunoblotting showed that serum of T1DM patients and non-
diabetic controls react against components of synaptosomal plasma membrane and also 
against overexpressed GluR subunits.  
Conclusion: Together, these results indicate that a range of functional KAR subunits 
and their interacting proteins are expressed in the endocrine pancreas. These KAR 
subunits identified could assemble as homomeric or heteromeric channels in both β-and 
α-cells of the pancreas. The activation of these receptors is likely to have an impact on 
pancreatic hormone secretion and viability of endocrine cells in the islets of 
Langerhans. Much work ought to be carried out to optimise the methods for 
identification of autoantibodies against GluR subunits in serum of T1DM patients. This 
will help to understand the potential role of GluRs in the pathogenesis of T1DM.    
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Chapter One 
Thesis Introduction 
1.1. β-cell physiology 
1.1.1. Pancreatic anatomy  
The pancreas is located in the upper part of the abdominal region, behind the stomach. 
The pancreas belongs to both the digestive (exocrine) and endocrine systems because it 
secretes digestive enzymes responsible for digestion of food, particularly lipids and also 
secretes hormones that control metabolism throughout the body. In an average adult 
human, the pancreas weighs 60g to 100g (Dolensek et al., 2015). The exocrine part of the 
pancreas is made up of acinar and duct cells and associated nerves, vessels and connective 
tissues. Acinar cells make up about 95% of the pancreatic mass and are responsible for 
synthesis and secretion of the bulk of digestive enzymes in the small intestine including 
pancreatic lipase, amylase and trypsinogen (Weir and Bonner-Weir, 2013). The ducts add 
bicarbonate and mucus to the secreted enzymes and then empty these into the duodenum 
of the small intestines (Dolensek et al., 2015). The endocrine part of the pancreas is made 
up of the islets of Langerhans which make up 1-2% of the total pancreatic mass. In 
humans, the pancreas contains about 1 million pancreatic islets with an average diameter 
of about 200 μM (Rorsman and Braun, 2013). Islet cells consist of five distinct specialised 
cells namely insulin-secreting beta cells beta cells (β-cells), glucagon-secreting alpha 
cells (α-cells), somatostatin-secreting delta cells (δ-cells), pancreatic polypeptide-
secreting PP cells and ghrelin-producing cells. β-cells make up majority of pancreatic 
endocrine cells. They make up 50-70% of islets in humans and 60-80% of rodent total 
islet cell mass. α-cells and δ-cells comprise about 30% and 10% of human islets and 15% 
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and 5% of rodent islets respectively (Kim et al., 2009; Dolensek et al., 2015). Also, islets 
receive about a tenth of the total blood supply to the pancreas, though they comprise only 
1-2% of the total pancreatic mass (Rorsman and Braun, 2013). This underscores the 
importance of islet function in the body.  
There are a number of differences and similarities in the anatomy of human and rodent 
islets of Langerhans. First, in rodents, islets consist of a core of β-cells surrounded by a 
region of α-cells and other islet subtypes and there is a clear demarcation between these 
two regions (Pfeifer et al., 2015). However, in human islets, this clear demarcation is not 
present and β-cells and non-β-cells lie next to each other in a fashion that enhances 
paracrine actions in human islets (Rorsman and Braun, 2013; Bosco et al., 2010). Also, 
though the diameter of human pancreatic lobules is larger relative to that of rodents, the 
diameters of individual rodent and human islets are comparable (Dolensek et al., 2015). 
Also, while only few and discreet regions of human islets are innervated, rodent islets are 
densely supplied with nerves (Rodriguez-Diaz et al., 2011; Pfeifer et al., 2015). However, 
distribution of autonomic nerves is similar in islets of mice and human (Dolensek et al., 
2015).  
In spite of some of these differences, rodents particularly mice, remain the most studied 
organism in pancreatic endocrine research and most of the findings from mice research 
are translated or extrapolated to humans. 
 
1.1.2. β-cell generation, development and programming 
During foetal development, β-cells are mostly produced as result of adult stem cell or 
progenitor cell differentiation in a process termed β-cell neogenesis (Miyatsuka, 2015). 
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These progenitor or stem cells are thought to be present in the spleen, bone marrow, and 
also in pancreatic acinar cells (Ding et al., 2013; Miyatsuka, 2015). In humans, islets are 
found to be fully organised and stain positive for insulin, somatostatin, pancreatic 
polypeptide, glucagon and ghrelin by about 3 months into foetal development (Levetan, 
2010). Formation and proliferation of β-cells during pancreatic development is controlled 
and influenced by transcription factors and cell-cycle regulators including the cell cycle 
inhibitor p16, Kip27, cyclin D1, cyclin D2 and cyclin D3 (Vetere et al., 2014). Also, 
eostrogen receptor-α (ER-α) has recently been shown to regulate β-cell proliferation 
during development as well as following injury (Yuchi et al., 2015). After birth, β-cell 
production (regeneration) is a result of replication by already-existing differentiated β-
cells (Miyatsuka, 2015).  
Furthermore, β-cell mass is thought to expand significantly by replication from birth to 
early stages of infancy in both rodents and human after which there is decline in 
replication at rates of 10% per day during the first three years of neonatal life and then to 
3% during adult lives (Mezza and Kulkarni, 2014; Cnop et al., 2011). However, in both 
physiological and pathological conditions, the rate of β-cell replication is significantly 
increased to compensate for a prevailing condition. In addition to a number of cell cycle 
regulators, some conditions stimulate changes in β-cell replication and β-cell mass in both 
humans and rodents. These conditions include peripheral insulin resistance (Cerf, 2013; 
Sharma et al,. 2015), injury to the pancreas (Brereton et al., 2014), hyperglycaemia 
(Sharma et al,. 2015), gestation/pregnancy (Toselli et al., 2014), obesity (Linnemann et 
al., 2014), ageing (Vetere et al., 2014). Also, hormones including insulin (Cerf et al., 
2013), prolactin (Hussain et al., 2016) and some incretin hormones (Hussain et al., 2016) 
stimulate and increase β-cell replication in both human and rodents. A recently-
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discovered gene, betatrophin has also been shown to specifically induce β-cell 
proliferation and expansion of β-cell mass significantly when overexpressed in rodents 
(Yi et al., 2013).  
In summary, β-cell replication and β-cell mass exhibit a dynamic characteristic whereby 
their rate is dependent on the prevailing situation to maintain effective metabolic control 
in the body. 
 
1.1.3. β-cell mass in health and in disease 
The β-cell mass of adults is thought to be influenced significantly by a fine balance 
between β-cell differentiation, proliferation, size, survival and death (Vetere et al., 2014).  
The most important pathological condition that alters β-cell mass is diabetes mellitus 
(DM). Existing evidence indicate that an average non-diabetic adult human can survive 
and carry out normal glycaemic function with only half the amount of the individual’s β-
cell mass (Ashcroft and Rorsman, 2012; Menge et al., 2008). Studies have also 
established that loss of β-cell mass in T2DM patients involve mechanisms including 
apoptosis, ER stress (Costes et al., 2013) as well as glucotoxicity and lipotoxicity (Shimo 
et al., 2015). Reduced β-cell mass may also be due to ‘wearing out’ of the cells as result 
of increased production of insulin subsequent to peripheral insulin resistance. The loss of 
β-cell mass in T2DM has also been recently attributed to Nkx6.1- and Pdx1-induced loss 
of β-cell identity (Spijker et al., 2015). In both in vivo and in vitro human studies, 
induction of diabetes resulted in β-cells becoming bi-hormonal (exhibiting characteristic 
of and secreting glucagon in addition to insulin) under the influence of β-cell transcription 
factors namely Nkx6.1- and Pdx1 (Spijker et al., 2013). All of these observations 
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underscore the suggestion that reduction in β-cell mass in T2DM is as important an 
episode just as reduced β-cell function. 
However, it remains unclear whether reduction in β-cell mass in T2DM patients is entirely 
as a result of persistent hyperglycaemia or whether some individuals may have started 
life with reduced β-cell mass.  
In T1DM, it is generally acknowledged that only about 10-20% of β-cell mass remains at 
the time of diagnosis (Crevecoeur et al., 2015). Loss in β-cell mass is thought to occur 
mainly due to the immune system recognising β-cells as foreign and attacking them, 
thereby causing a pathological loss of insulin-producing β-cells (Mannering et al., 2016). 
In addition to loss of β-cell mass, T1DM also presents with reduced or loss of β-cell 
function (Herold et al., 2015).  
Persistent β-cell function has been reported in diabetic patients to suggest that β-cells may 
be capable to restoring a fraction of their function in pathological situations. The presence 
of residual β-cell mass and insulin secretion has been reported in individuals who have 
had insulin-dependent diabetes for 50 years or more (Keenan et al., 2010) and also in 
T1DM patients (Oram et al., 2015). These residual β-cells in T1DM could be the result 
of regeneration from other islet subtypes or could have been due to the fact that not all β-
cells are killed during development of the disease. 
 
1.1.4. β-cell regeneration in health and in disease 
The generally-accepted concept is that β-cells are generated from stem/progenitor cells 
during pancreatic development (Miyatsuka, 2015). In addition, β-cells undergo 
replication in postnatal life in order to regulate and maintain β-cell mass and function 
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(Taylor et al., 2015). In pathological conditions such as in diabetes and injury to the 
pancreas, there is significant loss of β-cells, resulting in metabolic derangements. In spite 
of several therapeutic approaches to diabetes, the permanent and ideal ‘cure’ for the 
condition will involve replacing the lost β-cells in order to restore endocrine function for 
a maximum duration. For example, transplantation of cadaveric islets as a ‘cure’ for 
T1DM has been shown to be significantly effective at making the islet recipient become 
insulin independent for 5 years and over (Bellin et al., 2012). However, the difficulties in 
obtaining enough cadaveric pancreases coupled with surgical complications have posed 
significant limitations to this method. This has therefore necessitated much investigation 
into mechanisms via which β-cells can be generated in vivo or in vitro from stem cells or 
pre-existing pancreatic exocrine or from non-β-cells of the endocrine pancreas. This will 
not only be a very significant contribution to finding a permanent solution for treating 
diabetes; it will also present an unlimited source of β-cells for research and drug 
discovery. The quest for this method of β-cells regeneration follows the successful 
generation of cortical neurons and astrocytes (Pasca et al., 2015; Merkle et al., 2015) and 
cardiomyocytes (Fuerstenau-Sharp et al., 2015) among others from human pluripotent 
stem cells.  
Previous studies using genetic marking of β-cells in mice have argued against the theory 
of β-cell neogenesis or regeneration (Dor et al., 2004). This study refuted the idea of 
regeneration and suggested that the major source of new β-cells during post-natal and 
adult life is replication of pre-existing β-cells. Several studies have however reported of 
successes in mechanisms and procedures of β-cells regeneration from stem cells and non- 
β-cell sources (Pagliuca et al., 2014; Ye et al., 2015).  
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During pancreatic development, the transcription factor Pax4 significantly controls the 
conversion of progenitor cells into different subtypes of endocrine cells. Using pancreatic 
cells from mice, it has been observed that α-cells rapidly undergo reprogramming and re-
differentiation into insulin-secreting β-cells under the control of ectopic expression of 
Pax4. These α-cells were found to arise from the duct lining of the pancreas and expressed 
transcription factors including neurogenin 3 (Ngn3) (Collombat et al 2009). This study 
suggests the possibility that in addition to islet transplantation; an individual’s pre-
existing α-cells and progenitor cells could be genetically manipulated to produce new β-
cells as a relatively permanent approach to managing diabetes. This has been corroborated 
by other studies (Thorel et al., 2010; Ye et al., 2015; Chung et al., 2010).  
In another study, millions of functional human pancreatic β-cells were generated in vitro 
from human pluripotent stem cells (hPSC) using multiple signalling pathways in a 
scalable 3D cell culture system. In response to high glucose challenge, the generated β-
cells recorded an increased Ca2+ influx and were able to package and secrete insulin in 
mechanisms similar to those observed in β-cells from adult humans (Pagliuca et al., 
2014). The study also proposed a method of β-cell transplantation whereby the cells could 
be protected from the recipient’s immune system to prevent rejection. 
It has also been observed that in adult mouse models of diabetes, there is a significant 
proliferation of pancreatic multipotent progenitor (PMP) cells. Under diabetic conditions, 
the differentiation of the PMPs is significantly biased towards insulin-positive cells which 
are capable of secreting insulin (Razavi et al., 2015).  
These studies and others present a positive indication that β-cell neogenesis or 
regeneration could be utilised in the near future as a potent procedure to generate enough 
cells either inside or outside diabetic patients for therapeutic and research purposes. 
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1.2. Glucose Homeostasis 
1.2.1. Regulation of glucose level in the blood  
Glucose is the main substrate for the production of energy in cells and tissues. 
Maintenance of glucose level in a very narrow range in blood is of significant importance 
since elevated or severely reduced levels of glucose could lead to several complications 
including lethal brain damage and diabetes mellitus (Cantley and Ashcroft, 2015). In 
addition to intestinal absorption of glucose during the postprandial state, glucose is 
produced endogenously by the liver via the breakdown of stored glycogen 
(glycogenolysis), and also by synthesis of glucose from sources such as glycerol, lactate 
and amino acids (gluconeogenesis) (Guemes et al., 2015). Current evidence also points 
to a role of the kidney in the synthesis of glucose though it is suggested that this role is 
required particularly in periods of extreme starvation (Andrianesis and Doupis, 2013).  
Glucose is transported unbound in blood, and with the exception of the period shortly 
after birth, the concentration of blood glucose is kept tightly at a physiological range of 
3.9-5.5 mmol/L. This range is maintained by a balance between glucose 
absorption/production and utilisation, made possible by the action of hormones including 
insulin, glucagon, epinephrine, norepinephrine, cortisol and growth hormone (Guemes et 
al., 2015). When blood glucose levels deviate from the physiological range in certain 
situations (particularly in postprandial states), the level is rapidly reverted to normal 
through the action of hormones that suppress endogenous glucose production and 
increase glucose usage by the muscles, liver and adipose tissue (Giugliano et al., 2008). 
Under physiological conditions, insulin regulates blood glucose concentrations mostly 
during the post-prandial state whereas glucagon, epinephrine, norepinephrine, cortisol 
and growth hormone play their roles particularly in the fasting state (Guemes et al., 2015).  
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In spite of the rigid control of blood glucose, the levels may fall or rise drastically under 
certain physiological and pathological conditions including pregnancy and diabetes 
mellitus. The brain, which depends permanently on blood glucose for energy consumes 
about 120 g of glucose per day (van Praag et al., 2014). Blood glucose levels below 3 
mmol/L presents with hypoglycaemic coma whiles levels below 2.4 mmol/L results in 
functional neurological impairments and neuronal death (Yeo and Sawdon, 2013). 
Moreover, at blood glucose levels of 1.1 mmol/L and below, there is irreversible damage 
to the very vulnerable regions of the brain (Languren et al., 2013; Timon et al., 2015). 
Such low levels of glucose in blood can be as result of excessive insulin administration, 
insulinomas or medications (Martin-Timon et al., 2015).   
On the other hand, sustained rise in blood glucose (hyperglycaemia) results in short-term 
effects such as ketosis or long-term effects including severe organ complications as result 
of micro- and macro-vascular injury. These complications include cardiovascular 
accidents, stroke, nephropathy, retinal damage and neuropathy (Downs and Faulkner, 
2015).  
Complications associated with aberrant blood glucose concentrations underscore the 
importance of effective regulation of glucose metabolism, utilisation and concentration 
in blood.  
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1.2.2. Mechanisms of blood glucose regulation 
Several factors affect the concentration of glucose in blood. Of these, two hormones; 
insulin and glucagon play the most significant roles in glucose regulation.  
 
1.2.2a. Role of glucagon in regulation of blood glucose concentration 
Glucagon is a 29-amino acid hormone secreted from α-cells of the pancreas. This 
hormone ensures a sustained level of glucose in blood during fasting conditions by 
promoting glucose synthesis in the liver (Campbell and Drucker, 2015). Under conditions 
where blood glucose levels fall, there is increased secretion of glucagon from α-cells. 
This results in increased endogenous glucose via glycogenolysis and synthesis of glucose 
from amino acids and other substrates (Gylfe and Gilon, 2014). The liver is the major site 
of the physiological actions of glucagon. This is evidenced by the observation that the 
liver is exposed to 2-3 times higher concentrations of glucagon than any other organ 
(Edgerton and Cherrington, 2013). Three major mechanisms have been suggested for 
mediation of glucagon secretion and response during hypoglycaemia. First, reduced blood 
glucose attenuates the direct inhibitory effect of glucose on α-cell secretion of glucagon 
(Gylfe and Gilon, 2014). This is not thought to be a major mechanism since exposing 
isolated α-cell to low glucose in vitro does not result in significant release of glucagon 
(Franklin et al., 2005; Gylfe, 2013). Second, the paracrine effect of β-cells that results in 
inhibition of glucagon from α-cells is attenuated during hypoglycaemia. This mechanism 
is supported by reports that circulating insulin in T1DM patients inhibits glucagon 
secretion from α-cells (Unger and Cherrington, 2012; Campbell and Drucker, 2015). This 
mechanism could also explain why in humans with early-onset T1DM where there is 
significant reduction in endogenous insulin secretion, there is normal glucagon response 
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in hypoglycaemic conditions (Campbell and Drucker, 2015). This is however 
counteracted by reports of early loss of glucagon response to hypoglycaemia in 
adolescents with T1DM (Siafarikas et al., 2012; Campbell and Drucker, 2015). Third, the 
CNS is thought to act directly on α-cells to facilitate secretion of glucagon during 
hypoglycaemic states (Lamy et al., 2015). This autonomic activation of glucagon 
secretion is made possible by three inputs namely: parasympathetic nerves, sympathetic 
nerves (Taborsky and Mundinger, 2012; Gotoh et al., 2013) and circulating level of 
epinephrine (De Marinis et al., 2010). Studies have shown that pharmacological or 
surgical manipulations of these three inputs results in attenuation or significant reduction 
of glucagon secretion in vivo (Taborsky et al., 2012; Paranjape et al., 2010).  
 
1.2.2b. Role of insulin in regulation of blood glucose concentration 
Insulin, a 51-amino acid peptide is produced in the β-cells of the pancreas. The peptide is 
initially synthesised as preproinsulin, cleaved into proinsulin which later matures into two 
components; insulin and C-peptide. Many factors are known to influence insulin 
biosynthesis. The single most significant physiological process that stimulates 
transcription and translation of the insulin gene and RNA respectively is metabolism of 
glucose (Fu et al., 2013; Cantley and Ashcroft, 2015). In response to increased blood 
glucose following food ingestion and absorption, insulin is secreted in two phases and 
binds to insulin receptors expressed on liver, muscle and fat cells (Newsholme et al., 
2014). The main function of insulin is to reduce glucose concentration in blood by three 
distinct mechanisms. The first involves stimulation of peripheral glucose uptake by 
adipose tissue and muscle. This ensures that glucose is used as a major energy source in 
these cells thereby lowering the concentration of glucose in blood (Newsholme et al., 
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2014). Through the paracrine effect of insulin, the second mechanism involves 
suppression of endogenous glucose synthesis/production by the liver both directly and 
indirectly. The direct effect of insulin on the liver involves inhibition of hepatic glucose 
production via attenuation of glycogenolysis and gluconeogenesis (Lee et al., 2016). This 
process is responsible for suppressing up to 80% of hepatic glucose production (Herring 
et al., 2014). Indirectly, insulin reduces glucose synthesis by inhibiting the secretion of 
glucagon from α-cells as well as reducing the concentration of blood lipids and glycerol 
available for gluconeogenesis (Rojas and Schwartz, 2014). The third mechanism through 
which insulin decreases blood glucose is through promotion of hepatic glycogenesis in 
which glucose is converted into its storage molecule, glycogen (Newsholme et al., 2014).  
Homeostasis of blood glucose by insulin, glucagon and other hormones is illustrated in 
Figure 1.1. 
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Figure 1.1. Glucose homeostasis. During fasting state, reduced blood glucose stimulates release of glucagon which stimulates conversion of glycogen to glucose in 
the liver (1) and also promotes gluconeogenesis using non-carbohydrates sources as well as pyruvate (2). Epinephrine, growth hormone and cortisol also stimulate 
gluconeogenesis in the kidney using glutamine (3). Reduced blood glucose in the muscle stimulates epinephrine-induced conversion of glucose from glycogen (4). In 
the fed state (5), insulin is secreted from β-cells via mechanisms including control from the central nervous system (6). Insulin reduces blood glucose by inhibiting 
gluconeogenesis and glycogenolysis in the liver. It also enhances glycogenesis in the liver (7) and muscle tissue (8). In addition, insulin enhances uptake of glucose by 
the muscle and adipose tissue (9). Insulin also reduces the rate of lipolysis (10) and increase synthesis of fatty acids and triglycerides (11). Yeo and Sawdon (2013). 
Image used with copyright permission from Medicine Publishing Company Limited (2016). 
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1.2.3. Mechanism of glucose-stimulated insulin secretion 
Secretion of insulin from β-cells is stimulated by increase in blood concentration of 
amino acids, fatty acids and more significantly glucose following ingestion and 
absorption of food. In both humans and rodents, studies have shown that glucose elicits 
a higher insulin response relative to other nutrients.  In humans for example, oral 
administration of 75 g of glucose results in about tenfold increase in plasma insulin 
relative to the basal insulin level (from 20-30 ρmol/L to 200-300 ρmol/L) (Fu et al., 
2013). In contrast, the same amount of fat or combination of fat and protein results in 
just about a twofold increase in plasma insulin level relative to the basal level (Fu et 
al., 2013).  
Glucose is transported from circulating blood into β-cells predominantly via GLUT1 
and GLUT3 in humans and GLUT2 in rodents (Rorsman and Braun, 2013; McCulloch 
et al., 2011). The differences in the predominant glucose transporter in humans and 
rodents is thought to account for differences in physiological glucose range as well as 
the detectable glucose concentration that stimulates insulin secretion since these 
transporters transport glucose into the cells with different Km values (1 mM for 
GLUT1 and GLUT3; 15-20 mM for GLUT2) (Rorsman and Braun, 2013). Km values 
represent the affinity of glucose transporters for glucose. The values are inversely 
proportional to the degree of affinity of the transporters for glucose molecules 
(Rorsman and Braun, 2013). In both rodent and human β-cells, electrical activities are 
influenced significantly by the ATP-sensitive potassium (KATP) channels. These 
electrical activities result in elevated intracellular calcium ion concentrations, an 
important requirement for triggering of exocytosis of insulin-containing granules that 
are lodged close to the plasma membrane of β-cells.  
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Glucose-stimulated insulin secretion (GSIS) is thought to follow a biphasic 
mechanism. The first phase, which last about 10 minutes according to in vitro and in 
vivo studies (Krogvold et al., 2015; Fan et al., 2015) involves a finite release of the 
readily-releasable pool (RRP) of insulin-containing granules which are located very 
closely below the plasma membrane. The RRP granules make up 1% of the total 
insulin granules and they are depleted after repetitive stimulation or as result of 
reduction in the strength of action potentials during sustained GSIS (Rorsman and 
Braun, 2013). The second phase of GSIS, which lasts longer (about 60 minutes) than 
the first phase involves movement/trafficking of reserved pools (RP) of insulin (which 
are farther from the plasma membrane) to the cellular cortex to be secreted (Gilon et 
al., 2014; Fu et al., 2013). The biphasic mechanism of GSIS (Figure 1.2) has been 
shown to be absent in most transformed β-cell lines used in research (Rorsman and 
Braun, 2013).  
 
 
  
 
 
Chapter One                                                                                            Thesis Introduction 16 
 
   
 
 
  
 
Figure 1.2. Biphasic mechanism of β-cell insulin secretion recorded in isolated normal islets from rats and human. Upon perifusion of stimulatory 
concentrations (11-15 mM) of glucose, there is an initial rapid burst of insulin release from the readily releasable pool (RRP). This initial release declines after 
about 10 minutes due to lowered action potential as well as depletion of the RRP. The second phase of secretion involves trafficking of reserved pools of insulin 
further from the plasma membrane to the cellular cortex to be secreted. This phase is slower, takes longer and involves about 99% of the total insulin content in 
β-cells. Adapted from Rorsman and Braun, 2013; Henquin et al., 2006. 
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1.2.4. Regulation of insulin release by glucose 
After ingestion and absorption of a meal, glucose is transported into β-cells and then 
phosphorylated by glucokinase to undergo glycolysis. The glycolytic reaction yields 
pyruvate, which is then oxidised in the mitochondria via the TCA cycle to generate 
ATP. This mechanism increases the overall ATP and results in an increase in the 
ATP/ADP ratio in the cell which subsequently causes the closure of the KATP channels. 
Closure of these channels results in the opening of voltage-dependent calcium 
channels (VDCC) and the eventual influx of calcium ions (Ca2+). The increase in Ca2+ 
triggers priming of exocytosis of insulin-containing granules. A recent study indicates 
that in β-cells of rats, an increase in influx of Ca2+ results in activation of adenylyl 
cyclase 8, which further ensures a sustained exocytosis of releasable insulin granules 
as well as the priming of reserved pools into readily releasable pools (Dou et al., 2015). 
Moreover, there is another suggested mechanism which triggers insulin secretion. This 
mechanism is thought to be independent of the KATP channels and works by enhancing 
the effects of calcium ions on insulin exocytosis without the influence of an increased 
concentration of intracellular calcium ions in the cells (Seino et al., 2011).  
β-cells have several metabolic features that help to prevent excessive insulin secretion; 
a situation that could lead to hypoglycaemia. One very significant mechanism to avoid 
excessive insulin secretion is the coupling of glucose metabolism to insulin secretion 
through ATP levels and insulin vesicle exocytosis. This ensures that insulin secretion 
remains significantly sensitive to fluctuations in blood glucose levels (Cantley and 
Ashcroft, 2015). Another recently-discovered mechanism through which β-cells 
regulate insulin secretion is through control of macroautophagy (Feng et al., 2014). 
Macroautophagy is a form of autophagy that involves the assembly of cellular contents 
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into a phagophore and its eventual degradation by lysosomes and vacuoles. The 
degraded cellular contents are released back into the cytoplasm to be recycled. This is 
an important mechanism employed by most eukaryotic cells to generate energy and 
maintain their viability in stressful situations such as starvation (Feng et al., 2014). A 
recent study has suggested that macroautophagy is supressed in β-cells during 
starvation in order to control insulin secretion. In contrast to most mammalian cells, 
there is suppression of macroautophagy in β-cells in an mTOR-dependent manner 
during fasting (Goginashvili et al., 2015). The suppression of macroautophagy and 
selective degradation of nascent insulin-secreting granules may be a critical 
mechanism employed by β-cells to ensure that there is low insulin secretion during 
starvation in order to avoid hypoglycaemia.  
The mechanisms of glucose-stimulated insulin secretion are illustrated in Figure 1.3.  
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 Figure 1.3. Mechanism of glucose-stimulated insulin secretion in human and rodent β-cells: In β-cells, the KATP channels are open in 
unstimulated states. This ensures that the resting membrane potential remains around -70 mV. After ingestion of a meal, glucose enters the β-cell via 
GLUT1 and GLUT3 (in humans) or GLUT2 (in rodents) (A) and is phosphorylated before undergoing glycolysis. Pyruvate from glycolysis is then 
oxidised in the mitochondria to yield ATP (B) to cause an increase in the ATP/ADP ratio. This subsequently closes the KATP channels, causes 
depolarisation (C) which then open the voltage-gated calcium channels (D) to increase influx of calcium ions. Increased influx of calcium ions in the 
cell eventually triggers exocytosis of insulin vesicles. De Leon and Stanley, 2007; Rorsman and Braun, 2013. Image used with copyright permission 
from Nature Publishing Group (2016). 
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1.2.5. Physiological actions of insulin 
The physiological actions of insulin are exerted by binding of insulin to a cell surface 
insulin receptor present on many cells including the liver, muscles and fat cells 
(Newsholme et al., 2014). By binding to these receptors, insulin facilitates uptake of 
amino acids and glucose into the cells. Insulin also promotes storage of triglycerides in 
fat cells, suppresses postprandial secretion of glucagon, and promotes synthesis of 
proteins, glycogen and fat (Yeo and Sawdon, 2013). Insulin as a hormone has also been 
suggested to act as a neurotrophic agent responsible for enhancing brain function. In a 
triple-transgenic female mouse model of Alzheimer’s disease (3xTg-AD), a high-fat diet 
induces increased formation of β-amyloid peptide (Aβ) and glucose intolerance (Vandal 
et al., 2014). These high-fat-induced observations were reversed following injection of 
3.8 units/Kg of human insulin into these mice. The study showed that the Aβ levels were 
significantly lowered because insulin caused reduced production and increased clearance 
of the peptides. These observations underscore the link between neurodegenerative 
conditions such as Alzheimer's disease and insulin levels/function.   
In spite of strict regulation of insulin secretion by β-cells, certain conditions including 
DM and insulinomas can result in absent, reduced or excessive insulin secretion as well 
as non-responsiveness of cells to insulin. These situations underlie the pathophysiology 
of diabetes mellitus, a life-threatening condition which affects millions of individuals 
worldwide. 
In addition to glucagon and insulin, growth hormone from the pituitary gland (Moller and 
Jorgensen, 2009), epinephrine secreted from the medulla of the adrenal glands (Jensen et 
al., 2011) and thyroxine secreted from the thyroid (Klieverik et al., 2009) have all been 
suggested to contribute to regulation of glucose level in blood. 
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1.3. Diabetes mellitus  
1.3.1. Definition and epidemiology of diabetes mellitus 
Diabetes mellitus (DM) refers to a group of multifactorial metabolic disorders 
characterised by persistent hyperglycaemia. The chronic hyperglycaemia is as a result of 
defective insulin secretion, defect in insulin action or both (Kharroubi and Darwish, 
2015). These deficiencies can present with several systemic complications including 
micro- and macrovascular abnormalities, coma and even death. The disease remains one 
of the biggest public health challenges in the world, imposing significant financial and 
emotional costs on sufferers, families and the community in general. According to the 
2015 International Diabetes Federation (IDF) Diabetes Atlas, 415 million adults around 
the world have diabetes and this is expected to rise to 642 million by 2040 (IDF, 2015). 
From the same IDF report, it was observed that about 5 million people died of diabetes 
in 2015 and 5-20% of total health expenditure on adults was spent on management of 
diabetes mellitus and its related complications. Also, countries that have not been 
generally associated high prevalence of diabetes mellitus have recorded significant 
increases in prevalence recently. Example, more than 10% of adults in the Middle East 
now have diabetes whiles about 21 million people in Africa have diabetes with the 
number estimated to double by 2035. These figures underscore the fast-growing and 
pandemic nature of diabetes mellitus (IDF, 2015).  
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1.3.2. Classification of diabetes mellitus  
Classification of DM remains a controversial subject owing to the increasing 
heterogeneous nature of the disease. The majority of DM cases fall into two major 
subdivisions based on pathogenesis and aetiology. T1DM refers to the type caused by 
total cessation of insulin secretion from the pancreas. T1DM has a multifactorial 
aetiology and represents 7-12% of all diabetes mellitus cases. T2DM accounts for 87-
91% of all cases and is also caused by a combination of several factors particularly obesity 
and insulin resistance (IDF, 2015). Outside these two major types, other specific types of 
diabetes mellitus have been recognised and categorised. Maturity onset diabetes of the 
young (MODY) refers to monogenic forms of the disease which result from genetic 
defects of β-cells and presents with ‘age-onset’ diabetes at early age (Leslie et al., 2015). 
MODY accounts for 1-4% of all diabetes mellitus cases. Another form of specific 
diabetes categorised outside the two main subtypes is gestational diabetes mellitus 
(GDM). This refers to abnormal levels of blood glucose and glucose intolerance first 
recognised during pregnancy. GDM is most associated with maternal obesity and affects 
almost 7% of all pregnancies, resulting in some complications during pregnancy or after 
birth. It has been suggested that women suffering from GDM have about seven-fold 
increased risk of developing T2DM as well as some metabolic complications after birth 
(Bellamy et al., 2009; Hod et al., 2015). The current classification of diabetes presents 
with some challenges in terms of management of the disease hence a more effective 
system of classification is required to accommodate all the challenges and the increasing 
heterogeneity associated with it. 
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1.3.3. Type 1 Diabetes Mellitus 
T1DM is a life-threatening condition which involves the autoimmune destruction of 
insulin-secreting β-cells of the pancreas. The lack of insulin results in hyperglycaemia 
together with abnormalities in fat and protein metabolism (Atkinson et al., 2014). These 
metabolic abnormalities contribute to T1DM complications including diabetic 
ketoacidosis, microvascular complications, neuropathies, coma and death (Rohrer et al., 
2015; Rewers et al,. 2015). The disease is one of the commonest chronic non-
communicable conditions and requires life-long insulin administration alongside glucose 
monitoring and diet modification at significant financial and emotional cost to patients, 
carers and relatives (Freeborn et al., 2013; Balfe et al., 2013). T1DM has long been 
established as a disease of children and young adults, but recent observations of 
increasing prevalence in adults have raised the question of using age as an important 
parameter in diagnosis of the condition (Atkinson et al., 2014). Though there is a 
significant variation in incidence and prevalence of T1DM amongst countries (Patterson 
et al., 2014), the number of cases worldwide is increasing especially in children and 
young adults. It is estimated that about 79,000 children under the age of 14 years around 
the world develop T1DM each year (Patterson et al., 2014).  
It is widely accepted that T1DM is a multifactorial autoimmune disease, but the exact 
cause or trigger of the autoimmune process remains uncertain. This has contributed to the 
difficulties associated with research into ways of delaying the progression of the disease 
in high-risk individuals. The current understanding is that the autoimmune process in 
T1DM results from interaction between genetic predisposition and some environmental 
factors.  
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Environmental factors that have been implicated in initiation/development of T1DM 
include viral infections (enteroviruses, rubella, rotaviruses and cytomegaloviruses) 
(Krogvold et al., 2015; Craig et al., 2013), time-onset and duration of breastfeeding (Hall 
et al., 2015; Lund-Blix et al., 2015), infant diet regimen (Lamb et al., 2015), mode of 
delivery with Caesarean section being a high risk factor (Puff et al., 2015) and levels of 
vitamin D (Vehik et al., 2013). Other environmental factors that have been suggested to 
increase the risk for T1DM development include maternal lifestyle such as high BMI 
(Hussen et al., 2015), smoking (Mattsson et al., 2015), diet during pregnancy and 
lactation (Niinisto et al., 2014), high birthweight (Cardwell et al., 2010a), childhood 
obesity (Verbeeten et al., 2011), maternal age (Cardwell et al., 2010b) and order of birth 
(Cardwell et al., 2011). 
Though the role of environmental factors as triggers or promoters of T1DM development 
remain a developing area of research, the current understanding of T1DM aetiology is 
that genetic predisposition and environmental factors may be independent risk factors for 
T1DM, but their combined effect increases the risk of developing the disease.  
Evidence for an autoimmune process in T1DM has been reported in several studies over 
a long period of time.  
 
1.3.3a. Role of genetics in autoimmune process of T1DM 
There is evidence for an association of T1DM with genetic polymorphisms that 
predispose individuals to an altered immune response. Genome-wide association studies 
(GWAS) have helped to reveal that polymorphisms in almost fifty genes contribute to the 
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autoimmune pathogenesis of T1DM (Ehlers, 2016; Mannering et al., 2015; Dirice and 
Kulkarni, 2016). 
Polymorphisms at class II HLA gene loci account for about 50% of the overall genetic 
risk for T1DM (Noble, 2015). The strongest association between risk for initiation of 
T1DM autoimmune process and HLA is observed in the genotype coded by the 
DRB1*0401-DQB1*0302 and DRB1*0301-DQB1*0201 loci (Noble, 2015; Silva et al., 
2016). These polymorphisms are likely to alter the function of antigen presenting cells 
which may subsequently lead to activation of cytotoxic autoreactive CD8+ T cells and 
eventual killing of β-cells of the pancreas (Noble, 2015).  
Beyond HLA, several genes have been associated with the autoimmune process in T1DM 
but only few confer relatively high risk for the disease. A nucleotide polymorphism in 
PTPN22 is thought to result in T cell hyperresponsiveness, reduced function of Tregs as 
well as altered antigen presentation all of which can lead to enhanced autoimmune β-cell 
destruction (Sarmiento et al., 2015; Sharp et al., 2015). Polymorphisms in CTLA-4 gene 
also lead to impaired regulatory T cell (Tregs) function and reduced control of T cell 
proliferation and function which subsequently increase the likelihood of autoimmune β-
cell destruction of cells (de Jong et al., 2016; Almasi et al., 2015). Also, a polymorphism 
in IFIH1 gene impairs response of the innate immune system to viral infections and 
increases risks for autoimmune process in T1DM (Zurawek et al., 2015). This link is 
interesting considering the long-standing association between T1DM and viral infections.  
Emerging candidate genes for autoimmune T1DM risk include HIP14, STAT4, DLK1, 
CCR5 and CTSH (Mannering et al., 2015).  
A summary of the major genetic polymorphisms associated with the autoimmune process 
in T1DM is shown in Table 1.1. 
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Gene Locus Expression in 
Human islets 
Odds Ratio Effect of polymorphism                      References 
 
 
HLA 
 
6p21 
 
Yes 
 
Up to 11.4 
 
Altered antigen presentation 
 
Noble, 2015; Silva et al., 2015 
 
PTPN22 
 
1p13 
 
Yes 
 
Up to 1.8 
 
T cell hyperresponsiveness, 
impaired Treg function, 
altered antigen presentation 
   
Sarmiento et al., 2015; Sharp et al., 2015 
 
IFIH1 
 
2q24 
 
Yes 
 
Up to 1.2 
 
Impaired response to viral infections 
 
Storling and Brorsson (2013), 
Zurawek et al., 2015 
 
CTLA-4 
 
2q33 
 
No 
 
Up to 1.1 
 
Impaired T-cell regulation 
impaired Treg function 
 
Jong et al., 2016; Almasi et al., 2015 
Table 1.1 Summary of the major genetic polymorphisms associated with risk for autoimmune process in T1DM. The odds ratio defines the strength of 
association between polymorphisms in the genes and susceptibility to developing autoimmune T1DM. The higher the odds ratio, the greater the risk of 
autoimmune process in T1DM.                                                                                                                                                                                                     
 
 
 
 
 
 
 
 
 
Agonist 
 
 
GluK1 
 
 
GluK2 
 
 
GluK3 
 
 
GluK1/ 
GluK2 
 
 
GluK1/ 
GluK5 
 
 
GluK2/ 
GluK5 
 
 
Native KARs 
Glutamate Very potent Very potent Potent Potent Very potent Very potent Very potent 
Kainate Potent Potent Potent Potent Potent Potent Potent 
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1.3.3b. Antigen targets and autoantibodies in T1DM 
T1DM is thought to be a T cell-mediated disease where autoreactive CD8+ and CD4+ T 
cells target antigens in β-cells of the pancreas (Mannering et al., 2015). Autoantibodies 
to these β-cell autoantigens have been the most important components of the autoimmune 
process and they serve as biomarkers and targets of immune therapies for T1DM. This is 
due to their role in presenting β-cell antigens to cytotoxic T-cells during the autoimmune 
process (Bonifacio, 2015).  
The most-characterised autoantigens in T1DM are insulinoma antigen 2 (IA-2), glutamic 
acid decarboxylase 65 (GAD65), insulin and zinc transporter 8 (ZnT8) (Morran et al., 
2015). Studies suggest that combining metabolic investigations with identification of 
autoantibodies to these four antigens is the best tool to identify β-cell autoimmunity; with 
about 96% of individuals with β-cell autoimmunity expressing at least one of these four 
autoantibodies (Bonifacio, 2015; Mannering et al., 2015). 
Although β-cell antigen targets and their autoantibodies have been explored in clinical 
and laboratory procedures aimed at delaying T1DM progression, these interventions have 
not been particularly successful for the following reasons: (i) it is not known if a single 
β-cell antigen is able to drive the autoimmune process, (ii) it is not clear which of the 
antigens trigger pathogenic autoimmunity when targeted by autoantibodies (Yu et al., 
2012; Bonifacio, 2015), (iii) All the known β-cell antigens are predominantly intracellular 
(Arvan et al., 2012); hence it is unlikely that they trigger the initial stages of the 
autoimmune process, (iv) the mechanisms that lead to loss of immune tolerance to these 
intracellular proteins remain uncertain (Arvan et al., 2012). Thus, an antigen located on 
the surface of β-cells may be the first targeted the immune system. This could then trigger 
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an autoimmune process which can result in exposure of intracellular β-cell antigen targets 
such as IA-2 and GAD65 to the immune cells. These observations underscore the need to 
probe further for new β-cell-associated antigen targets and autoantibodies that may 
unlock the mystery surrounding the role of the autoimmune process in the early stages of 
T1DM.  
 
1.3.4. Type 2 Diabetes Mellitus (T2DM) 
T2DM is characterised by chronic hyperglycaemia, reduced insulin secretion and 
impaired insulin action as result of resistance by target cells (adipose, muscle and liver 
cells) (Cantley and Ashcroft, 2015). T2DM has long been thought to be a disease of adults 
but accumulating evidence has shown that incidence of the disease is significantly 
increasing in children and young adults (Tuomi et al., 2014). Moreover, results from 
studies in the United State for instance have reported that there has been a 21% increase 
in T2DM cases among young adults from 2001 to 2009 (Imperatore et al., 2012). This 
rise in T2DM among the youth is several times higher in China compared to the United 
States (Li et al., 2012). These increasing incidence of T2DM among the young has been 
attributed partly to corresponding increase in incidence of obesity among individuals in 
the same age group (Tuomi et al., 2014).  
Furthermore, the worldwide incidence of T2DM is increasing at an alarming rate. 
According to the 2015 report of the IDF, 345-370 million people, representing close to 
8% of the world’s population have T2DM. This is projected to reach about 560 million 
(almost 9.5% of the world’s population) by the year 2035 (IDF, 2015). The increasing 
incidence is being observed in every geographic region of the world. For instance, almost 
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12% of China’s population has T2DM (Xu et al., 2013) while almost 8% of adults in 
Europe are estimated to be suffering from the disease (Tamayo et al., 2014).  
 
1.3.4a. Causes of T2DM 
Like T1DM, T2DM is thought to be caused by a complex interaction between the 
environment and predisposing genetic factors. Several studies have helped to establish 
the role of genetics in T2DM development. An individual stands a 40% increased risk of 
developing the disease if one parent already has/had it while the risks of having the 
disease is 70% if both parents have T2DM (Prasad and Groop, 2015). The genetic 
predisposition to T2DM is further supported by the high prevalence of the disease among 
certain ethnic groups. For instance, almost 50% of Pima Indians in America have T2DM 
while less than 10% of Caucasians in Europe are affected (Shaw et al., 2010; IDF, 2015). 
The introduction of genome-wide association studies (GWAS) have contributed 
significantly to the study of genetic contribution to T2DM development. As of 2014, more 
than 90 gene loci had been linked to T2DM with the most studied of these variants being 
Calpain 10, TCF7L2 (Reynisdottir et al., 2013), PPARG (Grarup et al., 2014), SLC30A8 
(Imamura et al., 2012), HHEX (Sladek et al., 2007) and ANKI (Imamura et al., 2012). 
Most of these gene variants are thought to contribute to the disease development through 
varied mechanisms including reduction in insulin sensitivity, β-cell destruction, 
decreased β-cell function, and increased insulin resistance among others (Singh, 2015).  
Several environmental factors have also been implicated in the development of the 
T2DM. The most significant of these factors is obesity and it has been established that 
the risk of developing T2DM increases considerably among obese individuals (Tuomi et 
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al., 2014). There is evidence to suggest that the global increase in T2DM incidence shows 
a similar trend and geographic distribution as that of obesity (Cantley and Ashcroft, 
2015). Though obesity remains a major risk factor for T2DM, the recent report that 
obesity is associated with a 50% increase in β-cell mass suggests that the effect of obesity 
on T2DM may vary from person to person depending on how an individual’s system 
respond these effects (Cantley and Ashcroft, 2015; Saisho et al., 2013).  
Other environmental factors that have been implicated in increasing the risk for 
development of T2DM include maternal malnutrition and low protein diet (Tarry-Adkins 
et al., 2010), maternal or infant overnutrition (Lee et al., 2013; Black et al., 2013), 
alcoholism (Ramirez et al., 2013), maternal smoking (Thiering et al., 2011), prenatal 
psychological stress (Virk et al., 2013), gestational diabetes (Bush et al., 2013), maternal 
hormonal levels during pregnancy (Roland et al., 2012), early weaning (Lima et al., 
2011), neonatal monosodium glutamate intake (Roman-Ramos et al., 2011), low socio-
economic status (Tamayo et al., 2010) as well as long duration of night-shift work among 
women (Vimalananda et al., 2015).  
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1.4. Glutamate Receptors (GluRs) 
Glutamate, a non-essential amino acid is the major excitatory neurotransmitter in the CNS 
involved in mediating several range of neural functions including synaptic plasticity, fast 
excitatory synaptic transmission, learning and memory, long term potentiation (LTP) as 
well as neuronal development (Edwards, 2015; Willard and Koochekpour, 2013). The 
highest concentrations of glutamate in the CNS are mostly present in synaptic vesicles 
located in nerve terminals of presynaptic neurons from where they are released by 
exocytosis to bind to glutamate receptors (GluRs) (Zhou and Danbolt, 2014). GluRs are 
located primarily on the surface of various brain cells including neurons and glial cells 
(oligodendrocytes and astrocytes) (Parpura and Verkhrastsky, 2013). Due to the 
characteristic expression of GluRs on neuronal and other brain cells, these receptors can 
only be activated from the outside by extracellular glutamate (Zhou and Danbolt, 2014). 
This observation underscores the significant importance that glutamate’s release into and 
uptake from the extracellular fluid (ECF) by glutamate transporters play in activation of 
GluRs (Vandenberg and Ryan, 2013). Moreover, it has long been established that 
glutamate as an excitatory neurotransmitter can cause death of neurons and other cells in 
the brain in a phenomenon termed excitotoxicity. This is a mechanism whereby GluRs 
are chronically over-activated to cause death of cells via cellular mechanisms including 
apoptosis and necrosis (Del Rosario et al., 2015). To protect the cells from excitotoxicity, 
glutamate transporters are actively involved in removal of glutamate from ECF. The 
function of these transporters are particularly important considering that no enzyme is 
known to degrade glutamate extracellularly (Zhou and Danbolt, 2014). Also, to protect 
against glutamate-induced excitotoxicity, the brain in general and neuronal cells in 
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particular are protected from the high glutamate concentration in blood by the blood-brain 
barrier. 
In the CNS, glutamate activates 2 groups of GluRs namely ionotropic (iGluRs) and 
metabotropic (mGluRs) glutamate receptors. GluR subtypes and their respective subunits 
are summarised in Figure 1.4 while the mechanism of glutamate signalling and eventual 
clearance from the synaptic cleft is shown in Figure 1.5. 
 
 
  
 
 
Chapter One                                                                                            Thesis Introduction 33 
 
 
 
 
 
 
 
 
 
 
 
 
GluRs 
GluA1 
iGluRs mGluRs 
Group I  Group II Group III  AMPAR NMDAR KAR 
mGluR1 
mGluR5 
mGluR2 
mGluR3 
mGluR4 
mGluR6 
mGluR7 
mGluR8 
GluA2 
GluA3 
GluA4 
GluN1 
GluN2A-D 
GluN3A-B 
GluK1 
GluK2 
GluK3 
GluK4 
GluK5 
Figure 1.4. Classification of glutamate receptors into groups, subtypes and respective subunits. GluRs are classified into two groups namely ionotropic 
(iGluRs) and metabotropic (mGluRs) glutamate receptors. The iGluRs are further divided into three main subtypes named after the glutamate analogues that 
selectively activate these subtypes: AMPA, NMDA and kainate. These three iGluR subtypes are classified into respective subunits based on the genes that 
encode these subunits. mGluRs are classified into three main groups based on their ligand-binding profile, intracellular signal transduction pathways and 
sequence homology. The three groups of mGluRs consist of respective isoforms. Traynelis et al., 2010; Willard and Koochekpour, 2013; Amalric et al., 2015. 
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Figure 1.5. Glutamate signalling and recycling between neurons and glial cells. Glutamate is stored in vesicles in presynaptic neuronal cells from where they 
are released into the synaptic cleft. Release of glutamate from presynaptic neurons into the synaptic cleft is under the modulation of GluRs present on these 
presynaptic neurons. The released glutamate in the synaptic cleft bind and activate GluRs on postsynaptic neurons to initiate excitatory neurotransmission. After the 
signalling process excess glutamate is removed from the synaptic cleft by glutamate (amino acid) transporters located on glial cells. The removed glutamate is then 
converted into glutamine by glutamine synthetase (1) and transported back via glutamate transporters into the presynaptic neuronal cell. In the presynaptic neuron, 
glutamine is converted into glutamate by glutaminase (2) and then packaged into vesicles ready to be released into the synaptic cleft. Julio-Pieper et al., 2011; 
Amalric et al., 2015. Image used with copyright permission from American Society for Pharmacology and Experimental Therapeutics (2016). 
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1.4.1. Ionotropic glutamate receptors (iGluRs) 
Molecular cloning has helped to establish that there are three subtypes of iGluRs namely 
N-methyl-D-aspartate receptors (NMDARs), (S)-2-amino-3-(3-hydroxy-5-methyl-4-
isoxazolyl) propionic acid receptors (AMPARs) and kainate receptors KARs. These three 
subtypes are named after the potent analogues of glutamate that preferentially activate the 
receptors (Paoletti et al., 2013). Structurally, iGluRs are quaternary ligand-gated ion-
channel receptors that bind and interact with specific agonists. The ligand-gated ion-
channels of iGluRs consists of four domains namely ligand-binding domain (LBD), 
amino terminal domain (ATD), transmembrane domain (TMD) and an intracellular C-
terminal domain (CTD) (Willard and Koochekpour, 2013; Lodge, 2009). Binding of 
glutamate or an analogue of glutamate to the LBD induces a conformational change in 
the TMD resulting in influx of cations (sodium, potassium or calcium ions) through the 
TMD. Stimulation of iGluRs through this mechanism results in significant influx of 
calcium and firing of an action potential (Traynelis et al., 2010). After firing of the action 
potential, glutamate in the synaptic cleft is removed by glutamate transporters, which are 
expressed on postsynaptic neuronal and glial cells, to turn off the signal in preparation for 
a new series of transmission (Willard and Koochekpour, 2013). The basic structure and 
activation of iGluRs are illustrated in Figure 1.6. 
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Figure 1.6. Structure and activation of ionotropic glutamate receptors by glutamate. (A) A native resting conformation of an iGluR showing 
only two instead of four subunits. The receptor consists of an extracellular N-terminal domain (N) and a shorter C-terminal domain (CTD) which is 
intracellular. The extracellular amino terminal domain (ATD) is followed by an extracellular ligand-binding domain ((LBD). The four subunits of a 
resting iGluR are arranged in such a way that they form a channel pore through the plasma membrane. (B) iGluR receptor upon binding of glutamate 
(Glu) induces a conformational change in one of the four transmembrane domain (TMD) to allow opening and influx of calcium ions through this 
transmembrane domain. Willard and Koochekpour, 2013. Image used with copyright permission from International Journal of Biological Sciences 
(2016). 
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NMDARs are calcium-permeable iGluRs which consist of seven distinct subunits; 
GluN1, four subunits of GluN2 (GluN2A, GluN2B, GluN2C and GluN2D) which are 
encoded by four different genes and two units of GluN3 (GluN3A, GluN3B) also encoded 
by two different genes (Vyklicky et al., 2014). For NMDARs to be functional, it must be 
in the form of a hetero-tetramer containing two GluN2 subunits (or in some cases one 
GluN2 and one GluN3 subunit) together with two obligatory GluN1 subunits (Paoletti et 
al., 2013). The opening of NMDAR voltage-gated channel requires binding of glutamate 
(or its analogue) as well as glycine, the co-agonist of NMDARs. Studies have shown that 
glutamate binds to the GluN2 subunit while glycine binds to the GluN1 subunit of the 
functional hetero-tetramer (Yang et al., 2014). Binding of these agonists open the ion-
channels by stabilising a close-cleft conformation whereas binding by antagonists of 
NMDARs impedes the closure of the cleft and hence prevents the opening of the ion 
channels. However, recent studies have shown that D-serine is a preferred co-agonist for 
NMDARs in adult human brain (Mothet et al., 2015). NMDARs are thought to be mainly 
involved in long term potentiation and long term depression of synaptic transmission 
(Papouin and Oliet, 2014). Dysfunction of NMDARs in the CNS have been linked to 
several neurological abnormalities including pathological pain, stroke and 
neurodegenerative diseases (Paoletti et al., 2013). 
AMPARs are also tetrameric cation-permeable subtypes of iGluRs which are expressed 
throughout the CNS but more especially at excitatory glutamergic synapses. There are 
four distinct subunits of AMPAR, namely GluA1, GluA2, GluA3 and GluA4 that are 
encoded by four distinct genes (Traynelis et al., 2010). These subunits are mostly 
assembled as hetero-tetramers but evidence also suggests that they can be assembled as 
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homo-tetrameric (Lu et al., 2009). When glutamate or its analogue binds to AMPAR, the 
cation-permeable pores open and allows influx of sodium ions resulting in depolarisation. 
Calcium ions can also be permitted entry depending on the subunit composition of the 
AMPAR (GluA2-containing receptors are calcium ion impermeable) (Chater and Goda, 
2014). The subunit composition of AMPARs play significant role in determining the 
functions of the receptors (Monyer and Engelhardt, 2015). AMPARs are primarily 
involved in mediation of fast excitatory neurotransmission and dysfunction of these 
receptors have been linked to neurological conditions including progressive memory loss 
in AD (Tang, 2009).  
The third subtype of iGluRs, KARs form the basis of this study hence will be discussed 
in detail in section 1.5.  
 
1.4.2. Metabotropic glutamate receptors (mGluRs) 
mGluRs belong to the class C G-protein-coupled receptor superfamily. This C G-protein 
receptor superfamily also include the receptors for sweet and umami tastes, calcium and 
GABAB (Kniazeff et al., 2011). mGluRs are made up of three distinct groups that have 
eight isoforms. The grouping of mGluRs is based on their ligand-binding profile, 
intracellular signal transduction pathways as well as on the homology of the sequences 
(Amalric et al., 2015). Group I mGluR consists of mGluR1 and mGluR5, group II consists 
of mGluR2 and mGluR3 while mGluR4, mGluR6, mGluR7 and mGluR8 make up group 
III (Niswender and Conn, 2010). These receptors are expressed mostly in the basal 
ganglia where they are responsible for modulation of synaptic transmission as well as 
neuronal plasticity (Hovelso et al., 2011). Structurally, mGluRs consist of a large ligand 
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(glutamate)-binding region (LBD) made up of a large extracellular N-terminal domain 
(NTD) and seven α-helical transmembrane domains (7TM) that contain a binding site for 
synthetic allosteric modulators (Yin and Niswender, 2014; Rondard and Pin, 2015). The 
most conserved structures or domains of mGluRs are thought to be the sites involved in 
coupling to the G-protein and the glutamate-binding site (Hovelso et al., 2012). The NTD, 
also called the Venus flytrap domain (VFD), consists of two lobes which upon binding of 
glutamate or another agonist undergoes a conformational change resulting in closure of 
these two lobes to initiate activation of the receptor (Yin and Niswender, 2014). The 
change in conformation of the ligand-binding domain induces rearrangements of a 
cysteine-rich domain and eventual trigger and activation of the 7TMs.  
In the context of downstream signalling, group I mGluRs are coupled to Gq/II proteins and 
activate phospholipase C which results in downstream activation of protein kinase C 
(PKC) and calcium influx (Niswender and Conn, 2010). On the other hand, group II and 
group III mGluRs are coupled to Gi/0 protein which upon activation inhibits adenylyl 
cyclase and followed by downstream signalling pathways through the activation of 
potassium ion channels and inhibition of calcium ion channels (Yin and Niswender, 
2014).  
In the CNS, mGluRs are thought to be primarily involved in modulation of synaptic 
transmission, neuronal excitability and regulation of neurotransmitter release. Moreover, 
dysfunction of mGluRs have been linked to several neurological conditions including 
depression, anxiety disorders, schizophrenia, Parkinson’s disease, Alzheimer’s disease 
and epilepsy (Nicoletti et al., 2015). 
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1.5. Kainate Receptors 
Among the iGluRs, KARs remain the least studied over the years due to the lack of 
specific antibodies against KARs as well as inadequate pharmacological tools and 
transgenic animals to study the properties of this iGluR subtype (Lerma and Marques, 
2013). However, there has been considerable research and accumulation of information 
about the biological and pharmacological properties of KARs since the cloning of GluK1 
in 1990 (Contractor et al., 2011).  
 
1.5.1. Subunit classification and receptor combinations of KARs 
Molecular cloning of KAR subunits has shown that these receptors represent a distinct 
family of iGluRs in terms of structure and function. KARs consists of five distinct 
subunits namely GluK1, GluK2, GluK3, GluK4 and GluK5 which co-assemble to form 
functional homomeric or heteromeric receptors. While GluK1-3 can form functional 
homomeric receptors, GluK4 and GluK5 can only function when in heteromeric 
combinations with any of GluK1-3 subunits (Crepel and Mulle, 2015). KAR subunits can 
also be classified based on their affinity for kainate; GluK1-3 have relatively low-affinity 
for kainate while GluK4 and GluK5 are classified as the high-affinity KAR subunits (Pahl 
et al., 2014). These classifications and properties of KARs indicate that there are 
considerable limitations in the number of functional KAR combinations since it is 
necessary that a functional unit of KAR should be a combination of a low-affinity 
homomeric subunit and a high-affinity obligate heteromeric subunit. Moreover, the low-
affinity KAR subunits are also prone to rapid and complete desensitisation upon 
stimulation with even very low concentrations of glutamate (Fisher and Fisher, 2014). 
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Also, incorporation of the high-affinity KAR subunits into a functional combination of 
KARs results in significant changes in the physiological functions and pharmacological 
properties of recombinant receptors (Fisher and Fisher, 2014). Among these changes 
include increased affinity for glutamate, enhanced activation by AMPA and other 
agonists, changes in the concentration-dependence of desensitisation as well as slowing 
of receptor deactivation (Mott et al., 2010; Fisher and Fisher, 2014).  
Furthermore, because each of the five KAR subunits has a ligand-binding site, it has been 
suggested that each subunit is capable of binding to a ligand to initiate and contribute to 
activation and gating of the receptor channels (Lerma and Marques, 2013). However, 
other studies suggest that binding of glutamate to the high-affinity subunits within a 
heteromeric functional receptor combination is sufficient to activate the receptors channel 
while a higher concentration of glutamate is required to desensitise the receptor 
combination through binding to the low-affinity GluK2 subunit (Fisher and Mott, 2011). 
These observations suggest that activation or desensitisation of a KAR subunit 
combination is considerably dependent on the subunit composition as well as the 
concentration of ligand. The importance of a high-affinity subunit in KAR combination 
is further enhanced by the observation that homomeric subunits GluK1 and GluK2 are 
irreversibly desensitised by dysiherbaine, a high-affinity KAR agonist but GluK2 
undergoes a rapid recovery from dysiherbaine-induced desensitisation when co-expressed 
with GluK5 (Mott et al., 2010). Another study also observed that in GluK2/GluK5 
heteromeric subunit composition, binding of a ligand to only GluK5 is mandatory and 
sufficient to induce trafficking of this heteromeric assembly to the plasma/cell membrane 
(Fisher and Housley, 2013). The study also reported that binding of a ligand to GluK2 
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only failed to elicit the same response as binding to GluK5. These observations futher 
support the suggestion that high-affinity KAR subunits play significant roles in regulating 
the surface expression of heteromeric KARs of which these high-affinity subunits form 
part.  
1.5.2. Structure of KAR subunits 
The structure of KARs consists of a large extracellular NTD which has two or more 
component lobes. The extracellular NTD is followed by a single transmembrane domain 
referred to as M1, a re-entrant or pore-loop known as M2 which penetrates the membrane 
from its intracellular side between M1 and another transmembrane domain (M3). This is 
followed by another transmembrane domain (M4) that precedes a cytoplasmic C-terminal 
domain (Contractor et al., 2011; Fisher, 2015). KARs also contain a LBD comprising of 
two modular lobes (R1 and R2) that are formed from a pre-M1 domain (S1) and the loop 
formed between M3 and M4 (S2) (Pahl et al., 2014).  
The subunit topology of KARs is depicted in Figure 1.7. 
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 Figure 1.7. KAR subunit topology. A KAR subunit consist of an extracellular large N-terminal domain (which has two component lobes; R1 and R2) 
with its detailed crystal structure shown. The three transmembrane domains (M1, M3, M4) and the pore loop (M2) are also depicted followed by the 
intracellular C-terminal domain. Also shown is the ligand-binding domain (LBD) with its two lobes (D1 and D2) and detailed crystal structure. Contractor 
et al. (2011). Image used with copyright permission from Elsevier Limited (2016). 
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1.5.3. KAR subunit diversity 
Previous studies have suggested that there is significant diversity among the KAR 
subunits in the context of structure. mRNAs that encode for GluK1 and GluK2 subunits 
are subject to enzymatic editing by RNA deaminase which results in alternate 
incorporation of an important amino acid in the pore-forming P-loop (the ‘Q/R’ site) 
(Carta et al., 2014). This insertion of amino acid results in GluK1 and GluK2 having 
significantly reduced permeability for divalent cations as well as having very low single-
channel conductance (Contractor et al., 2011; Carta et al., 2014). The physiological 
relevance of these changes however, remain unclear.  
KAR subunits GluK1-3 undergo alternative splicing in different components of the 
receptors. GluK1 undergo alternative splicing within the NTD and CTD which results in 
two splice variants (GluK1-1 and GluK1-2) in the NTD and four splice variants (GluK1a, 
GluK1b, GluK1c and GluK1d) in the CTD (Pahl et al., 2014). In GluK2, there is 
alternative splicing within the CTD which results in three GluK2 variants (GluK2a, 
GluK2b and GluK2c) (Pinheiro and Mulle, 2006; Pahl et al., 2014). There is an alternative 
splicing in the CTD of GluK3 which results in two splice variants; GluK3a and GluK3b 
(Pahl et al., 2014). The KAR subunit diversity as result of alternative splicing as well as 
mRNA enzymatic editing is shown in Figure 1.8. 
Alternative splicing has been suggested to have significant effect on GluK1-3 subunits in 
areas of cellular trafficking, surface expression as well as how these receptors interact 
with accessory proteins and intracellular partners (Carta et al., 2014; Lerma and Marques, 
2013).  
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 Figure 1.8. KAR subunits and their splice variants. GluK1-3 show significant sequence homology but they differ from GluK4 and GluK5 in the context 
of sequences as well as affinity for agonists. The black boxes in each subunit represent the four membrane domains (M1, M2, M3 and M4) and the triangles 
represent positions of RNA editing. Alternative splicing of these subunits leads to splice variants such as GluK2a and GluK2B for the GluK2 KAR subunit. 
This figure is from Contractor et al. 2011. Image used with copyright permission from Elsevier Limited (2016). 
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1.5.4. Localisation of KAR subunits in the CNS 
Due to inadequate pharmacological tools, transgenic animals and specific antibodies 
against KAR subunits, most studies regarding the expression of these receptors in the 
CNS have used in situ hybridisation and electrophysiological approaches. These methods 
however do not provide enough information about the subcellular distribution of KAR 
subunits (Lerma and Marques, 2013). The most widely-expressed KAR subunit in the 
CNS is GluK2 and it is significantly expressed in most parts in the brain but particularly 
at the mossy fiber-CA3 synapse in the hippocampus where they primarily modulate post-
synaptic responses (Carta et al., 2014). GluK1 expression is however significantly 
restricted in the adult brain but widely expressed in the developing brain of rodents and 
humans including the Purkinje cells of the cerebellum as well as in the spinal cord (Fisher, 
2014; Perrais et al., 2010). It is suggested that the pattern of GluK1 expression in the 
brain may be related to its function of modulating neuronal maturation in rodents and 
humans (Carta et al., 2014; Fisher and Fisher, 2014). For instance, expression of GluK1 
in adult rodents and humans is thought to be primarily in the hippocampal and cortical 
interneurons where they contribute to the pre- and post-synaptic populations of KARs 
(Carta et al., 2014; Fisher and Fisher, 2014). KAR subunit GluK3 which has not been 
investigated extensively as other subunits has been shown to be expressed in vast sections 
of the brain including the dentate gyrus of the hippocampus and also in the neocortex 
(Perrais et al., 2010). In the hippocampus, GluK3 is involved in pre-synaptic functions 
including modulation of neurotransmitter release. GluK3 modulation of neurotransmitter 
release is thought to occur in combination with GluK4 (Fisher, 2014). Expression of 
GluK4 has been observed in the neocortex, Purkinje cells of the cerebellum, CA3 
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pyramidal neurons as well as in the dentate gyrus (Lerma and Marques, 2013) while 
GluK5 is widely expressed in several parts of the brain. The heteromeric combination of 
GluK2 and GluK5 is thought to be the most common KAR unit in the brain (Perrais et 
al., 2010; Fisher, 2015).  
The diverse localisation and expression of the various KAR subunits in the CNS may be 
indicative of specific and distinct roles that each subunit or subunit combination play. 
These may also explain the diversity of KAR signalling in the CNS. 
 
1.5.5. Pharmacology of KARs 
Studies into the properties and functions of KARs have not seen much progress compared 
to the other iGluRs. This is due in part to lack of appropriate and specific pharmacological 
tools for KAR subunits (Jane et al., 2009). The use of pharmacological tools represents 
an important area in the study of structural and functional diversity of KAR subunits. In 
addition to glutamate and kainate, several agonists and antagonists of KARs have been 
discovered or synthesised over the years.  
The activities of some of the important KAR agonists and antagonists are is shown in 
Table 1.2 and Table 1.3 respectively.  
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Agonist 
 
 
GluK1 
 
 
GluK2 
 
 
        GluK3 
 
 
GluK1/ GluK2 
 
 
GluK1/ GluK5 
 
 
GluK2/ GluK5 
Glutamate 47 9 5900 48 19 8 
Kainate 4.9 1.1 - 7.4 1.5 0.6 
Domoate 0.36 0.07 - 0.19 0.05 0.12 
ATPA 0.33 NE - 0.8 0.38 106 
SYM2081 0.18 0.29 - 0.38 0.06 0.34 
LY339434 2.5 >100 - - - - 
Dysiherbaine 0.0005 0.0013 - - - - 
5-Iodowillardiine 0.21 1000 300 0.47 0.06 30 
Table 1.2. KAR agonist activity (EC50 in µM) on recombinant subunit receptors. -: not known or determined; NE: no effect. EC50 refers to the 
molar concentration of an agonist the results in 50% of the maximum response or effect of the drug. The table is based on data from: Matute, 2011; 
Jane et al., 2009; Pinheiro et al., 2013; Artinian et al., 2011; Fisher and Mott, 2011; Peret et al., 2014; Traynelis et al. 2010. 
 
 
 
 
 
Agonist 
 
 
GluK1 
 
 
GluK2 
 
 
GluK3 
 
 
GluK1/ 
GluK2 
 
 
GluK1/ 
GluK5 
 
 
GluK2/ 
GluK5 
 
 
Native KARs 
Glutamate Very potent Very potent Potent Potent Very potent Very potent Very potent 
Kainate Potent Potent Potent Potent Potent Potent Potent 
Domoate Potent Potent - - - - Potent 
ATPA Less potent Weak - - - - Less potent 
SYM2081 Potent Potent Very potent - - - Potent 
LY339434 Weak - - - - - - 
Dysiherbaine Potent Potent - - Weak - - 
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Antagonist 
 
GluK1 
 
GluK2 
 
GluK3 
 
GluK1/ GluK2 
 
GluK1/ GluK5 
 
GluK2/ GluK5 
 
UBP310 0.010 NE 0.023 - 0.008 NE  
Kynurenate 415 391 - 482 621 NE  
CNQX 8 18 - 4 10 72  
NBQX 25 21 18 19 26 87  
UBP296 0.6 NE 374 0.8 1.0 NE  
LY382884 2 NE NE 4 4 NE  
LY377770 0.2 NE - 0.4 1.0 NE  
NS102 6 1.4 - - - -  
NS3763 1.6 NE - NE NE NE  
Table 1.3. KAR antagonists and their dissociation constant (in µM) on recombinant subunit receptors. -: not known or determined; 
NE: no effect; Kd: dissociation constant. Dissociation constant is the molar concentration of the drug which occupies 50% of the receptors at 
equilibrium. The table is based on data from: Matute, 2011; Jane et al., 2009; Pinheiro et al., 2013; Artinian et al., 2011; Fisher and Mott, 
2011; Peret et al., 2014; Traynelis et al. 2010. 
 
 
 
 
Agonist 
 
 
GluK1 
 
 
GluK2 
 
 
GluK3 
 
 
GluK1/ 
GluK2 
 
 
GluK1/ 
GluK5 
 
 
GluK2/ 
GluK5 
 
 
Native KARs 
Glutamate Very potent Very potent Potent Potent Very potent Very potent Very potent 
Kainate Potent Potent Potent Potent Potent Potent Potent 
Domoate Potent Potent - - - - Potent 
ATPA Less potent Weak - - - - Less potent 
SYM2081 Potent Potent Very potent - - - Potent 
LY339434 Weak - - - - - - 
Dysiherbaine Potent Potent - - Weak - - 
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1.5.6. KAR-interacting proteins  
Studies have shown that properties of KARs including agonist binding, molecular 
scaffolding, receptor trafficking, surface expression and localisation of KARs depend on 
interaction between KARs and some proteins (Zhang et al., 2014; Fisher, 2015). Though 
this is a relatively new area in terms of KAR research, the identification of these 
interacting proteins have contributed considerably to the understanding of KAR 
physiology as well as provided insights into the differences between native and 
recombinant KARs. Among the interacting proteins of KAR subunits include PDZ motif-
containing proteins (PSD-95, PICK1, GRIP, synthetin, SAP-97, SAP-102), cytoskeleton 
proteins (cadherins, β-catenin, Velis), BTB/Kelch proteins (actinfilin), 
calcium/calmodulin-dependent serine protein kinases (CASK), phosphatases 
(calcineurin), CUB proteins (Neto 1, Neto 2) and other proteins (calmodulin, contactin, 
SNAP25) (Pahl et al., 2014; Fisher, 2015). The key KAR-interacting proteins are 
summarised in Table 1.5. 
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Interacting protein 
 
Interacting 
domain 
 
 Interacting KAR subunit 
 
Role 
 
References 
 
Neto 1 
 
CUB2, RKK 
 
GluK1/Gluk2/GluK3/GluK5 
 
Trafficking, gating, rectification 
Sheng et al., 2015; Fisher, 2015; 
Howe, 2015 
 
Neto 2 
 
CUB2, RKK 
 
GluK1/Gluk2/GluK3/GluK5 
 
Trafficking, ion channel function 
Sheng et al., 2015; Fisher, 2015; 
Howe, 2015; Rutkowska-Wlodarczyk 
et al., 2015 
 
SNAP-25 
 
- 
 
GluK5 
 
Trafficking 
 
Pahl et al., 2014 
 
PSD95 
 
PDZ1, SH3 
 
GluK1/GluK2/GluK5 
 
Clustering, desensitisation 
 
Pahl et al., 2014 
 
PICK1 
 
PDZ 
 
GluK1/GluK2/GluK5 
 
Trafficking 
 
Pahl et al., 2014 
 
Cadherin 
 
- 
 
GluK2 
 
Localisation, trafficking 
 
Lerma and Marques, 2013 
 
Parkin 
 
- 
 
GluK2 
 
Gating 
 
Maraschi et al., 2014 
 
GRIP 
 
PDZ4, PDZ5 
 
GluK1/GluK2 
 
Trafficking 
 
Pahl et al., 2014 
 
4.1N 
 
- 
 
GluK1/GluK2 
 
Trafficking 
 
Lerma and Marques, 2013 
Table 1.4. KAR-interacting and auxiliary proteins. 
 
 
 
 
Agonist 
 
 
GluK1 
 
 
GluK2 
 
 
GluK3 
 
 
GluK1/ 
GluK2 
 
 
GluK1/ 
GluK5 
 
 
GluK2/ 
GluK5 
 
 
Native 
KARs 
Glutamate Very potent Very potent Potent Potent Very potent Very potent Very potent 
Kainate Potent Potent Potent Potent Potent Potent Potent 
Domoate Potent Potent - - - - Potent 
ATPA Less potent Weak - - - - Less potent 
SYM2081 Potent Potent Very potent - - - Potent 
LY339434 Weak - - - - - - 
Dysiherbaine Potent Potent - - Weak - - 
5-
Iodowillardiine 
Potent - - - - Weak Potent 
 Table 2.1. KAR agonists and their activity on recombinant subunits and native receptors. -: not known or determined; very potent: Kd <1.0 µM; potent: 
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1.5.6a. PDZ motif-containing interacting proteins of KARs 
Through transient interactions with KAR subunits, some PDZ domain-containing 
proteins regulate and promote several functions and properties of KARs. Binding PSD-
95 and SAP-102 to the C-terminal of GluK2 enhances the recovery of GluK2 homomeric 
and GluK2/GluK5 heteromeric assembly from desensitisation and also promotes the 
clustering of KARs (Suzuki and Kamiya, 2015; Pahl et al., 2014). Also, SAP-97 protein 
interacts with GluK2 to promote KAR clustering. Promotion of KAR clustering is also 
observed when SAP-102 interacts with GluK2/GluK5 heteromeric assembly (Lerma and 
Marques, 2013; Pahl et al., 2014). Another PDZ domain-containing protein, PICK1 
interacts with GluK1 and GluK2 subunits to promote KAR membrane anchoring and 
trafficking (Rutkowska-Wlodarczyk et al., 2015; Pahl et al., 2014).  
 
1.5.6b. Cytoskeleton interacting proteins of KARs 
Cytoskeleton interacting proteins include cadherins, β-catenin and catenin. They have 
been shown to interact with GluK2 to enhance localisation and stability of KARs at 
synaptic junctions. The 4.1N scaffolding proteins interact with GluK2 and GluK1 to 
promote stability, receptor trafficking as well as endocytosis of KARs (Rutkowska-
Wlodarczyk et al., 2015; Copits and Swanson, 2013). Also, interaction between profilin 
II and GluK2 has been observed to promote KAR trafficking (Mondin et al., 2010). 
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1.5.6c. CUB domain-mediated interactions with KARs 
Recently, Neto 1 and Neto 2 proteins have been identified as auxiliary or accessory 
proteins of KAR subunits. This is because Neto 1 and Neto 2 fulfil the four criteria for 
classification of iGluR auxiliary proteins (Fisher, 2015). First, Neto 1 and Neto 2 do not 
constitute an integral part of the structure or pathway of KARs. Second, Neto 1 and Neto 
2 have a stable interaction with KARs for most or the entire duration subsequent to the 
receptor’s assembly in the ER. The third criteria is that Neo 1 and Neto 2 significantly 
modulate or influence several components of KAR pharmacology, trafficking and 
channel properties. Fourth, co-assembly of the KARs with Neto 1 or Neto 2 is thought to 
be required for effective function of the receptors in vivo (Copits and Swanson, 2012; 
Yan and Tomita, 2012; Molnar et al., 2013). These underscore the significance of these 
transmembrane proteins for effective function of post-synaptic KAR subunits in 
particular.  
Structurally, Neto proteins carry two extracellularly-located CUB domains (Complement 
C1r/C1s, Uegf, Bmp1) followed by an extracellular juxtamembrane LDLa (low-
lipoprotein receptor class A) and an intracellular C-terminal domain (Griffith and 
Swanson, 2015). Studies suggest that regulation of KAR subunit function by Neto 1 and 
Neto 2 proteins is via mediation of the LDLa domain while interactions between KARs 
and Neto 1 and Neto 2 proteins are modulated primarily through the second CUB domain 
(Fisher, 2015; Pahl et al., 2014). However, other Neto 1- or Neto 2-induced effects on 
KARs including rectification characteristics are not thought to be mediated by CUB or 
LDLa domains but instead by three positively charged RKK residues in the 
transmembrane domains of Neto 1 and Neto 2 (Fisher and Mott, 2013). While Neto 1 has 
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a class I PDZ domain, Neto 2 has a class II PDZ ligand at their respective C-terminals 
(Pahl et al., 2014).  
In the CNS, Neto 1 is expressed predominantly in the CA3 region of the hippocampus 
while Neto 2 is abundantly expressed in the cerebellar granule cells and cortical neurons 
of the brain (Fisher, 2015; Tomita and Castillo, 2012). These proteins have also been 
shown to be expressed in the retina of rodents (Pahl et al., 2014).  
Neto 1 and Neto 2 subunits were initially thought to be auxiliary proteins of NMDAR 
subunits in the CNS (Ng et al., 2009) but recent observations do not support this 
suggestion (Molnar et al., 2013). However, accumulating evidence points to a strong 
interaction between these proteins and KARs that leads to significant modulation of 
function of these receptors.  
Studies have suggested an important role for Neto 1 and Neto 2 in regulation of KAR 
surface expression. In hippocampal neurons, co-expression of Neto 2 and GluK1 
enhances the surface expression and synaptic co-localisation of the latter (Sheng et al., 
2015; Copits et al., 2011). Moreover, in the PSD of cerebellum from Neto 2 knockout 
mice, there is reduced expression of GluK2. In other studies, expression of Neto 2 in the 
plasma membrane was enhanced by co-expression or interaction with GluK2 in oocytes 
of Xenopus which is also supported by significantly reduced expression of Neto 2 in the 
plasma membrane of cerebella from GluK2 knockout mice (Sheng et al., 2015; Zhang et 
al., 2009). The effect of Neto 2 on KAR subunit expression is further supported by 
evidence that Neto 2 promotes stabilisation of GluK2 at the synapse by promoting 
interaction of GluK2 with the scaffolding protein, GRIP (Rutkowska-Wlodarczyk et al., 
2015; Tang et al., 2012).  
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The effect of Neto 1 on surface expression of KAR subunits has also been reported. Neto 
1 knockout mice have been shown to have significantly reduced expression of GluK2 and 
GluK5 in the PSD of hippocampal neurons. However, the overall expression of GluK2 
and GluK5 in the hippocampus remained unchanged (Sheng et al., 2015; Tang et al., 
2012). GluK2/GluK3 in mossy-fiber-CA3 of the hippocampus has also been shown to be 
significantly decreased in Neto 1 knockout mice (Wyeth et al., 2014) though other studies 
reported of no change in expression of GluK2/GluK3 or GluK5 in Neto 1 knockout mice 
(Sheng et al., 2015; Straub et al., 2011a). The effect of Neto 1 and Neto 2 on KAR subunit 
expression may however not be entirely due to the interactions between KARs and Neto 
proteins. Possible factors leading to this reduced expression may include the genetic 
profile or background of the knockout mice.  
Furthermore, interactions between KAR subunits and Neto 1 or Neto 2 proteins result in 
significant changes in gating pharmacology of KARs. When Neto 1 and Neto 2 are co-
expressed with recombinant KAR subunits (GluK1, GluK2 and GluK2/GluK5) receptors, 
these receptors undergo significant changes in how they recover from desensitisation and 
their rates of deactivation (Fisher, 2015). These observations may however, be dependent 
on the type of Neto subunit. Co-expression of Neto 2 with GluK1 or GluK2 homomers 
slows onset of desensitisation and subsequent recovery of these subunits from 
desensitisation (Griffith and Swanson, 2015; Straub et al., 2011b; Zhang et al., 2009). In 
contrast, co-expression of KAR subunits (GluK1, GluK2 and GluK2/GluK5) with Neto 
1 accelerates the onset of desensitisation and subsequent recovery from desensitisation of 
these KAR subunits (Copits et al., 2011; Fisher and Mott, 2013; Howe, 2015).  
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Also, interactions between Neto proteins and KARs leads to enhanced affinity of KARs 
for glutamate and kainate. Silencing of Neto 1 and Neto 2 in the hippocampus does not 
terminate the excitatory post-synaptic current (EPSC) of kainate but reduces the affinity 
of CA3 neurons for kainate (Howe, 2015; Tang et al., 2011). This observation is 
supported by recent report that GluK1 forms functional homomeric channels whose 
sensitivity to glutamate increases in the presence of Neto 1 and Neto 2 in transiently-
transfected HEK293T cells (Fisher, 2015). Moreover, in Neto 1 knockout mice, there is 
alteration in synaptic KAR output characterised by fast mossy fiber EPSCKA decay 
kinetics (Straub et al., 2011a; Tang et al., 2011). This was observed only in post-synaptic 
but not in pre-synaptic KARs and was not present in Neto 2 knockout mice (Straub et al., 
2011b; Tang et al., 2011).  
Taken together, the roles of Neto 1 and Neto 2 proteins in expression, physiology and 
diversity of native KAR subunits cannot be understated and could become potential drug 
targets for certain conditions in which KARs are implicated. However, several questions 
remain unanswered about interactions of Neto 1 and Neto 2 proteins with KAR subunits. 
First, the mechanism by which kainate synaptic responses are kept at a minimal compared 
to the responses of AMPAR and NMDAR even though Neto 1 and Neto 2 enhance the 
affinity of KARs for kainate/glutamate remain unexplored. Secondly, the structural basis 
on which Neto proteins and KARs interact remains unclear while the role of Neto proteins 
in metabotropic signalling of KARs also remain unknown. The number of Neto subunits 
which are required in formation of a single receptor complex is unclear.  
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1.5.7. Metabotropic signalling of KARs 
KARs represent a unique subtype of iGluRs because some functions of KARs in the CNS 
have can be mediated through an unconventional non-canonical (metabotropic) signalling 
involving G-proteins and second messengers. This metabotropic signalling of KARs is 
particularly involved in the regulation of neurotransmitter release from pre-synaptic 
neurons (Gonzalez-Gonzalez and Henley, 2013; Crepel and Mulle, 2015). At the post-
synaptic terminal, mechanisms such as recycling and surface expression of KARs as well 
as modulation of neuronal excitability have been shown to involve metabotropic 
signalling (Crepel and Mulle, 2015). Co-localisation of KAR subunits (GluK4 and 
GluK5) with group I mGluR subunits has been reported in rat hippocampus and in 
cultured rat cortex (Rojas et al., 2013). In these tissues, activation of group I mGluRs 
enhanced KAR-induced calcium signals. The potentiation of KARs by group I mGluRs 
was observed only in heteromeric GluK2/GluK5 or GluK2/GluK4 subunit assembly but 
not in homomeric receptor combinations. The group I mGluR-potentiation of KARs was 
observed to involve PKC and calcium ion mobilisation (Rojas et al., 2013). Other studies 
have shown that KAR subunits and some mGluR subtypes exhibit interchangeable roles 
under certain circumstances. For instance, both KARs (GluK1) and mGluRs (mGluR1 
and mGluR5) are able to induce mossy fiber LTP in rat hippocampus and this role is 
interchangeable since activation of one of these receptors alone was sufficient to induce 
mossy fiber LTP in vivo (Wallis et al., 2015). Studies suggest that the most dominant 
KAR subunits which interact with G-proteins to induce non-canonical signalling are 
GluK1 and GluK5 (Salmen et al., 2012; Rutkowska-Wlodarczyk et al., 2015).  
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Moreover, G0 is thought to be the dominant G-protein that mediates the metabotropic 
effects of KAR subunits (Lerma and Marques, 2013; Rutkowska-Wlodarczyk et al., 
2015) although Gi has also been shown to play important roles in this signalling especially 
in KAR-induced inhibition of adenylate cyclase and cAMP reduction (Gelsomino et al., 
2013).  
However, due to the consensus that KARs do not possess conventional motifs in their C-
terminals, it is considerably unlikely that this metabotropic signalling of KARs occur 
through the direct coupling of the receptors to G-proteins (Contractor et al., 2011). This 
raises the possibility that some auxiliary proteins of KARs may be involved in the KAR-
G-protein signalling complex. A recent study using proteomic analysis has shown that 
already-established KAR-interacting proteins including β-catenin, synapsin II, Gα0, 
Rab3a, BASP1 interact with GluK1 in its metabotropic signalling action (Rutkowska-
Wlodarczyk et al., 2015). An overview of the putative effects of mGluRs and non-
canonical signalling on KAR function is shown in Figure 1.9. 
In spite of ongoing research into non-canonical signalling of KARs and the influence of 
metabotropic receptors on potentiation of KAR subunit function, several questions 
remain unanswered. The molecular mechanisms involved in activation of G-proteins by 
KARs as well as what determines the mode (conventional ionotropic versus 
metabotropic) of KARs at any point remain unclear. These issues however, has not 
overshadowed the unique signalling characteristics of KARs and the potential of KARs 
as an important target for development of therapies directed at both iGluRs and mGluRs 
signalling mechanisms.  
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Figure 1.9. Summary of the metabotropic effects of KARs in CNS function: At pre-synaptic terminals. KARs modulate the release of both GABA and 
glutamate in a bidirectional manner using metabotropic signalling which leads to modulation of synaptic activity and subsequently modulation of network 
activities. The regulation of neurotransmitter release by pre-synaptic KARs may also be in part to the inhibition of voltage-gated Ca2+ channels. This KAR-
induced inhibition of Ca2+ channels is via interaction of KARs with G-proteins and PKC. Using metabotropic mechanism, post-synaptic KARs induce inhibition 
of slow after-hyperpolarization currents (sAHP) which subsequently regulates neuronal excitability. Adapted from Crepe and Mulle, 2015; Wallis et al., 2015; 
Rodrigues and Lerma, 2012. 
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1.6. Roles of KARs in the CNS 
KARs have been linked to several roles in the CNS many of which are dependent on their 
distribution/expression as well as subunit combinations. Among the major roles of KARs 
in the CNS include modulation of synaptic transmission and network excitability, brain 
development and synaptic plasticity. Most of the functions of KARs have become evident 
due to the recent development of several selective pharmacological tools for KARs as 
well as the generation of KAR-knockout rodents. The functions of KARs in the CNS can 
be grouped into two main part; pre-synaptic functions and post-synaptic functions. 
 
1.6.1. Pre-synaptic roles of KARs 
Accumulating evidences support a pre-synaptic role of KARs in the CNS. An early study 
into this hypothesis indicated that activation of KARs by pharmacological agonists 
resulted in enhanced modulation of glutamate release from the synaptosomes via a Ca2+-
dependent mechanism (Chittajallu et al., 1996). Currently, it is thought that KARs 
modulate release of glutamate and GABA at excitatory and inhibitory synapses 
respectively (Lerma and Marques, 2013). As discussed previously, GluK2 subunits co-
assemble with GluK3 at the pre-synaptic neurons to regulate neurotransmitter release 
(Fisher, 2014). Though it was initially thought that pre-synaptic KARs were involved in 
depressing neurotransmitter release, emerging reports point to a biphasic modulatory 
effect at some of the glutamatergic synapses. At these synapses, low concentrations of 
kainate was observed to result in significant increase in KAR-induced release of 
glutamate whereas a high concentration of kainate resulted in depressed glutamate release 
(Lyon et al., 2011). The mechanism behind this biphasic mechanism of neurotransmitter 
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release at the glutamatergic synapse remains largely unexplored. The biphasic mechanism 
is thought to be occur only when KARs are activated by exogenous agonist since 
activation of KARs by endogenous glutamate almost always leads to facilitation of 
neurotransmitter release (Contractor et al., 2011). Recent studies have linked KAR-
induced modulation of glutamate release from the synaptosome of rats to the 
intrasynaptosomal Ca2+ stores as well as to the activation/inhibition of calmodulin (Sihra 
and Rodriguez-Moreno, 2013; Andrade-Talavera et al., 2012) indicating a conventional 
ionotropic mechanism for this modulation. KAR-induced depression of glutamate release 
from pre-synaptic neurons has however been linked to a non-canonical (metabotropic) 
mechanism by KARs. This observation is supported by studies which have shown that 
KAR-induced depression of glutamate release is negatively affected by application of 
pertussis toxin (PTX); a potent inhibitor of Gi/0 (Sihra and Rodriguez-Moreno, 2013; 
Negrete-Diaz et al., 2006). 
In the context of GABA release by KARs, earlier studies suggested that activation of 
KARs at the GABAergic synapses resulted in reduced GABA release (Rodriguez-Moreno 
et al., 1997). This has been supported by current studies which have shown that activation 
of GluK1-containing KARs results in depressed release of GABA from the hippocampus 
(Bonfardin et al., 2010; Caiati et al., 2011). These inhibitory effects on GABA release by 
KARs is thought to be via a G-protein-dependent mechanism (Lerma and Marques, 
2013).  
In summary, KAR subunits are present on pre-synaptic terminals where they play an 
important role in regulating release of inhibitory and excitatory neurotransmitters into the 
synaptic cleft for subsequent binding and downstream signalling. In addition to 
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modulation of neurotransmitter release, KAR subunits at the presynapse have been shown 
to contribute to the development and maintenance of synaptic connectivity and 
maturation. GluK1 remains the most significant subunit involved in development of the 
brain (Lerma and Marques, 2013). 
1.6.2. Post-synaptic roles of KARs 
At post-synaptic terminals, activation of KARs by glutamate have been observed to 
mediate excitatory neurotransmission and synaptic plasticity (Sihra et al., 2013). Studies 
have shown that activation of post-synaptic KARs by glutamate results in small-
amplitude EPSCs characterised by slow activation and deactivation compared to the 
currents induced AMPAR activation (Lerma and Marques, 2013). These EPSCs, unlike 
those of AMPARs and NMDARs are localised only to a select subset of neurons (Lerma 
and Marques, 2013). This characteristically slow kinetics of post-synaptic KARs are 
thought to enhance the capabilities of information transfer integration of KARs; a 
mechanism which is not significant in other iGluRs (Pinheiro et al., 2013). In terms of 
subunit composition, GluK2, GluK4 and GluK5 constitute the majority of post-synaptic 
KARs at mossy fiber to CA3 pyramidal cell synapses (Fernandes et al., 2009). These 
postsynaptic KAR subunits are also involved in regulation of slow Ca2+ and K+ currents.  
The varied roles of KAR subunits contribute to the balance that exist between excitation 
and inhibition of neuronal networks with subsequent effects on cognition as well as 
contributing to established forms of short and long-term plasticity. 
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1.7. Putative roles of KARs in CNS-related diseases 
Kainate is a potent neurotoxin and a neural excitant which when injected into the brain of 
rodents elicit persistent convulsion and neurotoxicity that mimic the classical 
symptomatic episodes of temporal lobe epilepsy (TLE) in human (Vincent and Mulle, 
2009). In addition to inducing seizures, injection of kainate leads to neurodegeneration 
(Vincent and Mulle, 2009). In the CNS, neurodegeneration is considered to be one of the 
important pathogenic mechanisms underlying acute and chronic neurodegenerative 
conditions such as TLE, Alzheimer’s disease, Parkinson’s disease and Huntington’s 
disease (Mohd Sairazi et al., 2015). The major mechanism underlying neurodegeneration 
is excitotoxicity; a consequence of prolonged excitation or activation of excitatory GluRs. 
Excitotoxicity-induced death of neuronal cells is thought to be mediated mainly through 
increased influx of Ca2+ with subsequent programmed-cell death and apoptosis (Mohd 
Sairazi et al., 2015).  
Seizures induced in rodents after injection of kainate results mainly from over-activation 
of KARs by kainate though few studies have implicated endogenous glutamate in 
induction of epileptic seizures (Crepel and Mulle, 2015; Matute, 2011). Due to the potent 
neurotoxic and excitatory action of glutamate and its analogues including kainate, KARs 
have been linked to pathogenesis of several neurological conditions including epilepsy, 
mood disorders, mental retardation, chronic pain, migraine, autism and Huntington’s.  
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1.7.1. Putative roles of KARs in epilepsy 
Epilepsy refers to the neurological disorder that involves prolonged and synchronised 
neuronal discharges leading to occurrence of spontaneous or chronic seizures (Crepel and 
Mulle, 2015). Several studies support a probable role of KARs in the pathogenesis of 
epilepsy. The most significant of these putative roles involve the contribution of KARs 
to the excitatory/inhibitory imbalances; the classical feature of epilepsy (Lerma and 
Marques, 2013). Intra-amygdaloid administration of kainate into adult rats have been 
shown to result in persistent seizures and neuronal damage that mimics details of human 
TLE (Crepel, 2013). The most cited KAR subunits in epilepsy studies are GluK1 and 
GluK2. Studies have suggested that GluK2 is highly expressed in hippocampal CA3; a 
region of the brain that is highly excitable and strongly linked to TLE (Crepel and Mulle, 
2015; Matute, 2011). Also, knockout of GluK2 in mice results in reduced vulnerability 
of these mice to kainate-induced seizures (Peret et al., 2014; Crepel, 2013). In addition, 
in both in vitro and in vivo models of TLE, GluK2/GluK5 receptor antagonist UBP310 
significantly reduced seizure-like activities induced by kainate (Peret et al., 2014) which 
suggests a role for GluK2/GluK5 heteromeric combination in generating recurrent 
seizures in chronic epilepsy and also provides evidence that activation of KARs by 
endogenous agonists plays a role in eliciting epileptic seizures. However, injection of 
considerably high concentrations of kainate into GluK2 knockout mice induced the same 
epileptic characteristics observed in wild type mice (Matute, 2011) which confirms the 
possible role of other KAR subunits in development of kainate-induced epileptic seizures. 
Moreover, high kainate concentration can also activate other iGluRs implicated in 
generation of epileptic seizures including AMPARs. 
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Furthermore, inhibition of GluK1 has been shown to prevent epileptic activities in certain 
areas of the hippocampus (Crepel and Mulle, 2015; Smolders et al., 2002) and one of the 
most successful anti-epileptic medications in clinical use; topiramate appears to exert its 
anti-epileptic actions in part through inhibition of GluK1 (Fritsch et al., 2014; Jane et al., 
2009). Use of tissues from human TLE patients has shown that there is significant 
upregulation of GluK1 expression in the hippocampus (Li et al., 2010) which may be 
indicative of a role for KARs in rearrangement of neural circuits in these patients (Lerma 
and Marques, 2013).  
Other KAR subunits have also been linked to epilepsy. For instance, in addition to GluK1 
and GluK2, expression of GluK4 and GluK5 was significantly upregulated in 
hippocampal astrocytes of rats after induction of status epilepticus (Vargas et al., 2013).  
Altogether, there is accumulating evidence to suggest a significant role for KAR subunits 
in pathogenesis of epilepsy. 
 
1.7.2. Putative roles of KARs in psychiatric disorders 
KARs have been linked to the pathogenesis of several psychiatric conditions including 
schizophrenia, autism, major depression, bipolar disease and obsessive-compulsive 
disorder (OCD). In patients suffering from schizophrenia, there is decreased in expression 
of GluK1, GluK2 and GluK3 subunits in the orbitofrontal cortex (Garey et al., 2006) 
whiles several polymorphic variants of GluK2 have been reported in patients suffering 
from autism, OCD and schizophrenia (Bowie, 2008). Also, genetic variants of GluK3 
have been observed to be present in patients suffering from major depression, bipolar 
disorder and schizophrenia (Matute, 2011). However, there was no evidence of change in 
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quantitative expression of KAR subunit mRNA or protein in brain samples of patients 
diagnosed with schizophrenia (Matute, 2011). A single nucleotide polymorphism in the 
Grik4 gene is thought to give protection from bipolar disorders (Sklar et al., 2011) while 
Grik4 knockout mice develop schizophrenia and learning deficits (Lowry et al., 2013). 
These contrasting observations indicate different roles and mechanisms for KAR subunits 
in psychiatric disorders. Also, Grik2 and Grik4 genes have been implicated in the 
pathogenesis of autism. Mice with significantly high expression of Grik4 in the brain 
displayed symptoms and behaviours consistent with autism spectrum disorders (Aller et 
al., 2015; Freitag, 2007).  
Though this is still an active area of research, there are significant evidences to suggest 
putative roles for KAR subunits in psychiatric disorders. 
 
1.7.3. Putative roles of KARs in mental retardation 
A single sequence change in the Grik2 gene has been linked to cognitive impairment and 
mental retardation arising from defective glutamatergic signalling (Lerma and Maques, 
2013). This observation is corroborated by a report that GluK2-deficient rodents display 
significant delay in maturation of important areas of the brain including hippocampus 
which is responsible for higher brain function (Lanore et al., 2012). This study however, 
did not report of the long-lasting effects of this delayed maturation in the animals hence 
it is debatable to relate delayed maturation of certain brain parts to cognitive impairment 
or mental retardation in adult life.  
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1.7.4. Putative roles of KARs in Huntington’s disease 
Prolonged activation of KARs leads to excitotoxicity which subsequently leads to 
neurodegeneration; one of the most noted mechanisms underlying Huntington’s (Mohd 
Sairazi et al., 2015). Though early studies suggested a link between age of onset of 
Huntington’s and polymorphisms in Grik2 (Rubinsztein et al., 1997), later studies 
involving larger sample of patients with Huntington’s did not observe such linkage (Lee 
et al., 2012). Moreover, 3-nitropropionic acid, a common drug used to induce 
Huntington-like symptoms in rodents did not induce these expected symptoms in GluK2 
knockout mice (Diguet et al., 2004). These studies therefore indicate an unlikely direct 
mechanism of KAR subunits in pathogenesis of Huntington’s. However, the probable 
contribution of KAR subunits might arise from excitotoxicity-induced neurodegeneration 
subsequent to prolonged activation of these receptors by endogenous glutamate. 
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1.8. GluRs as autoantibody targets in neurological diseases 
Subtypes of GluRs have been implicated as targets for autoantibodies in a number of 
autoimmune neurological conditions including Rasmussen’s encephalitis and epilepsy 
(Levite, 2014). Analysis of the levels and effects of autoantibodies in the CNS suggests 
that autoantibodies against GluRs represent the commonest, most potent and most 
dangerous type of autoantibodies involved in pathological processes in the CNS (Levite, 
2014). The most commonly identified GluR subtype that serve as antigen targets for 
autoantibodies are AMPARs and NMDARs whiles few studies also suggest mGluRs as 
autoantigens. 
 
1.8.1. AMPARs as antigen targets in autoimmune CNS disorders 
Autoantibodies to AMPARs have been linked to Rasmussen’s encephalitis, anti-
AMPAR-encephalitis and some focal epilepsies (Gleichman et al., 2014; Levite, 2014; 
Hoftberger et al., 2015). All these conditions present with varying degrees of seizures and 
the importance of AMPARs as autoantigens in these conditions is supported by the 
observation that almost 30% of all patients suffering from epilepsy have autoantibodies 
against GluA3 AMPAR subunit in their sera or CSF (Hoftberger et al., 2015). 
Rasmussen’s encephalitis is a rare childhood inflammatory neurological disorder 
characterised by mild dementia or cognitive decline, frequent severe drug-resistant 
seizures, hemiparesis and encephalitis (Nibber et al., 2016). There is no conclusive detail 
on the aetiology of Rasmussen’s encephalitis but previous and emerging evidences point 
to the role of autoantibodies to GluA3B and GluA2 in pathogenesis of the conditions 
(Nibber et al., 2016). Though autoantibodies to these AMPARs are not present in all 
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Rasmussen’s encephalitis patients, there is a temporary or long-lasting improvement in 
symptoms subsequent to plasma exchange or removal of GluA3B antibodies from serum 
of Rasmussen’s encephalitis patients (Varadkar et al., 2014; Golberg-Stern et al., 2014). 
These antibodies are however not restricted or specific for Rasmussen’s encephalitis since 
they are also present in other forms of epilepsy (Levite, 2014) and sera from GluA3B- or 
GluA2-positive Rasmussen’s encephalitis patients did not recognise singly-GluA2- or 
GluA3-transfected HEK293 cells (Nibber et al., 2016).  
Quite recently, analysis of sera and CSF of ten patients with limbic encephalitis revealed 
that these patients had autoantibodies against GluA1 and GluA2 subunits (Lai et al., 2009; 
Hoftberger et al., 2015). Limbic encephalitis is an autoimmune inflammatory condition 
characterised by seizures, emotional and behavioural disturbances as well as defects in 
short-term memory (Fauser et al., 2015; Lai et al., 2009). Application of purified IgG 
from anti-GluA1- and GluA2-positive LE patients to cultured hippocampal neuronal cells 
showed a dose-dependent decrease in amplitude and frequency of mEPSCAMPAR 
(Gleichman et al., 2014) implying a role of these autoantibodies is alterations or 
disruption in AMPAR signalling in the CNS.  
 
1.8.2. NMDARs as antigen targets in autoimmune CNS disorders  
Anti-NMDARs have been linked to autoimmune conditions such as systemic lupus 
erythematosus (SLE) and anti-NMDAR encephalitis. The effect these antibodies on 
survival and function of neurons in these conditions have also been reported (Levite, 
2014). 
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Anti-NMDAR encephalitis is a very severe but treatable disorder with about 4% mortality 
rate and was first described in 2007 in patients with ovarian teratomas. It is characterised 
by memory deficits, seizures, reduced consciousness, hypoventilation and psychiatric 
symptoms (Dalmau et al., 2007; Dalmau et al., 2011; Barry et al., 2015). Detection of 
GluN1 antibodies in serum or CSF correlates with severity and prognosis of the condition 
and also represents the gold-standard diagnostic feature (Dalmau et al., 2007; Dalmau et 
al., 2011). Moreover, there is significant intrathecal synthesis of anti-GluN1 antibodies 
in patients and there has not been a single case of the condition in which antibodies were 
present in serum but not in CSF (Pillai et al., 2015; Varma and Sapra, 2015). These 
observations indicate that there is a very potent, active and ongoing immune process 
against GluN1 subunits in anti-NMDAR encephalitis.  
Furthermore, autoantibodies to GluN2A and GluN2B have been detected in serum and 
CSF of about 30% of patients suffering from SLE and the antibody titre correlates 
positively with cognitive and psychiatric impairments associated with the disease (Levite, 
2014). Injection of these autoantibodies into mice have been shown to activate NMDARs 
and cause excitotoxicity-mediated death of hippocampal neurons (Lauvsnes et al., 2013).  
 
1.8.3. mGluRs as antigen targets in autoimmune CNS disorders 
Autoantibodies against mGluR1 have been detected in serum and CSF of patients with 
paraneoplastic cerebellar ataxia (PCA), an autoimmune condition associated with 
ovarian, lung and breast cancers and Hodgkin’s Lymphoma. Some of the patients showed 
intrathecal synthesis of anti-mGluR1 (Levite, 2014). Moreover, purified antibodies from 
CSF and serum of PCA patients have been shown to bind strongly and impair basal 
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actions of Purkinje cells in brain slices and cultured mouse Purkinje cells of both human 
and mice (Levite, 2014). Autoantibodies against mGluR5 have been detected in CSF and 
serum of some individuals suffering from Hodgkin’s lymphoma-associated limbic 
encephalitis (Ophelia syndrome). Sera from these patients were observed to bind and react 
with isolated hippocampal rat neurons in vitro (Mat et al., 2013; Levite, 2014). 
Taken together, some GluR subtypes serve as important autoantigen targets in a 
considerable number of autoimmune neurological conditions and some receptor subunits 
have been targeted in treatment and management of these conditions. 
Up to date, there has not been any studies suggesting KARs as potential antigen targets 
in autoimmune neurological conditions.  
A summary of some of the common autoimmune neurological disorders in which GluRs 
have been suggested as antigen targets is shown in Table 1.5. 
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Neurological disorder GluR subunit Sample  Methodology Immunotherapy response Reference 
Rasmussen’s encephalitis  GluA2, GluA3 Serum, CSF Radioimmunoassay 
Immunohistochemistry 
Yes Nibber et al., 2015    
Rogers et al., 1994 
Anti-AMPAR-encephalitis GluA1, GluA2 Serum, CSF Immunoblotting 
ELISA 
Yes, with frequent relapses Gleichman et al., 2014 
Lai et al., 2009 
anti-NMDA receptor 
encephalitis 
GluN1 Serum, CSF Immunohistochemistry 
Immunocytochemistry 
Yes Barry et al., 2015 
Dalmau et al., 2008 
Systemic lupus erythematosus  GluN2A, GluN2B Serum, CSF ELISA 
Immunofluorescence  
Yes Steup-Beekman et al., 2007 
Lauvsnes et al., 2014 
Paraneoplastic cerebellar 
ataxia 
mGluR1 Serum, CSF Immunohistochemistry 
 
Poor Smitt et al., 2000 
Marignier et al., 2010 
Ophelia syndrome mGluR5 Serum, CSF Immunohistochemistry 
Immunoprecipitation  
Unknown Mat et al., 2013  
Lancaster et al., 2011 
Table 1.5. Summary of autoimmune neurological disorders in which GluRs have been suggested as autoantibody targets including GluR targets, methods 
of antibody identification, response of patients to immunotherapies directed against the respective GluR subunit as well as the type of sample for 
investigation. 
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Native KARs 
Glutamate Very potent Very potent Potent Potent Very potent Very potent Very potent 
Kainate Potent Potent Potent Potent Potent Potent Potent 
Domoate Potent Potent - - - - Potent 
ATPA Less potent Weak - - - - Less potent 
SYM2081 Potent Potent Very potent - - - Potent 
LY339434 Weak - - - - - - 
Dysiherbaine Potent Potent - - Weak - - 
5-
Iodowillardiine 
Potent - - - - Weak Potent 
 Table 2.1. KAR agonists and their activity on recombinant subunits and native receptors. -: not known or determined; very potent: Kd <1.0 µM; potent: Kd 1.0-30 
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1.9. GluRs outside the CNS 
1.9.1. NMDARs, AMPARs and mGluRs in non-neuronal tissues 
Outside of the CNS, mRNAs and proteins of GluR subunits have been shown to be 
present in cells of the pancreas, skin, heart, adrenal gland, platelets and lymphocytes 
(Davalli et al., 2012). Several studies have proposed roles for GluRs in cells and tissues 
outside of the CNS. NMDARs have been shown to be present in several components of 
human renal system including glomeruli, podocytes, medulla and collecting ducts (Dryer, 
2015). In these cells, activation, dysfunction or polymorphisms in NMDARs have been 
linked to alterations in several components of renal function including proximal 
reabsorption and glomerular filtration (Anderson et al., 2011; Dryer, 2015). Within the 
circulatory system, mRNA and protein of GluRs including KARs (GluK1 and GluK2) 
(Sun et al., 2009), NMDARs (GluN1, GluN2A, GluN2D and GluN3A) (Kalev-Zylinska 
et al., 2014) and AMPARs (Morrell et al., 2008) are expressed in human platelets. 
Activation of these iGluRs induce platelet activation and aggregation while 
polymorphisms in KAR subunits are thought to be associated with altered human platelet 
functions including defective activation and aggregation (Sun et al., 2009). Cultured 
mouse macrophages express AMPARs and activation of these receptors plays an 
important role in inflammation via stimulation of release of tumour-necrosis factor 
(TNF)-α in macrophages as well as generation of reactive oxygen species (ROS) (Cheng 
et al., 2015). GluK4, GluN1 and mGluR2 subunits are expressed in human tendon tissues 
where they regulate the resolution of pain in several pathological conditions associated 
with the tendons including human rotator cuff tendinopathy (Dean et al., 2015). Also, 
group III mGluRs are expressed in the GIT of human (Julio-Pieper et al., 2013) and in 
  
 
 
Chapter One                                                                                            Thesis Introduction 74 
 
components of rat male reproductive (Marciniak et al., 2014). In human GIT, group III 
mGluRs are thought to be involved in regulation of intestinal motility, microbiota 
composition and intestinal fluid secretion (Julio-Pieper et al., 2013) whiles they are 
involved in erection, ejaculation mechanisms and formation /maturation of spermatozoa 
in rats (Marciniak et al., 2014).  Furthermore, GluA2, GluA3 and particularly mGluRs 
have been detected in human adrenocortical tissues and have been shown to significantly 
regulate synthesis of steroid hormones from cholesterol (Felizola et al., 2014). mGluRs 
within the taste buds have also been suggested to contribute to savoury or delicious taste 
(umami) (Choudhuri et al., 2015; Kurihara et al., 2015; Yasumatsu et al., 2015).  
 
1.9.2. KAR subunits outside the CNS 
Outside the CNS, not much is known about the expression and role of KARs. mRNAs 
and proteins of GluK2, GluK3, GluK4 and GluK5 have been shown to be present on 
primary B-cells where activation of these receptors increases proliferation and synthesis 
of IgG and IgE as well as enhances the promotion of IgE-mediated allergic lung 
inflammation (Sturgill et al., 2011). These actions have been shown to be mediated 
through KAR-induced increase in expression and activity of a cell surface protein called 
ADAM10 that cleaves the IgE receptor CD23 (Sturgill et al., 2011; Weskamp et al., 
2006).  
In cultured immature and mature calvarial osteoblasts of rats, GluK4 and GluK5 mRNA 
are expressed together with GluA1 (Hinoi et al., 2002) though the exact role or function 
of these KAR subunits were not reported.  
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A study using immunohistochemical techniques has shown expression of GluK5 in 
cartilage and synovial cells together with significantly high amounts of glutamate in 
human patients suffering from osteoarthritis and rheumatoid arthritis. In these patients, a 
single intra-articular injection of the KAR antagonist; NBQX significantly reduced 
inflammation, swelling, cartilage degradation and pain (Bonnet et al., 2015). These 
observations indicate a possible role of GluK5 in bone pathology and a potential for the 
use of KAR antagonists in management of complications associated with joint 
pathologies such as arthritis.  
Other non-neuronal tissues which have been reported to express some KAR subunits 
include adrenal gland where they stimulate release of cathecolamines (Gonzalez et al,. 
1998), pituitary gland where they facilitate secretion of growth hormones and 
gonadotropin (Niimi et al., 1994; Zanisi et al., 1994), pineal gland (Sato et al., 1993) and 
heart (Wang et al., 2007).  
 
1.9.3. GluRs in pancreatic endocrine cells 
Studies with rodent and human tissues have shown that both ionotropic and metabotropic 
GluRs are present in the endocrine pancreas and are able to modulate important functions 
in vitro and in vivo (Wu et al., 2012; Marquard et al., 2015; Gheni et al., 2014). Subunit 
mRNA and protein of kainate, AMPA, NMDA and mGlu receptors have been shown to 
be expressed in primary islets of Langerhans, cultured α-cells and β-cells, as well as in 
sorted β-cells and α-cells of human, rat and mouse. The expression of GluR subunits in 
pancreatic endocrine cells of mouse, rat and human are summarised in Table 1.6, 1.7, 1.8. 
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mRNA and protein of GluR subtypes and subunits 
 
Pancreatic endocrine cells 
 
GluN 
 
GluA 
 
   GluK 
 
mGluR 
 
MIN6 clonal β-cells  
 
mRNA: 1, 2C-D (Molnar et al., 1995; 
Gonoi et al., 1994) 
 
Protein: 1 (Molnar et al., 1995) 
 
1, 2, 3, 4 (Molnar et al., 1995; 
Gonoi et al., 1994; Wu et al., 
2012) 
2 (Wu et al., 2012) 
 
 
2, 4, 5 (Kutlu et al., 2009; 
Gonoi et al., 1994) 
 
5 (Molnar et al., 1995) 
 
 
2, 3, 5, 8 (Storto et al., 
2006; Brice et al., 2002) 
 
2, 3, 5 (Storto et al., 2006; 
Brice et al., 2002) 
 
Mouse α-cells 
 
mRNA: 1, 2A-D, 3A-B (Kutlu et al., 
2009) 
 
 
2, 3, 4 (Benner et al, 2014) 
 
 
 
 
Mouse β-cells 
 
mRNA: 1, 2A-D, 3A-B (Kutlu et al., 
2009) 
 
1, 2, 3, 4 (Benner et al, 2014; 
Wu et al., 2012) 
 
 
       1, 2, 4, 5 (Kutlu et al., 
2009) 
 
 
Mouse islets 
 
mRNA: 1, 2A, 2C-D (Inagaki et al., 
1995) 
Protein: 1 (Molnar et al., 1995) 
 
2, 3 (Kutlu et al., 2009) 
 
4 (Kutlu et al., 2009) 
 
 
3, 4, 5, 8 (Brice et al., 2002) 
2, 3, 4, 5 (Brice et al., 2002) 
Table 1.6. Review of GluR subtype mRNAs and proteins in pancreatic endocrine cells of mouse.  
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 mRNA and protein of GluR subtypes and subunits 
Pancreatic endocrine cells  
GluN 
 
GluA 
 
GluK 
 
mGluR 
INS-1 clonal β-cells (rat) mRNA: 1, 2A-D, 3A-B (Kutlu et al., 2009) 
 
1, 2, 3, 4 (Kutlu et al., 2009) 
 
3, 4, 5 (Kutlu et al., 2009)  
 
RINm5F clonal β-cells (rat) 
mRNA: 1, 2D (Molnar et al., 1995) 
Protein: 1 (Molnar et al., 1995) 
2 (Inagaki et al., 1995) 
 
5 (Inagaki et al., 1995) 
5 (Molnar et al., 1995) 
 
3,5,8 (Brice et al., 2002) 
Rat α-cells mRNA: 1, 2A-D, 3A-B (Benner et al, 2014;  
Bramswig et al., 2013; Dorrel et al., 2011) 
1, 2, 3, 4 (Kutlu et al., 2009) 
 
1, 2, 3, 4, 5 (ref a, h, i, l)  
Rat β-cells mRNA: 1, 2A-D, 3A-B (Kutlu et al., 2009; 
Inagaki et al., 1995) 
 
1, 2, 3, 4 (Kutlu et al., 2009) 
 
1, 2, 3, 4, 5 (Kutlu et al., 2009; 
Bramswig et al., 2013; Nica et 
al., 2013; Dorrel et al., 2011) 
1, 2, 4, 7 (Uhlen et al., 2015) 
 
1, 2, 4, 7 (f) 
Rat islets mRNA: 1, 2A-D, 3A-B (Kutlu et al., 2009;  
Eizirik et al, 2012; Uhlen et al., 2015) 
Protein: 1 (Molnar et al., 1995) 
3 (Inagaki et al., 1995) 5 (Inagaki et al., 1995) 
             
5 (Molnar et al., 1995) 
 
1, 2, 3, 4, 5, 7, 8 (Brice et al., 
2002) 
2,3,5 (Brice et al., 2002) 
Table 1.7. Review of GluR subtype mRNAs and proteins in pancreatic endocrine cells of rat.  
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 mRNA and protein of GluR subtypes and subunits 
 
Pancreatic endocrine cells 
 
GluN 
 
GluA 
 
GluK 
 
mGluR 
 
 
Human α-cells 
 
 
mRNA: 1, 2C-D, 3A-B (Benner et 
al, 2014) 
 
 
1, 2, 3, 4 (Bramswig et al., 
2013; Cabrera et al., 2008; 
Dorrel et al., 2011) 
 
 
 
2, 4, 5 (Benner et al, 2014) 
 
 
 
Human β-cells 
 
mRNA: 
 
 
1, 2, 3, 4 (Bramswig et al., 
2013; Cabrera et al., 2008; 
Dorrel et al., 2011)                       
 
 
3, 5 (Kutlu et al., 2009) 
 
 
 
Human islets 
 
mRNA: 1, 2C-D, 3A-B (Benner et 
al, 2014) 
 
 
1, 2, 3, 4 (Kutlu et al., 2009; 
Eizirik et al, 2012) 
 
 
1, 2, 3, 4, 5 (Eizirik et al, 2012; 
Uhlen et al., 2015; Benner et 
al, 2014) 
 
 
3,5 (Brice et al., 2002) 
Table 1.8. Review of GluR subtype mRNAs and proteins in pancreatic endocrine cells of human.  
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The most important physiological function of pancreatic β-cells is synthesis and secretion 
of insulin to regulate blood glucose concentration. Studies have shown that activation or 
inhibition of GluR subunits in β-cells or islets of Langerhans can significantly alter GSIS 
from these cells. Of particular emphasis is the observation that some of these β-cell GluRs 
are able to induce or enhance GSIS is a manner similar to the effect of stimulatory glucose 
concentrations (Rorsman and Braun, 2013; Marquard et al., 2015).  
In a recent study, inhibition of β-cell NMDARs in both mouse and human islets using 
dextromethorphan resulted in significant increase in [Ca2+]c and GSIS in these cells as 
well as enhanced viability of the islets (Marquard et al., 2015). Results from the study 
also suggested that dextromethorphan-induced inhibition of NMDARs enhanced glucose 
tolerance and also resulted in increased serum insulin concentrations in human subjects. 
This was the first conclusive report on the effect of NMDARs in rodent and human β-
cells and islets. Another study has recently reported similar observations where activation 
of NMDARs in cultured BRIN-BD11 β-cells significantly reduced GSIS but the NMDAR 
antagonist did not have any effect on GSIS in the cells (Patterson et al., 2015). Previous 
studies (Gonoi et al., 1994; Inagaki et al., 1995) have however reported conflicting 
observations where activation of NMDARs by NMDA resulted in increased [Ca2+]i as 
well as enhanced GSIS in clonal β-cells and isolated pancreatic islets. Also, activation of 
β-cell NMDARs did not result in any change in GSIS or [Ca2+]i  (Bertrand et al.,1992) 
whereas another study reported of an increase in GSIS upon NMDAR activation but this 
increase was not significant compared to the baseline insulin secretion (Molnar et al. 
1995). These observations indicate an important role of β-cell NMDARs in the regulation 
and control of insulin secretion.  
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AMPARs are also present in pancreatic β-cells and their activation by agonists enhances 
GSIS and increases [Ca2+]i. Using isolated rat pancreas (Bertrand et al.,1992) and cultured 
MIN6 β-cells (Gonoi et al.,1994), a significant increase in GSIS subsequent to activation 
of AMPAR by AMPA was observed. These observations have been corroborated by a 
recent study in mouse β-cells (Wu et al., 2012). The study observed that activation of 
GluA2 by glutamate resulted in increased cytosolic [Ca2+] as well as enhanced GSIS in 
the presence of stimulatory (16 mM) glucose. However, these effects of AMPAR 
activation on GSIS were absent in the presence of 5 mM glucose hence raising an 
interesting possibility that the actions of AMPARs in β-cells may be glucose-dependent. 
Another study observed an increase in [Ca2+]i in single β-cells in the presence of high 
glucose concentration subsequent to the initial exposure to AMPA but this effect was 
absent in the second application of AMPA (Inagaki et al., 1995). This can be explained 
in the context of the agonist depolarising the cells after the initial application hence the 
second application did not have significant response.  
Furthermore, the effect of mGluR activation on the function of β-cells appears to depend 
significantly on the group of mGluRs that are activated in the cells. This follows 
observations from studies which have shown that activation of group II and group III 
mGluRs significantly decrease the plasma insulin concentration in rats (Babic et al., 
2012). In contrast, activation of group I mGluRs have been shown to enhance GSIS and 
increase [Ca2+]i in both clonal β-cells and mouse islets (Storto et al., 2006). Moreover, the 
type of mGluR group activated in β-cells may also play an important role in determining 
the concentration of glucose required for the activated mGluRs to modulate insulin 
secretion and calcium influx. Agonists of group I mGluRs activate these receptors to 
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induce an increase in GSIS at 3 and 10 mM glucose while agonists of group II mGluRs 
stimulate GSIS at both low (3 Mm) and high (25 mM) glucose concentrations. Group III 
mGluRs however, stimulate GSIS at 10-25 mM glucose (Brice et al., 2002). 
 
1.9.4. KAR subunits in pancreatic endocrine cells 
Subunit mRNA and protein of KARs have been detected in pancreatic endocrine cells 
including clonal cells, isolated α-cells and β-cells as well as in primary islets of rodents 
as summarised in Tables 1.6, 1.7 and 1.8. 
Functional studies have reported that application of kainate results in increased [Ca2+]i 
and enhanced GSIS in rat pancreas (Bertrand et al., 1992), isolated single β-cells of rats 
(Inagaki et al., 1995) as well as in cultured MIN6 β-cells (Gonoi et al., 1994) although 
these effects were observed subsequent to application of varying kainate concentrations 
and also in the presence of different glucose concentrations. Other studies however, did 
not observe any significant increase in GSIS in rat islets of Langerhans after application 
of kainate at stimulatory (8.3-16.7 mM) and non-stimulatory (3.3 mM) glucose 
concentrations (Molnar et al., 1995). These contrasting results raise the possibility that 
the effect of kainate on β-cell GSIS may be dependent on series of factors including 
species and cell type.  
Furthermore, no single study has characterised the molecular organisation of KARs and 
their auxiliary proteins neither has any study reported of putative role for KAR 
dysfunction in pancreatic endocrine cell function or the development of any pancreatic-
related conditions such as diabetes mellitus.  
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1.10. Potential role of glutamate and GluRs in diabetes mellitus  
1.10.1. Potential role of glutamate in diabetes mellitus development and progression 
The link between diabetes and glutamate is not clearly defined but several studies have 
reported of similar effects of glutamate on neuronal cells and pancreatic β-cells. First, 
studies have shown that β-cells and neurons share many common features including cell 
surface receptors, (Del Rosario et al., 2015; Marquard et al., 2015), transporters (Di 
Cairano et al., 2011; Cheng et al., 2015; Hanson et al., 2015), cell adhesion molecules, 
genes and proteins that are involved in transmission of signals between cells (Selway et 
al., 2012; Otter and Lammert, 2016). Second, glutamate is released together with 
glucagon by α-cells (Cho et al., 2010) of the pancreas which implies that concentration 
of this neurotransmitter in islets is partly dependent on the hormonal activities in the 
pancreas. This suggestion is however disputed by another study which reported that 
glutamate is not co-secreted with glucagon from α-cells but is rather released through 
glutamate transporters located in α-cells (Feldman et al., 2011). Inhibition of these 
transporters in rat results in increased intracellular concentration of glutamate and 
eventual increase in GSIS from β-cells (Feldmann et al., 2011). Another indirect link 
between glutamate and diabetes stems from reports which shows that children who later 
progressed to T1DM had significantly high concentration of glutamate in blood compared 
to children who remained non-diabetic (Oresic et al., 2008). Also, in obese mouse and rat 
models of T2DM, dietary supplementation with monosodium glutamate (MSG) resulted 
in reduced β-cell mass (Boonnate et al., 2015), insulin resistance (Nagata et al., 2006), 
high fasting blood glucose levels and subsequently T2DM (Sasaki et al., 2009). Though 
this observation may not necessarily be linked to diabetes mellitus, it is possible that 
hyperglutamataemia could result in excessive activation of GluRs on β-cells with 
subsequent cell death via apoptosis and necrosis. Hyperglutamataemia may also alter the 
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activity of GAD65, one of the main β-cell antigen targets in autoimmune T1DM. Though 
increased activity of GAD is likely to enhance conversion of glutamate to GABA to 
reduce glutamate levels (Guerriero et al., 2015), change in activity of this enzyme in β-
cells may also make it prone to autoimmune attack. Moreover, a study has shown that 
chronic exposure to glutamate is able to induce a relatively high increase in insulin 
secretion from human islets than induction with high concentration of glucose (Di 
Caraino et al., 2011). Further evidence from the study suggests that β-cells, not α-cells 
are vulnerable to chronic exposure to glutamate and large population of these cells 
undergo apoptosis. The prevalent mechanism of glutamate-induced β-cell death is via 
oxidative stress-induced cytotoxicity (Guemez-Gamboa et al., 2011).  
Other studies have however reported of an inverse relationship between the concentration 
of monosodium glutamate (MSG) in blood and the risk of hyperglycaemia (Shi et al., 
2013). This study was conducted among an adult population in China over a period of 
twenty years. These observations underscore the importance of glutamate in β-cell 
function.  
Furthermore, studies have suggested that glutamate acts as a positive signal for insulin 
secretion from pancreatic β-cells. In one study, it was observed that cytosolic glutamate 
from the malate-aspartate shuttle serve as the positive link between cAMP action in 
incretin-induced insulin secretion and elevated glucose concentration in β-cells (Gheni et 
al., 2014). Also, glutamate is generated from glucose in the mitochondria of β-cells 
through a number of cycles. Uptake of this glutamate by insulin-containing granules 
results in enhanced secretion of insulin, particularly the second phase of insulin secretion 
(Carobbio et al., 2009). These studies, coupled with the observation that elevated glucose 
in rat clonal INS-1 β-cells and isolated human pancreatic islets increases the concentration 
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of glutamate followed by enhanced insulin secretion (Carobbio et al., 2009) underscore 
the importance of glutamate in insulin secretion from pancreatic β-cells.  
Though no study is yet to record a direct link between glutamate levels or action and 
diabetes mellitus, accumulating evidences strongly indicate that glutamate is a significant 
molecule in the function, proliferation, viability and survival of pancreatic endocrine cells 
including β-cells.  
 
1.10.2. Potential role of glutamate receptors in diabetes mellitus development and 
progression 
To date, no study has shown a direct causal effect of GluRs in diabetes mellitus but several 
studies have suggested a role of GluRs in pancreatic endocrine function and dysfunction.  
First, inhibition of NMDARs in pancreatic β-cells and islets of mouse and human have 
been shown to induce significant increase in glucose-stimulated insulin secretion as well 
as enhanced proliferation and viability of these cells (Marquard et al., 2015). Also, 
according to the study, inhibition of NMDARs with dextromethorphan greatly enhanced 
glucose tolerance, improved glucose control, improved β-cell mass, enhanced insulin 
content in islets and also increased the effect of exendin-4 (anti-diabetic drug) on inducing 
glucose-stimulated insulin secretion in T2DM patients. This study represents a significant 
contribution to understanding how GluRs influence β-cell function and dysfunction.  
Second, diabetes mellitus has been linked to significant cognitive impairment in both 
rodent and humans (Mayeda et al., 2015). This cognitive impairment is attributed in part 
to alterations in the expression of both iGluRs and mGluRs in the brain (Anu et al., 2010; 
Viswaprakash et al., 2015). Though these do not give a direct causal relationship between 
diabetes and GluRs, the observation that insulin treatment of streptozotocin-induced 
T1DM rats restores cognitive impairments by correcting AMPAR dysfunction suggests a 
significant mutual relationship between the function of GluRs and diabetes mellitus.  
Chapter One                                                                                           Thesis Introduction 85 
 
Moreover, GPRC5B, an orphan receptor of the group C family of GPCRs is highly 
expressed and play important roles in human islets of Langerhans (Amisten et al., 2013). 
Dysregulation of GPRC5B in intact human and mice islets results in significant increase 
in basal and glucose-stimulated insulin secretion as well as enhanced positive effect of 
glutamate on insulin secretion (Soni et al., 2013). Also, GPRC5B mRNA and protein 
have been shown to be significantly higher in islets form T2DM patients compared to 
healthy controls. Though not directly classified under GluRs, GPRC5B shares lots of 
similar properties with mGluRs and hence their function and role in β-cell function is of 
significant interest in understanding the possible role of GluRs in diabetes mellitus (Soni 
et al., 2013).  
T1DM has also been linked to excitotoxicity-induced epileptic conditions. There appear 
to be a higher prevalence of epilepsy in children and adolescents with T1DM compared 
to non-T1DM controls (McCorry et al., 2006; Schober et al., 2012). Other studies have 
found similar prevalence of epilepsy in T1DM and controls (O’Connell et al., 2008). 
However, the observation that T1DM patients who also have epilepsy are twice as likely 
to develop both mild and severe diabetic ketoacidosis (Schober et al., 2012) gives a fairly 
strong indication of how GluRs affect development and progression of diabetes mellitus. 
The possibility that T1DM also affect development of epilepsy cannot be ruled out. These 
suggestions are enforced further by observations that GAD autoantibodies play a major 
role in both acute and chronic epilepsy (Liimatainen and Peltola, 2012) considering that 
autoantibodies to this enzyme are implicated in T1DM. Another interesting observation 
about GluRs and T1DM is how drugs which are prescribed for management of T1DM 
have similar effect on epilepsy and vice versa. Interestingly, antidiabetic drugs such as 
exenatide (Tsunekawa et al., 2007) and glitazones (Cunha et al., 2009) which are known 
to preserve β-cell integrity and survival also possess neuroprotective properties, while the 
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anti-epileptic drug topiramate which attenuates glutamate-induced excitotoxicity also 
have antidiabetic properties and preserve β-cell survival and function (Davalli et al., 
2012; Toplak et al., 2007; Angehagen et al., 2003). 
Even though these observations provide circumstantial evidence to implicate glutamate 
and GluRs in triggering or progression of diabetes mellitus, they provide very good 
insight into the possibility that glutamate and GluRs may be involved in both β-cell 
function and death. They also provide a good foundation for investigating GluR 
expression and function in α-cells, β-cells and islets. The observation that all the well-
established autoantigens in T1DM are involved in the secretory pathway in β-cells (Arvan 
et al., 2012) enforces the quest to explore the possible role of GluRs as a possible T1DM 
autoantigen.  
 
 
 
 
 
 
 
 
 
 
Chapter One                                                                                           Thesis Introduction 87 
 
1.11. Aims and objectives of the study 
Based on existing data, not much is known about KARs outside the CNS. The aim of this 
study is to investigate the presence and role of KAR subunits in pancreatic endocrine 
function and in the pathogenesis of T1DM. 
The first part will investigate the molecular composition and function of KARs in 
pancreatic endocrine cells as well as the role of these receptors in the viability of 
pancreatic endocrine cells. 
The second part of the study will investigate the presence of autoantibodies against GluR 
subunits in sera of newly-diagnosed T1DM patients. This will help to assess the potential 
role of KARs in the development of T1DM.  
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Chapter Two 
Kainate Receptors in Pancreatic Endocrine Cells 
2.1. Introduction 
The presence of some KAR subunit mRNA and protein in pancreatic endocrine cells has 
been investigated (Chapter one, section 1.10 and Tables 1.5-1.7). However, no study has 
conclusively characterised the molecular organisation of these receptors in pancreatic 
endocrine cells in general and β-cells in particular. Moreover, the only KAR subunit 
protein which has been identified in rodent β-cell lines or islets of Langerhans is GluK5 
(Molnar et al, 1995). Since this subunit (GluK5) can only form heteromeric combinations 
with any of GluK1-3 subunits (Crepel and Mulle, 2015), existing data are not sufficient 
to explain how these receptors assemble or function in pancreatic endocrine cells. Also, 
the presence of KAR-interacting or auxiliary mRNA and protein in these cells remains 
unexplored. In addition, the specific role of KAR subunits and their interacting/auxiliary 
proteins in modulating the functions and survival of pancreatic endocrine cells remain 
uncertain.  
Because of the emerging role of KARs in the CNS and their unique dual signalling 
properties, these receptors represent potential targets for therapeutic agents for several 
neurological conditions. Also, since NMDARs have recently been reported to modulate 
β-cell function and contribute directly to glucose tolerance in both rodent and human 
diabetic patients (Marquard et al., 2015), it is likely that the other iGluRs including KARs 
modulate specific functions of the endocrine pancreas and may also represent important 
factors in dysfunction of these cells. Thus, this current study investigates the molecular 
characterisation, organisation and function of KAR subunits in pancreatic endocrine cells. 
This would be a significant contribution to understanding the function of KARs in non-
neuronal cells and also provides a good foundation for understanding the role of these 
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receptor subunits and their ligands in modulation of pancreatic β-cell function, survival 
and the development of T1DM.  
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2.2. Aims 
This section of the study aims to establish the molecular composition and function of 
KAR subunits in pancreatic endocrine cells and how these receptors affect the survival of 
pancreatic endocrine cells.  
The specific objectives of this section were: 
1) To investigate the presence of KAR subunit mRNA and protein in mouse clonal 
MIN6 β-cells, rat clonal INS-1 β-cells and mouse clonal α-TC16 α-cells and in rat 
primary islets of Langerhans 
2) To investigate the presence of Neto 1 and Neto 2 mRNA and protein in clonal 
MIN6 and INS-1 β-cells and α-TC cells and in rat primary islets of Langerhans 
3) To analyse the effect of varying concentrations of glutamate and kainate on [Ca2+]i 
in clonal MIN6 β-cells. 
4) To investigate the effect of kainate on glucose-stimulated insulin secretion (GSIS) 
in MIN6 and INS-1 β-cells.  
5) To investigate the effect of chronic exposure to glutamate, kainate and 
dihydrokainic acid on viability of INS-1 and MIN6 β-cells and α-TC cells.  
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2.3. Materials and Method 
2.3.1. Materials 
Details of materials are supplied in Appendix 1. 
 
2.3.2. Cell culture 
Mouse insulinoma pancreatic β-cell line (MIN6) was cultured in DMEM cell culture 
medium supplemented with 15% (v/v) foetal calf serum (FCS), 100 U/ml penicillin, 0.1 
mg/ml streptomycin, 2 mM L-glutamine and 0.05 mM β-mercaptoethanol (Diraison et al., 
2011; Brozzi et al., 2012). Mouse adenoma α-TC1 clone 6 (α-TC) pancreatic α-cells were 
cultured in RPMI-1640 cell culture medium supplemented with 10% (v/v) FCS, 100 U/ml 
penicillin, 0.1 mg/ml streptomycin, 2 mM L-glutamine, 0.05 mM β-mercaptoethanol and 
11.0 mM glucose (Piro et al., 2014). Rat insulinoma pancreatic β-cell line (INS-1) was 
cultured in RPMI-1640 medium supplemented with 10% (v/v) FCS, 100 U/ml penicillin, 
0.1 mg/ml streptomycin, 2 mM L-glutamine, 0.05 mM β-mercaptoethanol, 10 mM 
HEPES, 1 mM sodium pyruvate and 11.1 mM glucose (Pepaj et al., 2014). Human 
neuroblastoma cell line (SH-SY5Y) was cultured in Advanced DMEM supplemented with 
10% (v/v) FCS, 2 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin and 1X 
RPMI-1640 amino acids solution (Zheng et al., 2014). Human embryonic kidney 
(HEK)293 cells were cultured in DMEM supplemented with 10% (v/v) FBS, 100 U/ml 
penicillin, 0.1 mg/ml streptomycin, 2 mM L-glutamine and 0.05 mM β-mercaptoethanol 
(Copik et al., 2015). Cells were maintained at 37°C in 95% humidified atmosphere and 
5% CO2. The culture medium was replaced every 48 hours and cells were passaged every 
4 days (Diraison et al., 2011). Cells between passage numbers 18-38 (MIN6, α-TC and 
INS-1), 20-30 (HEK293) and 6-14 (SH-SY5Y) were used for experiments (Cheng et al., 
2012; Copik et al., 2015).  
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2.3.3. Isolation of total RNA from cell lines and tissues  
MIN6, INS-1, HEK293 and α-TC cells at about 80% confluency were detached from the 
culture flask by incubating with 3 ml of 0.25 M sterile trypsin-EDTA at 37oC for 5 
minutes. Cells were transferred into sterile 15 mL conical tubes and centrifuged at 900 x 
g for 5 minutes. The supernatant was discarded and 3 mL of TRIzol® reagent was added 
to the cell pellet. For islets of Langerhans and brain/liver tissue, 3 mL of TRIzol® was 
added to 300 individual islets or 300 mg brain/liver. The TRIzol® reagent-cell/tissue 
mixture was incubated for 10 minutes at room temperature (RT) and then 600 µL of 
chloroform was added, mixed and incubated for 5 minutes. The mixture was centrifuged 
at 14,000 x g for 15 minutes. The top and middle layers were retained for RNA isolation 
and protein extraction, respectively. The top layer was incubated with 1.5 mL of 
isopropanol for 10 minutes at RT and centrifuged at 12,000 x g for 10 minutes. The 
supernatant was discarded and the pellet was incubated with 900 µL of 75% (v/v) ethanol 
for 5 minutes at RT. The mixture was centrifuged at 7,500 x g for 5 minutes and the 
supernatant was discarded after which the pellets were air-dried for 5 minutes and re-
suspended in 30 µL of diethylpyrocarbonate (DEPC)-treated water (Rio et al., 2010). The 
concentration and purity of the RNA was determined using a NanoDrop-1000 
spectrophotometer (Thermo Scientific, Leicestershire, UK). The ratio of absorbance at 
260 nm to 280 nm was used to assess the purity of RNA and samples with ratio above 
1.80 were used to avoid sample contamination with DNA and protein (Eldh et al., 2012).  
 
2.3.4. Protein extraction from TRIzol®-treated tissue samples 
The middle layer retained from the RNA isolation (section 2.3.3) was incubated with 300 
µL of absolute ethanol for 3 minutes at RT and centrifuged at 3,000 x g for 5 minutes. 
The supernatant was transferred into a new tube and incubated with 1.5 mL of absolute 
(v/v) isopropanol for 10 minutes at RT. The mixture was then centrifuged at 12,000 x g 
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for 15 minutes and the resulting pellets were washed three times by incubating with 2 mL 
of 0.3 M guanidine hydrochloride for 20 minutes and centrifuged at 7,500 x g. The pellets 
were then incubated with 2 mL absolute ethanol for 20 minutes and then centrifuged at 
7,500 x g for 5 minutes. The pellets were resuspended in 50 µL of 1% (w/v) sodium 
dodecyl sulfate (SDS) and centrifuged at 10,000 x g. The supernatant (protein) was 
retained and quantified by Bradford assay using Coomassie Brilliant Blue (Sigma, UK). 
The extracted proteins were then used for gel electrophoresis and immunoblotting 
(Likhite and Warawdekar, 2011).  
 
2.3.5. Preparation of membrane lysate from MIN6, α-TC, INS-1 and HEK293 cells  
The culture medium was removed and the cells were rinsed twice with 1X PBS (137 mM 
NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4, pH 7.4) and incubated with 
250 µL of RIPA buffer (150 mM NaCl, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) 
SDS, 25 mM Tris, pH 7.5, 0.1 mM EDTA, 1% (v/v) Triton-X), 1X protease inhibitor 
cocktail (2 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride, 1 mM 
phosphoramidon disodium salt, 130 mM bestatin hydrochloride, 14 mM N-(trans-
epoxysuccinyl)-L-leucine 4-guanidinobutylamide, 1 mM leupeptin, 0.2 mM aprotinin, 10 
mM pepstatin A), 1 mM sodium orthovanadate and 1 mM PMSF) at 4oC for 15 minutes 
with occasional agitation. The cells were scraped off the culture flask and transferred into 
1.5 mL Eppendorf tubes and then passed through a 1 mL syringe attached to a 25 x 1 inch 
(0.5 x 25 mm) needle 20-25 times. The mixture was incubated at 4oC with gentle rotation 
for 40 minutes and centrifuged at 15000 x g for 15 minutes at 4oC. The supernatant 
(protein) was collected, quantified and used immediately or stored at -80oC (Diraison et 
al., 2011).  
2.3.6. Bradford Assay for protein quantification 
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Bradford assay was set up in a 96-well plate with 1 μg/μL standard bovine serum albumin 
(BSA) as shown in Table 2.1. Triplicates of 1:5 and 1:10 dilutions of each test protein 
sample were prepared in separate wells of the plate. All dilutions were made with de-
ionised water and each well contained 5 μl dilutions of BSA standard or test proteins.  
 
 
 
 
 
To each well, 200 μL of 0.6 M Coomassie Brilliant Blue dye was added and optical 
density at 610 nm was measured with Fluostar Optima plate reader (BMG Labtech, 
Aylesbury, UK). A standard curve of concentration against absorbance for BSA was 
generated using the following equation: y = mx + c, (where y: optical density, m: gradient 
of the curve, x: concentration and c: y intercept). The optical density of the test samples 
was inserted into the equation to determine the concentration (x) of protein (Luther et al., 
2005). 
 
 
 
 
 
 
 
 
2.3.7. Reverse transcription and PCR 
 
Rows 
 
A1-3 
 
B1-3 
 
C1-3 
 
D1-3 
 
E1-3 
 
F1-3 
 
G1-3 
BSA (μg/μL) 0.0 0.2 0.4 0.6 0.8 1.0 1.2 
Table 2.1. Concentration of BSA standard in each well of the 96-well plate  
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Total RNA was revere-transcribed at 45oC for 30 minutes in 20 µL of reaction mixture 
containing 3 µg RNA, 0.5 mM of dNTP, 2.5 µM of oligo (dT)18 primers, 1X reverse 
transcriptase buffer (50 mM Tris-HCl, pH 8.6, 40 mM KCl, 1 mM MnSO4, 1 mM 
dithiothreitol, 0.5 mM [methyl-3H] thymidine 5'-triphosphate), 0.5 U/µL RNase inhibitor 
and 10 U/µL reverse transcriptase. The reaction was terminated at 85oC for 5 minutes and 
cooled on ice (Balkowiec-Iskra et al., 2011; Luyt et al., 2007).  
Primers specific for KAR, Neto 1 and Neto 2 subunits were designed using the NCBI 
Primer-Blast design tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). To optimise 
PCR conditions for the primers, rat and mouse brain cDNA were subjected to gradient 
PCR using annealing temperatures between 50oC and 65oC. The PCR reaction mixture 
containing 3 µg cDNA, 2 mM dNTP mix, 1X PCR buffer (200 mM Tris-HCl, pH 8.4, 
500 mM KCl), 0.8 mM of each primer, 2.0 mM MgCl2 and 0.1 U/µL BIOTAQ
TM DNA 
polymerase was used with PCR conditions of 95oC for 5 minutes, followed by 34 cycles 
(except in experiments in which linear phase was determined) at 95oC for 30 seconds, 
annealing temperature of 50oC-65oC for 30 seconds and then 72oC for 30 seconds. The 
last cycle was followed by a final extension step at 72oC for 10 minutes in a VWR 
Thermal Cycler (Biorad, Hertfordshire, UK) (Varadi et al., 1996; Rajatileka et al., 2013). 
The selected PCR conditions for the primers are detailed in Tables 2.2-2.4. Using these 
conditions, cDNA of MIN6, α-TC, INS-1, islets of Langerhans and brain were used for 
PCR.  
The housekeeping β-actin gene has been shown to be expressed in all cells including 
MIN6 (Gao et al., 2015), α-TC (Klein et al., 2013), INS-1 and rodent islets of Langerhans 
(Skrzypski et al., 2015). Thus primers specific for mouse and rat β-actin were used as 
control to test the quality and integrity of templates. 
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KAR subunit transcripts have been detected in brain tissues of mice, rats and humans 
(Sihra and Rodriguez-Moreno, 2013). Thus, cDNA templates synthesised from rat and 
mouse brain tissues were used as a positive control for the different stages of PCR. 
The PCR products were separated on 2% (w/v) agarose gels containing 0.4 μg ethidium 
bromide in 1X TAE buffer (40 mM Tris-acetate, 1 mM EDTA, pH 8.3) and the bands 
were visualised using the Syngene gel imaging and analysis system (Cambridge, UK).  
For negative control, RNA taken through cDNA synthesis in the absence of reverse 
transcriptase enzyme was used as template for each set of primers. In addition, PCR was 
ran for each primer pair in the absence of template.  
The PCR products were purified using the Wizard® SV Gel and PCR Clean-Up System. 
The separated DNA bands were excised from the gel and transferred into pre-weighed 
1.5 ml eppendorf tubes. Membrane binding solution (MBS) was added to the excised gel 
at ratio of 10 µL MBS to 10 mg of excised gel. The mixture was incubated at 65oC for 10 
minutes to dissolve the gel in the MBS, transferred into a minicolumn-collection tube 
system and centrifuged at 12,000 x g for 1 minute. The DNA in the column was washed 
by adding 700 µL of membrane wash solution to the column followed by centrifugation 
at 12,000 x g for 5 minutes. Elution of DNA from the column into new DNase-free tube 
was performed by adding 40 µL of nuclease-free water followed by centrifugation at 
12,000 x g for 1 minute (Uil et al., 2011; Rajatileka et al., 2013; Luyt et al., 2007). The 
purified PCR products were sequenced (Eurofins MWG, Ebersberg, Germany).  
Three independent experiments using cDNA templates from different RNA preparations 
were carried out.  
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Gene 
 
Forward primer (5'-3') 
 
Reverse primer (5'-3') 
 
Size(bp) 
Annealing 
temperature (oC) 
MgCl2 
(mM) 
 
GluK 1 
(NM_010348) 
 
TCAGACTCGCTGGAAACACC 
(Position: 949-968) 
 
 
TGCTTCAGTTGTCATCACGC 
(Position: 1519-1500) 
 
571 
 
60 
 
2.0 
 
GluK 2 
(NM_001111268) 
 
GACTTCTCTTCCCTCAGCCG 
(Position: 867-886) 
 
CAGAGCAGCATCAGTCGTCA 
(Position: 1379-1360) 
 
 
513 
 
55 
 
2.0 
 
GluK 3 
(NM_001081097) 
 
GGTTCCGCATACTCAACGTG 
(Position: 842-861) 
 
 
ATGCAGTAGCCCTCAAACCG 
(Position: 1400-1381) 
 
 
559 
 
60 
 
2.0 
 
GluK 4 
(NM_175481) 
 
ATCCGGGATGACAAGACAGC 
(Position: 819-838) 
 
 
CAATGTGGCCGGTAAGACCT 
(Position: 1290-1271) 
 
 
472 
 
60 
 
2.0 
 
GluK 5 
(NM_008168) 
 
TGATGCCAATGCGTCCATCT 
(Position: 1028-1047) 
 
 
TACCACACCCCTATCTCACG 
(Position: 1555-1536) 
 
 
528 
 
55 
 
2.0 
β-actin 
(NM_007393.5) 
CATCCTGCGTCTGGACCTG 
(Position: 600-619) 
 TTCCATACCCAAGAAGGAAGGC 
           (Position: 887-865) 
             289                             56                     2.0 
Table 2.2. Primer sequences and PCR conditions for the amplification of the various mouse KAR subunits. The primers were based on 
mRNA sequences accessed from the NCBI GenBank database (http://www.ncbi.nlm.nih.gov/genbank/).   
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Gene 
 
Forward primer (5'-3') 
 
Reverse primer (5'-3') 
 
Size(bp) 
Annealing 
temperature (oC) 
MgCl2 
(mM) 
 
GluK 1 
(NM_001111117) 
 
 
GGAAGGAACTGAAAAGATTGGG 
(Position: 1376-1397) 
 
 
CCATTGGGCTTCCGGTAAAG 
(Position: 1825-1806) 
 
 
450 
 
56 
 
2.0 
 
GluK 2 
(NM_019309) 
 
 
CTTGACGTGGAGCCCTACAG 
(Position: 1070-1089) 
 
 
CGGTTCTTCCAAAATGGTGGT 
(Position: 1606-1586) 
 
 
537 
 
56 
 
2.0 
 
GluK 3 
(NM_181373) 
 
 
CCGAGGTCCTAATGTCACCG 
(Position: 1397-1416) 
 
 
AGGGCTGAATCTGGCAATGA 
(Position: 1895-1876) 
 
499 56 2.0 
 
GluK 4 
(NM_012572) 
 
 
CCACCATCCTGGAAAACCCA 
(Position: 1338-1357) 
 
 
CCAGGTTGGCTGTGTACGAT 
(Position: 1997-1978) 
 
 
660 
 
56 
 
2.0 
 
GluK 5 
(NM_031508) 
 
 
GGACTTCCCCATCCTGCATC 
(Position: 1045-1064) 
 
 
CCACACCCCTATCTCACGGT 
(Position: 1477-1458) 
 
 
433 
 
59 
 
2.0 
β-actin 
(NM_031144.3) 
CATCCTGCGTCTGGACCTG 
(Position: 599-618) 
 
TTCCATACCCAAGAAGGAAGGC 
(Position: 888-866) 
 
289 56 2.0 
Table 2.3. Primer sequences and PCR conditions for the amplification of the various rat KAR subunits. The primers were based on 
mRNA sequences accessed from the NCBI GenBank database (http://www.ncbi.nlm.nih.gov/genbank/).   
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Gene 
 
 
Forward primer (5’-3’) 
 
 
Reverse primer (5’-3’) 
 
 
Size(bp) 
 
Annealing 
temperature (oC) 
 
MgCl2 
(mM) 
 
Human Neto 1 
(NM_001201465) 
 
CACCAGTGGGACTGTCATTG 
[Positions: human (1304-1323); mice 
and rats (1951-1970)]. 
TCTGCCACATCTGCAAAGTC 
[(Positions: human (1525-1505); mice 
(2166-2146) and rats (2167-2147)]. 
 
216 
 
50.2 
 
2.0 
 
Human Neto 2  
(NM_001201477) 
 
TTTGCTTCGCCAAATTATCC 
[(Positions: human (582-601); mice 
(309-329) and rats (168-188)]. 
TTAATGGAGGGCTTTTCACG 
[(Positions: human (801-782); mice (529-
509) and rats (388-368)]. 
 
220 
 
50.2 
 
2.0 
 
Mouse Neto1 
(NM_144946) 
 
 
TTGAAACCATTGCCAGCGTG 
 
AACCTGCTGTTACGGCTACC 
 
344 
 
 
50.2 
 
2.0 
 
Mouse Neto2 
(NM_001081324) 
 
 
TTTTGGAAGCTGCTCCTCGT 
 
CCAGAGAGCTCAAACTGGCA 
 
304 
 
 
50.2 
 
2.0 
 
Rat Neto1 
(NM_001107371) 
 
 
TCTTTGCTGATGGGGAGCTG 
 
TTGCCTTCACAGGGAGGTTC 
 
475 
 
50.2 
 
2.0 
 
Rat Neto2 
(NM_001107417) 
 
 
 TGCCGGTTTGATCACTTGGA  
 
GTACAGGGAGGCTCCACAAAG 
 
596 
 
 
50.2 
 
2.0 
Table 2.4. Primer sequences and PCR conditions for the amplification Neto 1 and Neto 2. The primers were based on mRNA sequences 
accessed from the NCBI GenBank database (http://www.ncbi.nlm.nih.gov/genbank/).  Human Neto 1 and Neto 2 primers were used to 
investigate presence of Neto 1 and Neto 2 in the cell lines and tissues whiles mouse and rat Neto 1 and Neto 2 were used for the semi-quantitative 
analysis. 
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2.3.8. Semi-quantitative analysis KAR subunits, Neto 1 and Neto 2 mRNA in pancreatic 
endocrine cells. 
To determine the optimum number of PCR cycles required for the amplification of KAR 
subunits, Neto 1 and Neto 2 to be within the linear phase, mouse brain cDNA was 
subjected to PCR with specific primers for β-actin, KAR (GluK2, GluK5), Neto 1 and 
Neto 2 with conditions described in section 2.3.7 and PCR cycles of 15, 20, 25, 30 and 
35. PCR products were separated on 2% (w/v) agarose gels and visualised using Syngene 
gel imaging and analysis system. The tagged image format (TIF) file of the gel images 
were loaded on to ImageJ image processing software (Maryland, USA) and the image 
background was subtracted. The ‘Rectangle Area Selection Tool’ of the software was 
selected to draw a rectangle around the first band of interest to create an area that will be 
operated on separately from the rest of the image. The mean intensity of the selected band 
was measured using the software. The rectangle was then moved to other bands to 
measure the mean intensity of these bands. A profile plot representing the relative density 
of the contents of the rectangle over each lane was plotted the area under the plots 
represented the amount of signal in the band (pixel volume).  A curve of pixel volume 
against PCR cycle number was plotted for each primer and used to establish the linear 
phase of the reaction (Luyt et al., 2007; Varadi et al., 1996). The cycle numbers for PCR 
were narrowed down to intervals of 2 for primers which had curves with no distinct linear 
regions. Curves for each of the primers were used to select PCR cycle numbers at which 
amplification of the target mRNA is in linear phase.   
Pancreatic β- (MIN6 and INS-1) and α-cells (α-TC) and mouse brain cDNA were used in 
PCR with the selected number of PCR cycles for the GluK2, GluK5, Neto 1, Neto 2 and 
β-actin primers. The PCR products were separated on 2% agarose gels and visualised. 
ImageJ was used to determine the pixel volumes. Pixel volume of GluK2 was divided 
with that of β-actin and the obtained ratio from each experiment was averaged to give the 
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relative amount of GluK2 mRNA in the cells. The same procedure was carried out for 
GluK5, Neto 1 and Neto 2 to determine their relative amounts. 
Three independent experiments each carried out in duplicate were performed and bar 
charts representing the means ± standard error of means (SEM) from the three 
experiments were plotted. One-way ANOVA analysis was used to compare mean relative 
amounts of KAR (GluK2, GluK5), Neto 1 and Neto 2 mRNA between β- (MIN6 and 
INS-1) and α-cells (α-TC). 
 
2.3.9. Immunoblotting  
Membrane lysate prepared from cell lines (10-60 μg) or brain tissue (5 μg) was added to 
equal volume of  2X loading buffer (0.0625 M Tris-HCl; pH 6.8, 1% (v/v) SDS, 10% 
(w/v) bromophenol blue), heated for 5 minutes at 95oC and proteins separated by 
electrophoresis on 4% SDS PAGE stacking (4% acrylamide (v/v); 0.5M Tris, pH 6.8; 
0.1% (v/v) SDS; 0.1% (w/v) TEMED; 0.1% (w/v) APS) and 10% SDS PAGE resolving 
(10% (v/v) acrylamide, 1.5 M Tris, pH 8.8, 0.1% (w/v) SDS, 0.1% (v/v) TEMED, 0.1% 
(w/v) APS) gel in a Bio-Rad Protean II electrophoresis tank (Bio-Rad, Hertfordshire, UK) 
at 120 V for 35 minutes in SDS running buffer (0.025M Tris, 0.192 M Glycine and 0.1% 
(w/v) SDS) (Whitehead et al., 2013; Luyt et al., 2007). Proteins were transferred on to a 
polyvinyl difluoride (PVDF) membrane using Trans-Blot SD Semi-Dry Transfer Cell 
system (Biorad, Hertfordshire, UK) with discontinuous anode (40 mM CAPS, 60 mM 
Tris, 15% (v/v) methanol) and cathode (40 mM CAPS, 60 mM Tris, 0.1% (w/v) SDS) 
buffer solutions for 35 minutes at 25V. The membrane was washed twice in 1X TBS-T 
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% (v/v) Tween) for 5 minutes each, then 
blocked in 5% (w/v) non-fat milk for 1 hour and incubated overnight at 4oC with primary 
antibodies as shown in Table 2.5. The membrane was then washed six times in TBS-T 
for 5 minutes each and incubated at RT for 45 minutes with horseradish peroxidase 
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(HRP)-linked anti-mouse or anti-rabbit secondary antibody (dilution 1:4000) in 5% (w/v) 
non-fat milk. After incubation, the membrane was washed six times in TBS-T for 5 
minutes each and incubated with 2 mL of HRP substrate for 1 minute. Detection of 
immunopositive bands was performed by incubating the membrane with HRP substrate 
(Millipore, Hertfordshire, UK) for 1 minute followed by visualisation with Syngene gel 
imaging and analysis system (Syngene, Cambridge, UK). The β-actin content of each 
sample was assessed to confirm that comparable amount of membrane lysates was loaded 
(Storto et al., 2006; Whitehead et al., 2013; Diraison et al., 2010).   
 
2.3.10. Semi-quantitative analysis of immunoblot bands 
Immunoblot images acquired with the Syngene gel imaging system were analysed using 
ImageJ image processing software as described in section 2.3.8 to determine the pixel 
volume of immunopositive bands for KAR subunits (GluK2/3, GluK5), Neto 1, Neto 2 
and β-actin.  
Pixel volume of KAR subunits (GluK2/3, GluK5), Neto 1 and Neto 2 was divided with 
that of β-actin and the obtained ratio from each experiment was averaged to give the 
relative amount of KAR subunits (GluK2, GluK5), Neto 1 and Neto 2 protein (Luyt et 
al., 2007; Wicht et al., 1999). 
Three independent experiments were performed and bar charts representing the means ± 
standard error of means (SEM) from the three experiments were plotted. One-way 
ANOVA was used to compare mean relative amounts of KAR (GluK2/3, GluK5), Neto 1 
and Neto 2 protein between β- (MIN6 and INS-1) and α-cells (α-TC). 
 
 
 
Chapter Two                                                                                 2.3 Materials and Methods 103 
 
 
 
Antibody Dilution (in 5% milk) Species 
Anti-GluR6/7 (Millipore; 04-921) 1:2000 Rabbit 
Anti-KA2 (GluK 5) (Millipore; 06-315) 1:1000 Rabbit 
Anti-Neto1 (Tomita, Yale) (Straub et al., 2011) 1:1000 Rabbit 
Anti-Neto-2 (Tomita, Yale) 1:1000 Rabbit 
Anti-β actin (CST; #3700) 
Anti-pan-AMPAR (Molnar, Bristol) (Cathala et al., 2005) 
1:3000 
1:500 
Mouse 
Rabbit 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.5. Primary antibody dilutions used for the investigation of GluK protein in 
pancreatic endocrine cells 
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2.3.11. Measurement of intracellular calcium concentration [Ca2+]i in MIN6 pancreatic 
β-cells 
Sterile-filtered 0.01% (v/v) poly-l-lysine (PLL) solution in water was used to coat 13 mm 
coverslips by adding 100 μL of PLL to each coverslip and incubating for 5 minutes at 
RT. The coverslips were rinsed with sterile deionised water and dried at RT for 2 hours 
before use. MIN6 β-cells were seeded at a density of 1.0 x 105 onto PLL-treated coverslips 
in a 12-well cell culture plate and incubated at 37oC, 5% CO2 in 25 mM-containing 
DMEM (section 2.3.2) for 24 hours after which the medium was replaced with fresh 
complete DMEM containing 3 mM and incubated for further 24 hours. The media was 
removed and cells were rinsed with pre-warmed (37oC) Hanks' balanced salt solution 
(HBSS) (135 mM NaCl, 5 mM KCl, 10 mM HEPES, 1 mM MgCl2, 2 mM CaCl2, pH 7.3) 
supplemented with 3 mM glucose. FURA-2AM calcium dye solution was prepared to a 
concentration of 4 µM in 3 mM glucose-supplemented HBSS buffer. Cells were loaded 
with FURA-2AM calcium dye by incubating the cells with the dye for 90 minutes at 37oC 
in the dark. The dye was washed off with HBSS and cells kept away from light for 15 
minutes at RT for de-esterification of FURA-2AM before imaging. All drugs used in the 
experiment were diluted in HBSS buffer supplemented with either 3 mM or 30 mM 
glucose and were kept at room temperature during the experiment. The cells were then 
transferred onto a perifusion chamber and mounted on the stage of a Zeiss Axiovert 200 
inverted microscope (Oberkochen, Germany). The cells were perifused with HBSS buffer 
with or without drugs at constant flow rate of 3 mL/min with 1-minute delay in-between 
flows. This delay was corrected on the image traces. To test the responsiveness of the 
cells and sensitivity of the system, cell membranes were depolarised by application of 15 
mM KCl after every round of experiment. 
The cells were illuminated by excitation with a dual ultraviolet light source at 340 nm and 
380 nm. A dichroic mirror transmitted the emitted fluorescence from the cells through a 
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460 nm filter and images were captured with a high-sensitivity cooled Nikon charge-
coupled device (CCD) camera (Nikon, Surrey, UK).   
The background reading was subtracted from the region of interest (ROI) and the ratio 
channel of the intensity readings was measured using the ‘ratio’ tool of the Volocity 
Image Analysis software (PerkinElmer, Cambridgeshire, UK). The mean intensity ratio 
was measured by drawing a square around the whole field of ROI (containing 30-50 cells) 
and then using the ‘analysis’ tool of the software to acquire the raw data for mean intensity 
ratio for each time point (Tarasov et al., 2013; Varadi and Rutter, 2002; Varadi et al., 
2004).  
The time-lapse intensity ratio data was imported into Excel data analysis suite (Microsoft, 
Berkshire, UK) and the mean of 3-4 independent experiments was determined for each 
timepoint and then used to generate scatter plots of fluorescence ratio against time. The 
change in fluorescence ratio which represents the change in [Ca2+]i was determined by 
dividing the fluorescence ratio induced by a drug with the fluorescence ratio of the first 
four minutes of the experiment where no drug was applied to cells. The ratio obtained 
from each experiment was averaged and bar charts representing the mean change in 
fluorescence ratio ± SEM were plotted using Excel. Means of change in fluorescence ratio 
were compared statistically using Student’s t-test, one-way or two-way ANOVA.  
The different drugs and incubation times used in the experiment are shown in Figure 2.1. 
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Figure 2.1. Summary of drugs and perifusion times used in calcium imaging of MIN6 β-cells.  Experiments were performed with drugs dissolved in HBSS 
buffer containing 3 mM or 30 mM glucose. Drugs: kainate (KAR agonist), 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX: 
AMPAR/KAR antagonist); Gyki-hydrochloride (Gyki-52466: NMDAR/AMPAR antagonist); (S)-3,5-dihydroxyphenylglycine (DHPG: group I mGluR 
agonist); potassium chloride (KCl: depolarises cell membrane). 
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2.3.12. Measurement of cell viability using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl 
tetrazolium bromide (MTT) assay 
The MTT assay is based on conversion of the yellow MTT solution to dark-blue insoluble 
formazan crystals by mitochondrial dehydrogenase present in living cells (Wang et al., 
2010). The optical density of dissolved crystals at 550 nm is directly proportional to the 
amount of mitochondrial dehydrogenase in the cells.   
Pancreatic β- (INS-1) and α-cells (α-TC) and neuroblastoma cells (SH-SY5Y) were 
seeded at densities of 2 x 104 onto 96-well plates for 24 hours under culture conditions 
described in section 2.2.3. The media was replaced with fresh media containing different 
concentrations of glutamate, kainate, NBQX, DHK, Triton X-100 and ethanol as described 
in Figure 2.2. For kainate/NBQX treatment, cells were cells pre-incubated with 0.025-0.1 
mM NBQX for 12 hours followed by incubation with 0.1 mM-0.5 kainate for 60 hours. For 
glutamate/DHK, cells were treated with DHK for 12 hours followed by incubation with 
media containing 0.5 mM glutamate for 60 hours. Cells used as controls were cultured in 
growth media only.  
To test the specificity of the MTT assay, cultured INS-1, α-TC and SH-SY5Y cells were 
incubated with 40% ethanol or 2% triton X-100 for 72 hours. These concentrations of 
ethanol and triton X-100 have been shown to be lethal to cultured cells resulting in no 
formation of formazan crystals when these cells are incubated with MTT. Thus, these 
conditions were used as negative controls (Phonnok et al., 2010). SH-SY5Y cells were 
used as positive control for kainate- and glutamate-induced changes in cell viability (Zhu 
et al., 2016; Cannarsa et al., 2008).  
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Figure 2.2. Summary of treatment procedure for cell viability analysis in INS-1, α-TC and SH-SY5Y cells. Cells were seeded in 96-well 
culture plates for 24 hours. The media was replaced with fresh media containing different combinations of drugs and incubated for 72 hours.  
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After treatment, 20 µL of 1 mg/mL MTT solution (prepared in phenol- and serum-free 
media) was added to each well and incubated for 2 hours in 37°C in 95% humidified 
atmosphere and 5% CO2. The media was removed from the cells and 100 µL of DMSO 
was added to each well. Cells were incubated at 37°C on an orbital shaker (100 rpm) for 
30 minutes to dissolve the formazan crystal precipitates completely and optical density 
of the solution was measured at 550 nm (Maioli et al., 2009; Di Cairano et al., 2011).  
Experiments were carried out in triplicates and mean optical density of each treatment 
was expressed as percentage of the mean optical density of non-treated controls.  
Bar charts representing mean cell viability ± SEM of 3-6 experiments were plotted using 
Excel data analysis suite (Microsoft, Berkshire, UK) and comparisons in mean cell 
viability were performed using one-way ANOVA (Minitab, Pennsylvania, USA) or 
Student’s t-test. 
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2.3.13. Measurement of insulin release using ELISA 
Pancreatic β-cells (MIN6 and INS-1) were seeded at densities of 2 X 105 in 12-well cell 
culture plates for 24 hours in growth media (25 mM for MIN6 and 11.1 mM for INS-1) 
as discussed in section 2.2.3. The growth media was replaced with fresh media containing 
3 mM glucose for 24 hours. The media was removed and cells were rinsed three times 
with pre-warmed (37oC) PBS. Cells were then incubated in 0.5 mL pre-warmed (37oC) 
Krebs Ringer buffer (120 mM NaCl, 24 mM NaHCO3, 4.8 mM KCl, 2.5 mM 
CaCl2.6H2O, 1.2 mM MgCl2.6H2O and 0.1% (w/v) radioimmunoassay grade BSA freshly 
gassed with 95% O2 for 10 minutes, pH 7.5) containing 3 mM glucose at 37°C in a water 
bath for 1 hour. The buffer was replaced with 0.5 mL fresh Krebs Ringer buffer containing 
different glutamate receptor agonists and antagonists in the presence of 3 mM or 30 mM 
glucose as described in Figure 2.3.  
Experiments were conducted in triplicates and repeated a minimum of three times.  
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 Figure 2.3. Summary of experimental procedure for measurement of insulin secretion in MIN6 and INS-1 β-cells. Cells were seeded in 12-well 
plates for 24 hours in growth media containing 25 mM for MIN6 and 11 mM for INS-1. The media was replaced with fresh media containing 3 mM glucose 
for MIN6 and INS-1 for 24 hours. The media was removed and cells were incubated with different combinations of drugs.  
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After incubation, the supernatant was removed and centrifuged at 700 x g to remove dead 
cells and debris. The supernatant, which contains secreted insulin, were stored at -20°C 
for insulin assay. 100 µL of lysis buffer (75% (v/v) ethanol, 23.5% (v/v) deionised water, 
1.5% (v/v) HCl) supplemented with 1X (v/v) protease inhibitor cocktail (Roche complete 
mini EDTA-free) was added to the cells and incubated for 5 minutes at 4°C. The cells 
were scrapped from the wells and transferred into eppendorf tubes on ice. Another 100 
µL of lysis buffer was added to the wells to remove residual cells and transferred into 
eppendorf tubes. The mixture was passed through a GS 351 (21g x 1.5 inches; 0.8 x 
40mm) needle attached to a syringe for about 20-25 times to break down the cells. The 
lysate was centrifuged at 900 x g for 5 minutes at 4°C and the supernatant, which contains 
the retained insulin, were stored at -20°C for insulin assay. 
The insulin ELISA assay was carried out following the Mercodia Mouse or Rat Insulin 
ELISA instructions. MIN6 samples were diluted 1:15 for secreted insulin and 1:3000 for 
retained insulin while INS-1 samples were diluted 1:2 for secreted insulin and 1:20 for 
retained insulin.  
To prepare standard curves for the Mercodia mouse and rat insulin ELISA assays, 10 µL 
of standard calibrators (0, 0.2, 0.5, 1.5, 3.0 and 6.5 µg/µL for mouse and 0, 0.15, 0.4, 1.0, 
3.0 and 5.5 µg/µL for rat) and 100 µL enzyme conjugate were added to coated ELISA 
wells and incubated at room temperature for 2 hours on an ELISA plate shaker. The 
reaction mixture was discarded and the wells were rinsed four times with wash buffer 
solution after which 200 µL of TMB substrate solution was added to the wells and 
incubated at room temperature for 15 minutes away from light. The reaction was then 
stopped by adding 50 µL of stop solution for 10 seconds and optical density measured at 
450 nm using Fluostar Optima plate reader (BMG Labtech, Aylesbury, UK). The test 
samples were analysed using the same protocol as for the standards. 
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A calibration curve of optical density against concentration of the standard calibrators 
was plotted using the following: y = mx + c, (where y- optical density, m- gradient of the 
curve, x- concentration and c- y intercept).  
Secreted insulin was expressed as a percentage of total insulin (secreted + retained) and 
the proportion obtained from each experiment averaged.  
Bar charts representing mean insulin secretion (% of total insulin content) ± SEM of five 
experiments were plotted using Excel data analysis suite (Microsoft, Berkshire, UK) and 
means were compared using one-way or two-way ANOVA (Minitab, Pennsylvania, USA) 
or Student’s t-test. 
  
2.3.14. Statistical analysis 
Data are presented as means ± SEM/SD of at least three independent experiments with 
number of replicates stated in respective experiments. Statistical comparisons were 
performed by one-tailed Student’s t-test using Microsoft Excel, one-way or two-way 
ANOVA using Minitab data analysis software. Differences between means were 
considered statistically significant if the p value was less than 0.05.  
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2.4. Results 
2.4.1. KAR subunits in pancreatic endocrine cells 
To establish the molecular composition of KAR subunits in pancreatic endocrine cells, 
reverse transcription PCR and immunoblotting were used to investigate the presence of 
pore forming GluK1-5 subunits and auxiliary Neto1 and Neto 2 subunit mRNAs and 
proteins, respectively. The relative amounts of KAR subunit mRNA and protein in 
pancreatic endocrine cells were also determined. 
 
2.4.1a. KAR subunit transcripts are expressed in pancreatic α- and β-cells lines and rat 
islet of Langerhans  
To establish the molecular composition of KAR subunits in pancreatic endocrine cells, 
total RNA from MIN6 (mouse), INS-1 (rat), α-TC (mouse) cell lines and rat islets of 
Langerhans were reverse-transcribed and the cDNA was subjected to PCR. The primer 
sequences, annealing temperatures, PCR product sizes and Mg2+ concentration are shown 
in Tables 2.2-2.4.   
MIN6, INS-1 and α-TC cells expressed GluK2, GluK3, GluK4 and GluK5 KAR subunits 
(Figures 2.4 and 2.5) while all five (GluK1-5) pore forming KAR subunits were expressed 
in rat islets of Langerhans (Figure 2.5). These observations indicate that cultured 
pancreatic endocrine cells lack GluK1 subunit-containing KARs.  
As expected, all five KAR subunits were detected in both mouse and rat brain (Figures 
2.4 and 2.5). The housekeeping β-actin gene was also detected in all samples tested 
(Figures 2.4-2.6). These results confirmed the integrity of cDNA templates and also 
indicated that each step of the sample preparation and PCR worked appropriately. 
The sizes of PCR products of KAR subunits corresponded to those predicted by the 
primer design software. There were no PCR products in the negative controls, which 
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consisted of all reagents in the absence of cDNA templates. All PCR products were 
confirmed by sequencing (Appendix 1).  
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Figure 2.4. KAR subunit transcripts are expressed in cultured mouse pancreatic β- 
and α-cells. Mouse KAR subunit-specific primers were used to detect mRNAs for GluK1-
5 in MIN6 and α-TC cells. Mouse brain (MB) was used as positive control. Negative 
controls were PCR without template ((-) C). Sizes of the products are indicated at the 
bottom of the panel. PCR bands were purified and verified by sequencing. Figure is 
representative of three separate experiments performed using cells at different passages. 
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Figure 2.5. KAR subunit transcripts are expressed in cultured rat pancreatic β-cells and 
primary islets of Langerhans. Rat KAR subunit-specific primers were used to detect 
GluK1-5 in INS-1 β-cells and rat primary islets of Langerhans (RIL). Rat brain (RB) was 
used a positive control. Sizes of PCR products are indicated at the bottom of the panel. Figure 
is representative of three separate experiments performed using cells at different passages. 
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Previous studies have shown that KAR subunits are not expressed in mouse (Gonoi et al., 
1994) or rat liver (Chew et al., 2001). Mouse and rat liver cDNA were used in PCR using 
KAR subunit primers. β-actin was amplified from rat liver cDNA template. mRNAs of 
KAR subunits were not present in mouse or rat liver tissue (Figure 2.6). This observation 
confirms the specificity of the KAR primers. 
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Figure 2.6. KAR subunit transcripts are not expressed in the liver. KAR subunit specific primers were used to investigate expression of KAR subunits in 
mouse (A) or rat (B) liver. cDNA from mouse and rat brain were used in the reaction as positive control whiles negative controls were PCR without template 
((-) C). β-actin was amplified from rat liver cDNA template.  Sizes of the products are indicated at the bottom of the panel. B: brain; L: liver. Figure is 
representative of three separate experiments. 
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2.4.1b. Semi-quantitative analysis of KAR subunit mRNA expression in pancreatic α- and 
β-cell lines 
To investigate whether there are differences in KAR subunit mRNA expression between 
pancreatic α- and β-cells, amounts of GluK2 and GluK5 mRNAs normalised to β-actin in 
MIN6 and α-TC cells were determined. The optimum number of cycles of PCR required 
for the amplification of KAR subunit mRNA to be within the linear phase was determined 
using PCR cycle numbers of 15, 20, 25, 30 and 35 (Section 2.3.8). Pixel volume was 
plotted against PCR cycle number for GluK2, GluK5 and β-actin to select cycles within 
the linear phase of the reaction (Figure 2.7).  
Based on the initial curves obtained, the PCR cycle analysis was repeated for GluK2 (26, 
28, 30 cycles) and GluK5 (28, 30, 32) to select the optimum number of PCR cycles for 
these primers (Figure 2.8). 
The densitometry analysis and PCR curves indicated that the PCR reaction was linear at 
29 cycles for GluK2, 31 cycles for GluK5 and 20 cycles for β-actin. 
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Figure 2.7. Determination of the linear phase of GluK2 and GluK5 amplification. Mouse brain cDNA was subjected to PCR using primers specific for β-
actin, GluK2 and GluK5. PCR products were separated and visualised (A) and the pixel volume of the bands were measured using ImageJ. Pixel volume was 
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Figure 2.8. Determination of the linear phase of the PCR for GluK2 and GluK5 amplification. Mouse brain cDNA was used as templates for PCR using primers 
specific for GluK2 (cycles 26, 28, 30) and GluK5 (cycles 28, 30, 32). PCR products were separated and visualised (A and B) and the pixel volume of the bands were 
measured using ImageJ. Pixel volume was plotted against PCR cycle number for GluK2 (C) and GluK5 (D) and then PCR cycle numbers (29 for GluK2 and 31 for 
GluK5) were selected from the linear regions of each of the curves. Graphs represents means ± SD from one experiment performed in triplicate.  
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PCR using the selected number of cycles was performed and pixel volume of GluK2 was 
divided with that of β-actin and the obtained ratio from each experiment was averaged. 
The same procedure was used to determine the amount of GluK5 in islet cell lines and 
brain tissue. The obtained values were compared between the various samples using 
Student’s t-test analysis (Figure 2.9).   
There was no significant difference in expression of GluK2 or GluK5 subunit mRNAs 
between MIN6 β-cells and α-TC cells. Expression of GluK2 mRNA in the brain was 
significantly higher compared to MIN6 and α-TC whiles there was no significant 
difference in expression of GluK5 in the brain compared to MIN6 β-cells and α-TC cells 
(Figure 2.9). 
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Figure 2.9. Expression of GluK2 and GluK5 mRNA in MIN6 β-cells is not significantly different from α-TC cells. PCR products were separated on agarose 
gel and visualised (A). Pixel volume were measured for each PCR band using ImageJ and normalised to β-actin. The mean relative amounts of mRNA in the cells 
were compared using Student’s t-test (B). Bar chart represents means ± SEM from three separate experiments each performed in duplicate. *p<0.05; **p<0.01; 
***p<0.001. 
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2.4.1c. KAR subunit proteins are present in pancreatic α- and β-cell lines.  
The presence of KAR proteins in MIN6 and INS-1 β-cells and α-TC cells was investigated 
using antibodies specific for GluK2/3 and GluK5 subunits (section 2.3.9). 
Immunoblotting of KAR subunit proteins showed that both GluK2/3 and GluK5 are 
present in MIN6, α-TC and INS-1 pancreatic endocrine cells (Figure 2.10). As expected, 
GluK2/3 and GluK5 receptor protein were also present in the positive control, mouse 
brain.  
The relative amounts of KAR protein in MIN6, INS-1 and α-TC was determined by 
measuring the pixel volume of KAR immunopositive bands using the ImageJ software. 
The pixel volume of KAR bands were normalised to pixel volume of β-actin internal 
standards (section 2.3.10).  
Statistical analysis using Student’s t-test showed that there was no significant difference 
in KAR subunit protein (GluK2/3 and GluK5) levels between β-cells (MIN6, INS-1) and 
the α-cells (α-TC) (Figure 2.11).  
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Figure 2.10. Investigation of KAR subunit proteins in pancreatic endocrine cell lines. The presence of GluK2/3 and GluK5 proteins in mouse 
brain, MIN6 and α-TC (A) and INS-1 (B) was detected on immunoblots by subunit-specific antibodies. Figure (A) is representative of three 
independent experiments using cells at different passages. Each lane in Figure (B) represents protein lysate prepared from cells at different 
passages.  
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Figure 2.11. Analysis of relative amounts of KAR subunit protein in MIN6 and INS-1 β-cells 
and α-TC cells. Immunoblotting with specific antibodies against GluK2/3 (A) and GluK5 (B) were 
used to detect the proteins and the pixel volume of the bands was measured using ImageJ software. 
Pixel volume of the bands were normalised to their corresponding β-actin. Results represent means 
± SEM from three separate experiments. *p<0.05; **p<0.01; ***p<0.001.
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2.4.2. Investigation of KAR auxiliary subunits in pancreatic endocrine cells 
2.4.2a. Neto 1 and Neto 2 subunit mRNA are expressed in pancreatic α- and β-cells and 
in rat islet of Langerhans  
Neto 1 and Neto 2 are transmembrane auxiliary subunits of KARs therefore they are of 
significant importance for the function of pre- and post-synaptic KARs (Chapter one, 
section 1.5). The expression of Neto 1 and Neto 2 mRNAs in pancreatic endocrine cells 
was investigated using specific primers in PCR. Rat brain cDNA was used as positive 
control since Neto 1 and Neto 2 are expressed in rat brain (Tomita and Castillo, 2012). 
Neto 1 and Neto 2 mRNAs were shown to be expressed in MIN6 and INS-1 β-cells, α-
TC cells and in rat islets of Langerhans (Figure 2.12).  As expected, both were present in 
the positive control, rat brain.  
In addition to setting up PCR reactions without templates, cDNA from rat liver was used 
to test for specificity of Neto 1 and Neto 2 primers. Transcript of Neto 1 was present in 
rat liver but Neto 2 was not detected. cDNA from liver was used to determine whether 
the liver can be used as a reliable template for negative control of Neto 1 and Neto 2 PCR. 
Data from the EMBL Expression Atlas (https://www.ebi.ac.uk/gxa/home) and T1DBase 
(https://www.t1dbase.org/page/Welcome/display) show that detectable levels of Neto 1 
and Neto 2 subunit mRNA are present in rat liver. Thus, the liver is not a reliable source 
of template for negative control of PCR for Neto 1 and Neto 2 mRNA. 
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Figure 2.12. Neto 1 and Neto 2 mRNA are expressed in pancreatic α- and β-cells and rat islet of Langerhans. The presence of Neto 1 and Neto 2 
mRNAs was determined using specific primers in PCR. Negative controls were PCR reaction without template ((-) C). RB: rat brain, RIL: rat islets of 
Langerhans, LIV: rat liver. 
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2.4.2b. Semi-quantitative analysis of Neto 1 and Neto 2 mRNA expression in cultured 
pancreatic α- and β-cells.  
To investigate whether there is a difference in Neto 1 and Neto 2 subunit mRNA 
expression between α- and β-cells, the linear phase of the PCR for Neto 1 and Neto 2 
were determined using 15, 20, 25, 30 and 35 cycles for PCR (section 2.3.8). The pixel 
volume was plotted against number of PCR cycles to select cycles within the linear phase 
of the reaction (Figure 2.13). The plots indicated that the PCR reaction was linear at 30 
cycles for Neto 1 and 28 cycles for Neto 2, cycles used for β-actin was as described in 
section 2.4.1, Figure 2.7. The selected cycles were used for PCR with MIN6, α-TC and 
mouse brain cDNA templates and pixel volume of Neto 1 was divided with that of β-actin 
and the obtained ratio from each experiment was averaged. The same procedure was used 
to determine the amount Neto 2 in the cell lines and brain tissue. The obtained values 
were compared between the various samples using Student’s t-test analysis (Figure 2.14).   
Neto 1 mRNA expression was significantly higher in α-cells than in β-cells. In contrast, 
Neto 2 mRNA was higher in β-cells than in α-cells. Both Neto 1 and Neto 2 expression 
was significantly higher in brain tissue compared to either endocrine cells (Figure 2.14). 
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Figure 2.13. Determination of the linear phase of Neto 1 and Neto 2 PCR. Mouse brain cDNA was used as templates for PCR using primers specific for 
Neto 1 and Neto 2. PCR products were separated and visualised (A and B) and the pixel volume of the bands were measured using ImageJ. Pixel volume was 
plotted against PCR cycle number for Neto 1 (C) and Neto 2 (D) and then PCR cycle numbers (30 for Neto 1 and 28 for Neto 2) were selected from the linear 
regions of each of the curves. One experiment was performed. 
 Cycle curves of pixel volume against PCR cycle number were plotted for Neto 1 (B) and Neto 2 (C) and then PCR cycle numbers were selected from the linear 
regions of each of the curves.  
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Figure 2.14. Semi-quantitative analysis of Neto 1 and Neto 2 mRNA expression in MIN6 β-cells and α-TC cells. PCR products were separated on 
agarose gel and visualised (A). Pixel volume were measured for each PCR band using ImageJ and normalised to β-actin. The mean relative amounts of 
mRNA in the cells were compared using Student’s t-test analysis (B). Bar chart represents means ± SEM from three separate experiments each performed 
in duplicate. *p<0.05; **p<0.01; ***p<0.001. 
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2.4.2c. Neto 1 and Neto 2 subunit protein are present in pancreatic α- and β-cell lines.  
To investigate the presence of Neto 1 and Neto 2 protein in pancreatic endocrine cells, 
antibodies against these proteins were used in immunoblotting (section 2.3.9).  
Immunoblotting showed that Neto 1 and Neto 2 proteins are present in MIN6 and INS-1 
β-cells and α-TC cells (Figure 2.15). This indicates that KAR subunits proteins are present 
in pancreatic endocrine cells together with their auxiliary proteins. As expected, Neto 1 
and Neto 2 proteins were present in mouse brain. 
The relative amounts of Neto 1 and Neto 2 protein in MIN6 and INS-1 β-cells and α-TC 
cells were determined by measuring the pixel volumes of Neto 1 and Neto 2 
immunopositive bands (section 2.3.10). The pixel volume of Neto 1 and Neto 2 were 
normalised to β-actin internal standards. 
In agreement with the mRNA, the relative amount of Neto 1 protein in α-TC cells was 
found to be significantly higher than in MIN6 and INS-1 β-cells. In contrast, the relative 
amounts of Neto 2 proteins in MIN6 and INS-1 β-cells were significantly higher than in 
α-TC cells (Figure 2.16). 
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Figure 2.15. Neto 1 and Neto 2 proteins are present in pancreatic endocrine cells. The presence of Neto 1 and Neto 2 protein in MIN6, 
α-TC (A) and INS-1 cells (B) was detected on immunoblots by subunit-specific antibodies. Figure (A) is representative of three independent 
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Figure 2.16. Analysis of relative amounts of Neto 1 and Neto 2 protein in MIN6 and INS-1 
β-cells and α-TC cells. Immunoblotting with specific antibodies against Neto 1 (A) and Neto 2 
(B) were used to detect the proteins and the pixel volumes of the bands were measured using 
ImageJ software. Pixel volume of the bands were normalised to their corresponding β-actin 
immunoreactivities. Results represent means ± SEM from three separate experiments. *p<0.05; 
**p<0.01; ***p<0.001. 
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2.4.3. Measurement of changes in intracellular calcium ion concentration [Ca2+]i in 
cultured MIN6 pancreatic β-cells. 
KAR subunits are present in pancreatic α- and β-cells and islets of Langerhans together 
with Neto 1 and Neto 2 auxiliary subunits (Sections 2.4.1-2.4.2). These observations 
suggest that functional KARs could assemble in α- and β-cells of the pancreas.  
The main function of β-cells is secretion of insulin to regulate blood glucose (Rorsman 
and Braun, 2013) and studies have shown that exocytosis of insulin granules from β-cells 
is primarily dependent on the intracellular calcium concentration ([Ca2+]i) (Pedersen et 
al., 2011; Hou et al., 2009). Thus, the role of KARs in the regulation of [Ca2+]i  in MIN6 
β-cells was investigated.  
 
2.4.3a. Kainate induces transient changes in [Ca2+]i in MIN6 β-cells. 
MIN6 β-cells cultured in low (3 mM) glucose and loaded with FURA-2AM calcium was 
perifused with 25 µM kainate prepared in HBSS solution containing either 3 mM or 30 
mM glucose. The mean fluorescence intensity ratio which represents changes in [Ca2+]i 
was measured and analysed using Volocity Image Analysis software (section 2.3.11). A 
plot of fluorescence ratio against time after application of kainate is shown in Figure 2.17 
and bar charts representing the mean change in fluorescence ratio ± SEM are shown in 
Figure 2.18. Two-way ANOVA was used to determine if there is significant evidence for 
interaction between concentration of glucose and first/second stimulation. 
Activation of KARs in MIN6 β-cells with 25 µM kainate induced an increase in [Ca2+]i 
relative to the baseline measurements at both stimulatory (30 mM) and non-stimulatory 
(3 mM) glucose concentrations. These changes in [Ca2+]i were observed subsequent to 
both first and second applications of kainate (Figure 2.17).  
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Two-way ANOVA showed that mean increase in [Ca2+]i induced by kainate was 
significantly higher in the presence of 30 mM glucose compared to 3 mM glucose. In the 
presence of 3 mM or 30 mM glucose, the mean increase in [Ca2+]i induced by the first 
kainate perifusion was not significantly different from the second application (Figure 
2.18). The two-way ANOVA showed that there was no significant evidence for a glucose 
concentration*stimulation interaction effect on the mean increase in [Ca2+]i induced by 
kainate (p=0.557). 
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Figure 2.17. Kainate induces transient changes in [Ca2+]i in MIN6 β-cells. MIN6 β-cells were perifused with 25 µM kainate and fluorescence ratios 
were measured in 30-50 cells and normalised to ratios obtained during the first three minutes of recording under basal conditions. Results represent 
mean ± SEM of four independent experiments.  
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Figure 2.18. Kainate induces transient changes in [Ca2+]i in the presence of 3 mM and 30 mM glucose in MIN6 β-cells in. Means were 
compared using two-way ANOVA. Results are presented as mean ± SEM of four separate experiments. *p<0.05; **p<0.01; ***p<0.001. 
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2.4.3b. Kainate-induced change in [Ca2+]i is not affected by the inactivation of AMPA 
and NMDA receptors.  
 AMPARs and KARs have been shown to possess some similar characteristics including 
their response to agonists at specific concentrations (Rogawski, 2011). Moreover, both 
NMDA and AMPA receptors are expressed in pancreatic β-cells (Molnar et al., 1995; 
Gonoi et al., 1994). Thus, the observed kainate-induced change in [Ca2+]i could be due to 
AMPAR or NMDAR activation. To investigate this hypothesis, changes in [Ca2+]i  in 
MIN6 β-cells subsequent to application of kainate in the presence of Gyki-52466; a 
competitive inhibitor of NMDA and AMPA receptors was monitored using FURA-2AM 
calcium dye (section 2.3.11).  
Application of 25 µM kainate only or after pre-incubation of the cells with 100 µM Gyki-
52466 resulted in changes in [Ca2+]i (Figure 2.19). The mean increase in [Ca
2+]i 
normalised to the baseline was significantly higher in the presence of 30 mM glucose than 
3 mM glucose indicating a significant evidence for glucose concentration on the mean 
increase in [Ca2+]i induced by kainate (p<0.001). This was observed subsequent to 
application of kainate only or kainate after pre-incubation with Gyki-52466 (Figure 2.20). 
In addition, the increase in [Ca2+]i induced by 25µM kainate only was not statistically 
different from the increase in [Ca2+]i induced by 25µM kainate in the presence of 100 µM 
Gyki-52466. This was observed at both glucose concentrations and thus indicates that 
there is no significant evidence for Gyki-52466 on the mean increase in [Ca2+]i induced 
by kainate (p=0.285) (Figure 2.20).  
The two-way ANOVA also indicated that there was no significant evidence for a glucose 
concentration*stimulation interaction effect on the mean increase in [Ca2+]i induced by 
kainate (p=0.590). 
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These results indicate that the observed change in [Ca2+]i  subsequent to application of 
kainate was due to activation of KARs and that inhibition of NMDA and AMPA receptors 
had no significant effect on this change.  
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Figure 2.19. Kainate-induced [Ca2+]i change is not blocked by competitive inhibitor of AMPA/NMDA receptor, Gyki-52466. MIN6 β-cells were perifused 
with 25 µM kainate or kainate after pre-incubation with 100 µM Gyki-52466 and fluorescence ratios were measured in 30-50 cells and normalised to ratios 
obtained during the first three minutes of recording under basal conditions. Results represent mean ± SEM of four independent experiments.   
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Figure 2.20. Bar graph representing the maximal variation in the fluorescence ratio induced by kainate or kainate in the presence of AMPA/NMDA 
receptor antagonist Gyki-52466. Means were compared using two-way ANOVA. Results represent mean ± SEM for four independent experiments. *p<0.05; 
**p<0.01; ***p<0.001.  
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2.4.3c. Kainate-induced change in [Ca2+]i is specifically blocked by the KAR/AMPA 
receptor antagonist NBQX.  
NBQX has been shown to inhibit homomeric GluK1, GluK2, GluK3 as well as 
heteromeric combination of GluK2 and GluK5 (Matute, 2011; Jane et al., 2009) (Chapter 
one, section 1.5.5). Thus, to further confirm the effect of kainate on [Ca2+]i in MIN6 β-
cells, cells were perifused with 25 µM kainate only or kainate after pre-incubation with 
30 µM of a competitive AMPAR/KAR antagonist; NBQX,  
Application of kainate induced changes in [Ca2+]i in the presence of 3 mM or 30 mM 
glucose compared to the baseline measurements. In contrast, application of kainate 
subsequent to pre-incubation with NBQX in the presence of 3 mm or 30 mM glucose 
induced a minimal change in [Ca2+]i in MIN6 β-cells relative to baseline measurements 
(Figure 2.21). The mean increase in [Ca2+]i induced by kainate only and normalised to 
baseline measurements was significantly higher in the presence of 30 mM glucose 
compared to 3 mM glucose indicating that there is significant evidence for glucose 
concentration on the mean increase in [Ca2+]i induced by kainate (p<0.04). The increase 
in [Ca2+]i induced by kainate only and normalised to baseline measurements was 
significantly higher than the change induced by kainate subsequent to pre-incubation with 
NBQX at both glucose concentrations (Figure 2.22). The two-way ANOVA indicates that 
there is significant evidence for kainate inhibitor (NBQX) on the mean increase in [Ca2+]i 
induced by kainate (p<0.001). The analysis also indicates that there is significant evidence 
for a glucose concentration*inhibitor interaction effect on the mean increase in [Ca2+]i 
induced by kainate (p=0.031). 
These results suggest that the observed increase in [Ca2+]i were due to activation of KARs 
and that inhibition of these receptors by NBQX attenuated the observed effect. 
Chapter Two                                                                                                                                                                                                       2.4 Results 143 
 
 
 
 
                                                                                                                                                                                                                                                             
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                                                                      
Glucose 
30 mM   
  3 mM 
 
0.99
1.01
1.03
1.05
1.07
1.09
1.11
Kainate (25 µM) 
NBQX (30 µM) 
Kainate (25 µM) 
1min 
F
lu
o
re
s
c
e
n
c
e
 r
a
ti
o
 (
F
3
4
0
/F
3
8
0
) 
 
Figure 2.21. Kainate-induced changes in [Ca2+]i are blocked by KAR/AMPA receptor antagonist NBQX. MIN6 β-cells were perifused with 
25 µM kainate or kainate after pre-incubation with 30 µM NBQX and fluorescence ratios were measured in 30-50 cells and normalised to ratios 
obtained during the first three minutes of recording under basal conditions. Results represent mean ± SEM of three independent experiments.  
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Figure 2.22. Bar graph representing the maximal variation in the fluorescence ratio induced by kainate or kainate in the presence of KAR/AMPA 
receptor antagonist NBQX. Means were compared using two-way ANOVA. Results represent mean ± SEM for three independent experiments. *p<0.05; 
**p<0.01; ***p<0.001. p<0.05; **p<0.01; ***p<0.001. 
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2.4.3d. Kainate-induced change in [Ca2+]i is potentiated by the selective group I mGlu 
receptor agonist DHPG.  
KARs represent a unique subtype of iGluRs because some of the functions of KARs in 
the CNS are mediated through an unconventional non-canonical (metabotropic) 
signalling involving G-proteins and second messengers and activation of group I mGluRs 
also potentiates KAR signalling and action (Rutkowska-Wlodarczyk et al., 2015) (section 
1.5.8). To investigate this possibility with respect to changes in [Ca2+]i, MIN6 β-cells 
were perifused with 25 µM kainate only or kainate after pre-incubation with 50 µM of a 
selective group I mGlu receptor agonist, DHPG.  
Application of kainate only or kainate subsequent to pre-incubation of the cells with 
DHPG induced changes in [Ca2+]i in the presence of 3 mM or 30 mM glucose compared 
to the baseline measurements (Figure 2.23). In the presence of 30 mM glucose, incubation 
of the cells with DHPG induced minor changes in [Ca2+]i relative to baseline 
measurements (Figure 2.23).  
The mean increase in [Ca2+]i induced by kainate only and normalised to baseline 
measurements was significantly higher in the presence of 30 mM glucose compared to 3 
mM glucose indicating that there is significant evidence for glucose concentration effect 
on the mean increase in [Ca2+]i induced by kainate (p<0.001). Perifusion of the cells with 
kainate after pre-incubation with DHPG (normalised to DHPG only) induced 
significantly higher increase in [Ca2+]i  compared to increase in [Ca
2+]i induced by 
application of kainate (normalised to baseline measurements). This was observed at both 
glucose concentrations (Figure 2.24). The two-way ANOVA indicates that there is 
significant evidence for group I mGlu receptor agonist (DHPG) on the mean increase in 
[Ca2+]i induced by kainate (p<0.002). The analysis also indicates that there is no 
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significant evidence for a glucose concentration*DHPG effect on the mean increase in 
[Ca2+]i induced by kainate (p=0.190).  
These observations indicate that activation of group I mGluRs by DHPG in β-cells 
potentiates the kainate-induced increase in [Ca2+]i. 
The responsive of the cells and sensitivity of the calcium imaging system was tested by 
application of 15 mM KCl after each experiment. This concentration of KCl has been 
shown to depolarise cell membranes to cause influx of Ca2+ (Andersson et al., 2015). 
Application of 15 mM KCl resulted in increased [Ca2+]i in MIN6 β-cells which indicates 
that the cells were responsive during the experiment (Figure 2.25).  
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Figure 2.23. Kainate-induced change in [Ca2+]i is potentiated by mGluR I receptor agonist DHPG. MIN6 β-cells were perifused with 25 µM 
kainate or kainate after pre-incubation with 50 µM DHPG and fluorescence ratios were measured in 30-50 cells and normalised to ratios obtained 
during the first three minutes of recording under basal conditions. Results represent mean ± SEM of three independent experiments.  
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Figure 2.24. Bar graph representing the maximal variation in the fluorescence ratio induced by kainate or kainate in the presence of group I 
mGlu receptor agonist, DHPG. Means were compared using two-way ANOVA. Results represent mean ± SEM for three independent experiments. 
*p<0.05; **p<0.01; ***p<0.001. p<0.05; **p<0.01; ***p<0.001. 
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Figure 2.25. KCl-induced increase in [Ca2+]i in MIN6 β-cells. MIN6 β-cells were perifused with 15 mM KCl and fluorescence ratios were measured 
in 30-50 cells and normalised to ratios obtained during the first three minutes of recording under basal conditions (A). Bar graph representing the 
maximal variation in the fluorescence ratio induced by KCl (B). Results represent mean ± SEM of three independent experiments.  
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2.4.4. Investigation of the effect of KAR activation on insulin secretion in cultured 
MIN6 and INS-1 pancreatic β-cells  
The main function of pancreatic β-cells is insulin secretion (section 1.2). In these cells, 
secretion of insulin is primarily controlled by concentration of glucose but other nutrients 
including lipids and amino acids also modulate insulin release (Dou et al., 2015). Results 
from the calcium imaging studies (section 2.4.3) suggest that activation of KAR subunits 
by kainate increases [Ca2+]i in β-cells. Based on these observations; we tested the effect 
of kainate on insulin secretion from pancreatic β-cells was investigated.  
To investigate insulin secretion subsequent to KAR activation, MIN6 (mouse) and INS-
1 (rat) pancreatic β-cells were seeded and incubated with KAR agonists (kainate) and 
antagonists (NBQX), NMDAR/AMPAR antagonist (Gyki-52466) and group 1 mGluR 
agonist (DHPG) described in section 2.3.13 and Figure 2.3.  
A calibration curve was plotted for the Mercodia mouse and rat insulin ELISA assay 
(Diagenics, Milton Keynes, UK) and used to determine the amount of insulin secreted 
from the cells (section 2.3.13). Secreted insulin from MIN6 and INS-1 β-cells was 
calculated as a percentage of total insulin which includes the secreted and retained insulin. 
Insulin secretion was measured in both rat and mouse cell lines to ensure that the observed 
effect is not species-specific. Plots of optical density of the insulin standards against their 
concentration for mouse and rat ELISA assays are shown in Figures 2.26 and 2.27 
respectively.  
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Figure 2.26. Calibration curve of Mercodia mouse insulin ELISA assay. The equation of the standard curve was derived and used to estimate the 
concentration of insulin in the test samples. Results represent means ± SD from a single experiment performed in triplicate. 
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Figure 2.27. Calibration curve of Mercodia rat insulin ELISA assay. The equation of the standard curve was derived and used to estimate the 
concentration of insulin in the test samples. Results represent a single experiment performed.  
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2.4.4a. Activation of KARs by kainate potentiates glucose-stimulated insulin secretion 
(GSIS) from MIN6 and INS-1 β-cells. 
To determine the effect of KAR activation on GSIS, MIN6 and INS-1 β-cells were 
incubated with KAR agonists and antagonists as described in section 2.3.13.  
In both MIN6 and INS-1 β-cells, 25 µM kainate increased significantly the amount of 
insulin released from the cells compared to controls. This significant increase in insulin 
secretion was observed in the presence 3 mM or 30 mM glucose (Figures 2.28-2.31).  
Insulin secretion induced by incubation of MIN6 and INS-1 β-cells with kainate 
subsequent to pre-incubation with 30 µM NBQX (selective and competitive AMPA and 
kainate receptor antagonist) was significantly lower compared to insulin secretion 
induced by kainate only.  
In both MIN6 and INS-1 cells, insulin secretion induced by kainate in the presence of a 
competitive inhibitor of NMDA and AMPA receptors, Gyki-52466 was not statistically 
different from the amount of insulin induced by kainate only. 
In the presence of group 1 mGluR agonist, DHPG insulin secretion induced by kainate in 
MIN6 or INS-1 cells was not statistically different from the amount of insulin induced by 
kainate only.  
Incubating the cells with 15 mM KCl caused significant increase in insulin secretion from 
both MIN6 and INS-1 β-cells (Figures 2.28-2.31). The aim of incubating the cells with 
KCl was to test the responsiveness of the cells and the sensitivity of the assay since KCl 
has been shown to induce significant increase in GSIS in β-cell lines (Andersson et al., 
2015).   
Kainate-induced increase in insulin secretion from both MIN6 and INS-1 β-cells was 
shown to be dependent on the concentration of glucose. In both cell lines, kainate-induced 
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increase insulin secretion was significantly higher in the presence of 30 mM compared to 
3 mM glucose (Figure 2.32).  
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Figure 2.28. Activation of KARs potentiates insulin secretion from MIN6 mouse 
pancreatic β-cells in the presence of 3 mM glucose. Means were compared using Student’s 
t-test analysis. Results are presented as means ± SEM from five separate experiments. 
*p<0.05; **p<0.01; ***p<0.001. 
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Figure 2.29. KAR activation potentiates insulin secretion from MIN6 mouse 
pancreatic β-cells in the presence of 30 mM glucose. Student’s t-test was used to 
compare means. Results are presented as means ± SEM from five separate experiments. 
*p<0.05; **p<0.01; ***p<0.001. 
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Figure 2.30. Activation of KARs potentiates insulin secretion from INS-1 rat 
pancreatic β-cells in the presence of 3 mM glucose. Means were compared using 
Student’s t-test analysis. Results are presented as means ± SEM from five separate 
experiments. *p<0.05; **p<0.01; ***p<0.001. 
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Figure 2.31. Activation of KARs potentiates insulin secretion from INS-1 rat 
pancreatic β-cells in the presence of 30 mM glucose. Means were compared using 
Student’s t-test analysis. Results are presented as means ± SEM from five separate 
experiments. *p<0.05; **p<0.01; ***p<0.001. 
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Figure 2.32. Kainate-induced insulin secretion from MIN6 and INS-1 β-cells is dependent 
on glucose concentration. Means were compared using Student’s t-test analysis. Results are 
presented as means ± SEM from five separate experiments. *p<0.05; **p<0.01; ***p<0.001. 
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2.4.5. Effect of prolonged exposure to glutamate and kainate on the viability of 
pancreatic α-cells and β-cells.  
Extensive research has shown that cells of the CNS are vulnerable to chronic activation 
of iGluR subtypes. Prolonged exposure to kainate and glutamate has been shown to cause 
excitotoxicity in primary neurons, oligodendrocytes, astrocytes as well as in mice (Dong 
et al., 2012; Domin et al., 2010).  
Since KAR subunit mRNA and protein have been shown to be present in pancreatic 
endocrine cells (section 2.4.1), the effect of prolonged exposure of β-cells and α-cells to 
glutamate and kainate was investigated. 
 
2.4.5a. Prolonged exposure to glutamate and kainate results in significant reduction in 
viability of cultured pancreatic α-cells and β-cells.  
Change in cell viability subsequent to chronic exposure of cells to kainate and glutamate 
was investigated using the MTT assay. This assay has been used extensively to study the 
viability of cultured cells in several areas of research including endocrinology and 
neuroscience (Di Cairano et al., 2011; Zhu et al., 2016). Cultured INS-1 β-cells and α-
TC cells were incubated with different concentrations of kainate and glutamate for 72 
hours (section 2.3.12). As control INS-1, α-TC and SH-SY5Y cells were cultured under 
the same conditions in the absence of glutamate or kainate. Viability of the cells after 
treatment was determined by MTT assay (section 2.3.12). 
Similar to other neuronal cells, viability of SH-SY5Y cells have been shown to reduce 
significantly subsequent to prolonged exposure to kainate and glutamate (Zhu et al., 2016; 
Cannarsa et al., 2008) hence this cell line was used as a positive control for kainate- and 
glutamate-induced changes in cell viability.  
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Chronic exposure of α-TC and INS-1 cells to 0.25-12.0 mM glutamate or 0.1-0.5 mM 
kainate resulted in significantly reduced cell viability relative to controls (Figure 2.33). 
As expected, there was significant reduction in viability of SH-SY5Y cells after exposure 
to glutamate or kainate (Figure 2.33). Glutamate- and kainate-induced reduction in 
viability of INS-1 cells was dose-dependent (Figure 2.34). 
Moreover, as expected, viability of INS-1, α-TC and SH-SY5Y cells after incubation with 
40% ethanol or 2% triton X-100 was reduced to less than 2% of control (Figure 2.34).  
These observations suggest that similar to cells of the central nervous system, both α-
cells and β-cells of the pancreas are vulnerable to prolonged exposure to glutamate and 
kainate and show significant reduction in viability. 
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Figure 2.33. Prolonged exposure to glutamate and kainate results in reduced viability of pancreatic α-cells and β-cells. INS-1 β-cells and α-TC cells were 
cultured in the presence of varying concentrations of glutamate and kainate and then cell viability was measured using MTT assay. Viability was determined by 
expressing the optical density of treated cells as percentage of controls. Means were compared using Student’s t-test analysis. Results are presented as means ± SEM 
from four separate experiments each performed in triplicate. *p<0.05; **p<0.01; ***p<0.001. 
 
 
Figure 2.33. Prolonged exposure to glutamate and kainate results in reduced viability of pancreatic α-cells and β-cells. INS-1 β-cells and α-TC cells were 
cultured in the presence of varying concentrations of glutamate and kainate and then cell viability was measured using MTT assay. Viability of treated cells was 
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Figure 2.34. Reduction in cell viability of INS-1 β-cells after exposure to glutamate and kainate is concentration-dependent. INS-1 β-cells was cultured in 
the presence of varying concentrations of glutamate and kainate and then cell viability was measured using MTT assay. Viability was determined by expressing the 
optical density of treated cells as percentage of controls. Means were compared using Student’s t-test analysis. Results are presented as means ± SEM from four 
separate experiments each performed in triplicate. *p<0.05; **p<0.01; ***p<0.001. 
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2.4.5b. KAR antagonists reduces the effect of kainate on the viability of pancreatic α-cells 
and β-cells  
To determine whether kainate-induced reduction in cell viability involves KAR 
activation, INS-1 β-cells and α-TC cells were exposed to kainate after pre-incubation of 
the cells with NBQX (selective and competitive AMPA and kainate receptor antagonist). 
Viability of the cells was then measured (section 2.3.12).  
Prolonged exposure to 0.1 or 0.5 mM kainate significantly reduced the viability of α-TC 
cells and INS-1 β-cells. INS-1 and α-TC cells exposed to kainate alone showed 
significantly reduced viability compared to cells which were pre-incubated with 0.025 
mM or 0.1 mM NBQX prior to kainate (Figure 2.35).  
As expected, there was significant reduction in cell viability of SH-SY5Y neuronal cells 
after chronic exposure to 0.1-0.5 mM kainate and this effect was blocked by NBQX 
(Figure 2.35). 
These observations suggest that the reduced cell viability is linked to prolonged KAR 
activation.  
 
 
 
 
 
 
Chapter Two                                                                                                                                                                                                              2.4 Results 164                                                                                                                                                                                                                                                                                                                                                               
 
                                                                                                                                                                                                
 
 
 
 
 
0
20
40
60
80
100
120
α-TC
INS-1
SH-SY5Y
NBQX (0.025 mM) -           +  - -  + -      -          +              -          -             - 
NBQX (0.1 mM) -           -  + -  - +      -          -              +          -             - 
Kainate (0.1 mM) -           -  - +  + +      -          -              -          -             - 
Kainate (0.5 mM) -           -  - -  - -      +          +              +           -             - 
40% Ethanol -           -  -  -  - -      -          -               -          +             - 
2% Triton X -           -  - -  - -      -          -               -          -             + 
Figure 2.35 NBQX improves survival of pancreatic α-cells and β-cells following prolonged exposure to kainate. Cultured INS-1 β-cells and α-TC cells 
were pre-incubated with NBQX (0.025 and 0.1 mM) followed by chronic exposure to kainate (0.1 and 0.5 mM). Means were compared using Student’s t-test 
analysis. Results are presented as means ± SEM from four separate experiments each performed in triplicate. *p<0.05; **p<0.01; ***p<0.001. 
 
   
 
Figure 2.35 NBQX improves survival of pancreatic α-cells and β-cells following prolonged exposure to kainate. Cultured INS-1 β-cells and α-TC cells 
were pre-incubated with NBQX (0.025 and 0.1 mM) followed by chronic exposure to kainate (0.1 and 0.5 mM). Means were compared using one-way ANOVA. 
Results are presented as means ± SEM from four separate experiments each performed in triplicate. *p<0.05; **p<0.01; ***p<0.001. 
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2.4.5c. Dihydrokainic acid (DHK) enhances the effect of glutamate on pancreatic α-cell 
and β-cell viability. 
Studies have shown that the concentration of extracellular glutamate is kept at 
physiological levels by high affinity glutamate transporters including the glial glutamate 
transporter 1 (GLT 1) (Di Cairano et al., 2011). Dihydrokainic acid (DHK) is a potent 
selective inhibitor of GLT 1. Inhibition of GLT1 by DHK prevents the uptake of 
glutamate by cells (Di Cairano et al., 2011). 
To investigate if inhibition of glutamate transporters affects pancreatic cell viability, 
cultured MIN6, INS-1, α-TC cells were pre-incubated with DHK (0.1 mM) followed by 
prolonged exposure to glutamate (0.5 mM). Viability of the cells was determined and 
compared to viability of cells which have been exposed to glutamate only (section 2.3.12).  
There was no significant change in viability of MIN6 β-cells after chronic exposure to 
0.5 mM glutamate. In contrast, INS-1 and α-TC cells showed reduced viability 
subsequent to incubation with glutamate (Figures 2.36-2.37). Exposure of MIN6, INS-1 
and α-TC cells to glutamate in the presence of DHK resulted in significantly reduced cell 
viability compared to cells which were exposed to glutamate only (Figures 2.36-2.37).  
As expected, exposure of SH-SY5Y cells to glutamate after pre-incubation with DHK 
resulted in significant reduction in viability compared to cells exposed to glutamate 
without prior incubation with DHK (Figure 2.37).  
These observations suggest an important role of GLT 1 in the regulation of the 
extracellular concentration of glutamate and viability in pancreatic endocrine cells.  
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Figure 2.36. Dihydrokainic acid (DHK) enhances the effect of glutamate exposure on the 
viability of pancreatic β-cells. Means were compared using Student’s t-test analysis. Results 
are presented as means ± SEM from four separate experiments each performed in triplicate. 
*p<0.05; **p<0.01; ***p<0.001. 
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Figure 2.37. Dihydrokainic acid (DHK) enhances the effect of glutamate exposure on 
the viability of pancreatic α-cells and neuronal cells. Means were compared using 
Student’s t-test analysis. Results are presented as means ± SEM from four separate 
experiments each performed in triplicate. *p<0.05; **p<0.01; ***p<0.001. 
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2.5. Summary of results 
The aim of this chapter was to investigate the molecular composition and function of 
KAR subunits in pancreatic endocrine cells. The following is a summary of the results: 
 GluK2-5 subunit mRNAs are expressed in both α- and β-cells of the pancreas 
whiles GluK1-5 are expressed in pancreatic islets of Langerhans. 
 GluK2/3 and GluK5 subunit proteins are present in both α- and β-cells of the 
pancreas. There is no statistical differences in expression of GluK2/3 and GluK5 
in α- and β-cells.  
 Auxiliary Neto 1 and Neto 2 mRNAs and proteins are present in α- and β-cells 
and islets of Langerhans of the pancreas. There is preferential expression of Neto 
1 in α-cells and Neto 2 in β-cells 
 KAR stimulation with kainate increased both [Ca2+]i and GSIS secretion in 
pancreatic β-cells. These effects were attenuated by KAR antagonist (NBQX) but 
not AMPAR/NMDAR antagonist (Gyki-52466).  
 Group I mGluR agonist (DHPG) potentiated the effect of KAR stimulation on 
[Ca2+]i but had no significant effect on kainate-induced increase in GSIS from β-
cells. 
 Prolonged exposure to kainate or glutamate significantly reduced the viability of 
both α- and β-cells. The effect of kainate on viability of α- and β-cells was   
significantly reduced by KAR antagonist (NBQX).  
 DHK, an inhibitor of glutamate transporter 1 potentiated the effect of glutamate 
on the viability of both α- and β-cells.  
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2.6. Discussion 
Relatively little is known about the molecular composition and function of KARs in the 
CNS compared to other GluRs. The emergence of pharmacological tools, antibodies and 
transgenic animals created exciting opportunities for the investigation of KARs. 
However, even less is known about native KARs and their interacting partners outside 
the CNS. Up to now, relatively few studies have reported the expression of KARs in 
pancreatic endocrine cells (Molnar et al., 1995; Gonoi et al., 1994; Kutlu et al., 2009; 
Inagaki et al., 1995). The only KAR subunit protein which has been identified in 
pancreatic endocrine cells in previous studies is GluK5 (Molnar et al., 1995). Considering 
that GluK5 can only function when expressed in heteromeric combinations with GluK1-
3 subunits (Crepel and Mulle, 2015), it was important to investigate systematically the 
molecular composition and role of KARs in pancreatic endocrine cells.  
 
2.6.1. Functional KAR subunits are present in pancreatic endocrine cells 
In this study, mRNA and protein of all five KAR subunits was investigated in MIN6 
mouse β-cells, INS-1 rat β-cells, α-TC mouse cells and primary rat islets of Langerhans. 
Investigations using both mouse and rat tissues were to ensure that the presence of these 
KAR subunits in pancreatic endocrine cells was consistent in different species. 
Identification and characterisation of all the KAR subunits in pancreatic endocrine cells 
could lead to further investigations into the potential role, function and effect of these 
receptors in the endocrine pancreas.  
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2.6.1a. mRNAs and proteins of functional KARs are present in pancreatic β-cells 
In this study, four KAR subunit transcripts (GluK2, GluK3, GluK4 and GluK5) were 
identified in mouse MIN6 and rat INS-1 β-cells (Figures 2.4 and 2.5). Only mRNA of 
GluK5 has previously been identified in MIN6 β-cells using reverse-transcriptase PCR 
(Gonoi et al., 1994). Other studies have shown that KAR agonists have significant effect 
on insulin secretion, membrane potential and influx of calcium in MIN6 and other β-cell 
lines (Molnar et al, 1995; Inagaki et al, 1994; Gonoi et al., 1994). These observations 
indicate that functional KARs could be present in β-cells but the specific subunit 
composition of KARs in β-cells remains unknown. Thus, identification of GluK2-5 
subunit mRNA in MIN6 β-cells in this current study indicates that functional homomeric 
and heteromeric KAR channels could assemble in β-cells. The current study is the first to 
identify these four KAR subunit mRNAs in INS-1 β-cells using the RT-PCR technique. 
A study using microarray and MPSS analysis identified GluK2 in MIN6 β-cells, GluK4 
and GluK5 in INS-1 β-cells (Kutlu et al., 2009).  
Results from this current study support previous studies and provide further information 
to suggest that mRNA of heteromeric and homomeric KAR channels are expressed in β-
cells of both mouse and rat.  
At protein level, GluK2/3 and GluK5 were identified in MIN6 and INS-1 β-cells using 
immunoblotting (Figure 2.10). Previous studies using immunoblotting identified only 
GluK5 protein in MIN6 mouse and RINm5F rat β-cell lines (Molnar et al., 1995) but 
GluK5 does not form a functional homomeric channel. Thus this current study supports 
findings from the previous study (Molnar et al., 1995) of the presence of heteromeric 
GluK5 in β-cells and also provide new evidence for the presence of GluK2/3 in β-cell 
lines. Identification of these subunit proteins indicates that both low-affinity homomeric 
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and high affinity obligate heteromeric functional KAR channels could assemble in β-cells 
of the pancreas.  
 
2.6.1b. mRNAs and proteins of functional KARs are present in pancreatic α-cells 
In mouse pancreatic α-TC cells, mRNA transcripts of low-affinity homomeric (GluK2, 
GluK3) and high-affinity obligate heteromeric (GluK4, GluK5) KAR subunits were 
identified (Figure 2.4). In isolated primary human α-cells, mRNA of GluK2 has been 
identified (Cabrera et al., 2008). Thus, results from this current study indicate that KAR 
subunits which can form homomeric or heteromeric channels are present in pancreatic α-
cells. At protein level, GluK2/3 and GluK5 proteins were identified in α-TC cells. This is 
the first study to identify KAR subunit proteins in α-cells. 
It has been shown in previous studies that under low glucose conditions, glutamate is 
released from α-cells of the pancreas and subsequently bind and activate AMPAR and 
KAR subunits present on α-cells. This leads to increased release of glucagon from α-cells 
(Cabrera et al., 2008). Thus, identification of functional KAR subunits in α-cells of the 
pancreas provides evidence to support the role of KARs in modulating glucagon secretion 
from the α-cells. Studies have also shown that glutamate is co-secreted with glucagon 
from α-cells or released via glutamate transporters located in α-cells (Cho et al, 2010; 
Feldmann et al., 2011). Thus, in addition to enhancing glucagon secretion, KAR subunits 
in α-cells of the pancreas may modulate glutamate release from α-cells to regulate the 
concentration of extracellular glutamate in the islets of Langerhans.  
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2.6.1c. mRNAs and proteins of functional KARs are present in rat islets of Langerhans 
In rat islets of Langerhans, all five KAR subunit mRNA were detected (Figure 2.5). This 
is the first study to show that all five KAR subunits of KARs are expressed in rat islets of 
Langerhans. Previous investigations using reverse-transcriptase PCR identified only 
GluK5 mRNA in rat pancreatic islets of Langerhans (Inagaki et al., 1995).  
Identification of GluK1 mRNA in islets of Langerhans but not in β- or α-cells suggests 
that other cells within the islets of Langerhans (δ-cells, PP cells or ghrelin-producing 
cells) express mRNA of GluK1.  
KAR subunit mRNAs were not found in mouse or rat liver tissue (Figure 2.6). This 
observation is in agreement with previous studies (Gonoi et al., 1994; Chew et al., 2001) 
and shows that in addition to setting up template negative PCR reactions, liver tissue 
could be used as a reliable template for PCR negative control and also to test primers 
specific for KAR subunits.  
 
2.6.1d. KAR subunits show equal or similar expression in β-cells and α-cells of the 
pancreas  
The relative amounts of KAR subunit mRNA and protein in MIN6 β-cells and α-TC cells 
was investigated by a semi-quantitative reverse-transcription PCR and semi-quantitative 
immunoblotting (Section 2.3.8). Semi-quantitative analysis of immunopositive bands has 
been used in several studies to determine the relative amounts of proteins in cells and 
tissues (Luyt et al., 2007). This method is relatively less cumbersome and is a very 
feasible option when time is of essence in a study. A number of techniques are available 
for quantitative analysis of mRNAs in cells. Real-time PCR and competitive PCR give 
relatively accurate quantification of mRNA expression. However, competitive PCR 
requires a large volume of starting cDNA as template and also requires an internal 
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competitor DNA fragment that must contain sequences for which the primers intended 
for the mRNA of interest can amplify (Marone et al., 2001). On the other hand, there are 
several technical challenges with real-time PCR including normalisation and the use of 
reference (housekeeping) genes (Bustin and Nolan, 2004). Furthermore, both techniques 
are costly and time-consuming thus they were not feasible options at the time. Semi-
quantitative analysis represents a feasible and relatively simple method for investigating 
levels of receptor mRNAs and proteins in cells and tissue samples. In the semi-
quantitative reverse-transcription method, one of the most significant factors for 
consideration is the selection of appropriate number of PCR cycles at which the 
amplification of the transcripts is in a linear phase whiles at the same time, the amplified 
product can be visualised on agarose gel and quantified. This method has been shown to 
generate reliable semi-quantitative information when all the appropriate procedures and 
controls are set up (Marone et al., 2001).  
In this study, the relative amounts of GluK2 and GluK5 mRNA in MIN6 β-cells were not 
significantly different from the amount of these KAR subunits in α-TC cells (Figure 2.9). 
However, the amount of GluK2 mRNA in brain tissue was significantly higher than in 
MIN6 and α-TC cells indicating a preferential expression of this subunit for the brain 
relative to α- and β-cells. There was no significant differences between the amount of 
GluK5 mRNA in brain and the endocrine cells (MIN6 and α-TC cells) (Figure 2.9) which 
could indicate that KAR subunits may have different expression profiles in the CNS and 
pancreatic endocrine cells. Furthermore, there was no significant difference in the relative 
amounts of GluK2/3 and GluK5 proteins between β-cells (MIN6, INS-1) and α-cells (α-
TC) of the pancreas which (Figure 2.11) which confirms the mRNA results. The 
observation that the relative amounts of GluK2/3 and GluK5 proteins in mouse (MIN6) 
β-cells was not significantly different from rat (INS-1) β-cells (Figure 2.11) suggests that 
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relative levels of KAR subunit proteins in β-cells could be independent of species. No 
study has analysed or reported of the relative amounts of mRNA and proteins of KAR 
subunits in α- and β-cells of the pancreas. The semi-quantitative analyses in this study 
was carried out using cells that were cultured under their conventional conditions without 
treatments with any drug, thus the relative amounts of KARs could not be affected by any 
external agent or condition. The results suggest an equal or similar expression of these 
KAR subunits in β-cells and α-cells of the pancreas. The results also suggest equal or 
similar expression of GluK5 in brain and endocrine cells (β-cells and α-cells) whiles the 
amount GluK2 in the brain is significantly higher than in endocrine cells (β-cells and α-
cells). 
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2.6.2. Neto 1 and Neto 2 subunits in pancreatic endocrine cells  
The role of Neto 1 and Neto 2 subunits in modulating KAR subunit expression and 
receptor properties in the CNS is a subject of several studies but there is very little 
information about these KAR auxiliary subunits outside the CNS (Fisher, 2015; Copits 
and Swanson, 2012; Griffith and Swanson, 2015; Sheng et al., 2015; Rutkowska-
Wlodarczyk et al., 2015) (Chapter one, Section 1.5.6).  
 
2.6.2a. mRNAs and proteins of Neto 1 and Neto 2 are present in pancreatic endocrine 
cells 
In this study, mRNA of Neto 1 and Neto 2 were identified in β-cell (MIN6, INS-1) and 
α-cell (α-TC) lines and also in rat islets of Langerhans (Figure 2.12). This is the first study 
to detect both Neto 1 and Neto 2 in α-, β-cells and the islets of Langerhans in two different 
species. A previous study used massively parallel signature sequencing (MPSS) and 
microarray for quantitative mRNA expression profiling of Neto 1 and Neto 2 in pancreatic 
endocrine cells (Kutlu et al., 2009). The study reported that transcripts of Neto 1 are 
present in MIN6 β-cells but not in INS-1 β-cells or α-TC cells (Kutlu et al., 2009). The 
study also reported the expression of Neto 2 transcript in MIN6 β-cells, but in contrast to 
the current study, Neto 2 was not detected in rat islets of Langerhans (Kutlu et al., 2009). 
This conflicting findings may be due to the different methods used in these two studies 
as well as the method for the isolation of islets of Langerhans.  
Neto 1 and Neto 2 proteins were detected in β-cells (MIN6, INS-1) and α-cells (α-TC) of 
the pancreas (Figure 2.15). This is the first study to report of the presence of Neto 1 and 
Neto 2 subunit proteins in pancreatic α- and β-cell lines.  
The presence of both mRNA and protein of Neto 1 and Neto 2 in pancreatic endocrine 
cells suggests that these auxiliary proteins could have modulatory or regulatory effects 
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on KARs in the endocrine pancreas. In the CNS, Neto 1 and Neto 2 modulates the 
function and properties of KARs (Sheng et al., 2015; Fisher, 2015). Thus, expression of 
Neto 1 and Neto 2 in α-, β-cells and islets of Langerhans suggests that mechanisms by 
which Neto 1 and Neto 2 regulate KARs in the CNS may also be present in pancreatic 
endocrine cells.  
 
2.6.2b. There are differences in relative amounts of Neto 1 and Neto 2 in β-cells and α-
cells of the pancreas.  
Semi-quantitative analysis showed that the amount of Neto 1 mRNA and protein are 
significantly higher in α-TC cells than in MIN6 β-cells (Figure 2.14). On the other hand, 
levels of Neto 2 mRNA and protein are significantly higher in MIN6 β-cells than α-TC 
cells (Figure 2.14). These observations reveal a preferential expression of Neto 1 in α-
cells and Neto 2 in β-cells.  
Though both Neto 1 and Neto 2 are present, the preferential expression of Neto 1 mRNA 
and protein in α-cells is suggestive that Neto 1 interacts predominantly with KARs in α-
cells to influence characteristics including modulation of slow kinetics of KARs. The 
modulation of slow kinetics of KARs by Neto 1 has been reported in neurons (Copits et 
al., 2011; Fisher and Mott). Increased levels of Neto 2 mRNA and protein in β-cells 
indicates that Neto 2-related properties of KARs including agonist binding, membrane 
surface expression and synaptic co-localisation may be predominant in β-cells. These 
effects of Neto 2 on KARs have been reported in hippocampal neurons of the CNS (Sheng 
et al., 2015; Copits et al., 2011; Wyeth et al., 2014).  
Moreover, interactions of Neto 1 and Neto 2 with KARs results in enhanced affinity of 
KARs for glutamate and kainate (Howe, 2015; Tang et al., 2011). Thus, the presence 
Neto 1 and Neto 2 in both α- and β-cells of the pancreas indicates that the KARs in these 
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cells may likely have an increased affinity for glutamate and kainate. The preferential 
expression of Neto 1 for α-cells and Neto 2 for β-cells could result in KAR functions and 
properties being different between α-cells and β-cells of the pancreas. For instance, 
preferential expression of Neto 2 in β-cells could result in β-cell KARs having a higher 
affinity for glutamate compared to KARs on α-cells.  
In conclusion, mRNAs and proteins of KAR subunits are present in α- and β-cells and 
islets of Langerhans. This indicates that functional low-affinity homomeric and high-
affinity heteromeric functional KARs could assemble in these pancreatic endocrine cells. 
There was no significant difference in KAR subunit mRNA or protein between β- and α-
cells of the pancreas. In addition, Neto 1 and Neto 2 auxiliary subunits of KARs are 
present in α- and β-cells and islets of Langerhans. While Neto 1 shows relatively higher 
expression in α-cells, Neto 2 expression is higher in β-cells.  
These results suggest that properties of KARs in pancreatic endocrine cells could be 
modulated by Neto 1 and Neto 2 to control release of intracellular glutamate as well as 
binding to and controlling the concentration of extracellular glutamate. The preferential 
expression of Neto 1 and Neto 2 in α- and β-cells could also result in KAR functions and 
properties being different between these cells. 
 
 
 
 
2.6.3. Effect of KAR activation on intracellular calcium concentrations in pancreatic β-
cells [Ca2+]i. 
It has been established in this study that functional units of KARs together with their 
auxiliary proteins are present in pancreatic α-, β-cells and islets of Langerhans (Sections 
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2.4.1 and 2.4.2). To understand the functions of KAR subunits in β-cells, it was important 
to study the effect of KAR agonists on changes in intracellular calcium concentration 
[Ca2+]i in MIN6 β-cells.  
A number of studies have shown that several calcium channels are present in rat, mouse 
and human β-cells, with the most common being the L- and P/Q types (Rorsman and 
Braun, 2013; Pratt et al., 2016; Xie et al., 2016). Though the concentration of cytosolic 
calcium ions ([Ca2+]c) has been shown to contribute to insulin secretion from pancreatic 
β-cells (Marquard et al., 2015), majority of studies have established that exocytosis of 
insulin granules and other molecules from β-cells of the pancreas is primarily dependent 
on [Ca2+]i (Rorsman and Braun, 2013; Christensen et al, 2015; Thorn et al., 2016; Dou et 
al., 2015). Thus, it was important to establish the effect of β-cell KAR activation on the 
changes in [Ca2+]i. 
 
2.6.3a. Kainate induces transient increase in [Ca2+]i in MIN6 pancreatic β-cells.  
In the presence of 3 mM or 30 mM glucose, activation of β-cell KARs with 25 μM kainate 
induced an increase in [Ca2+]i which was significantly higher than the basal measurements 
(Figures 2.17-2.18). This observation is consistent with reports from previous studies 
albeit different concentrations of kainate were used in the previous studies. In one study, 
there was a dose-dependent transient increase in [Ca2+]i in MIN6 β-cells subsequent to 
perifusion with 0.01-1 mM kainate in the presence of 3.3 mM glucose (Gonoi et al., 
1994). Another study reported of transient increase in [Ca2+]i in isolated rat β-cells after 
application of 0.1 and 0.5 mM kainate in the presence of 8.3 mM glucose (Inagaki et al., 
1995). However, 0.1-1.0 mM kainate used in these previous studies could potentially 
activate AMPARs in addition to KARs. Thus, the increase in [Ca2+]i subsequent to 25 µM 
kainate in this current study has addressed the questions surrounding which or what 
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receptors are activated in β-cells by kainate to induce increase in [Ca2+]i. Washing out 
kainate after the initial application resulted in decrease in [Ca2+]i to basal levels (Figure 
2.17). A second application of kainate to the cells resulted in increased [Ca2+]i similar to 
the increase observed after the first exposure. Reduction in [Ca2+]i after washing out 
kainate could be the result of reduction in membrane potential as shown in previous 
studies (Gonoi et al., 1994).  
Results from this study thus indicate that similar to observations in the CNS, kainate 
induces a transient increase in [Ca2+]i in pancreatic β-cells. This may be a significant 
mechanism underlying potentiation of GSIS from β-cells by glutamate.  
Two mechanisms may account for the kainate-induced increase in [Ca2+]i in β-cells. First, 
variants of GluK2 and GluK3 subunits in the CNS have been shown to be Ca2+-permeable 
(Perrais et al., 2010; Sakha et al., 2016) hence KAR-induced increase in [Ca2+]i in MIN6 
β-cells may be the result of direct permeation of Ca2+ through these receptor channels 
when they are activated.  
Second, increase in [Ca2+]i in MIN6 β-cells could be via activation of voltage-dependent 
Ca2+ channels as a result of the depolarising effect of kainate. The first mechanism could 
involve the direct opening of the voltage-dependent Ca2+ channels (VDCCs) subsequent 
to kainate-induced depolarisation of the plasma membrane of pancreatic β-cells. The 
second mechanism could involve kainate-induced inhibition of KATP channels which will 
lead to increased Ca2+ influx (Otter and Lammert, 2016). One of the key mechanisms that 
induces inhibition of KATP channels in pancreatic β-cells involves increase in cyclic GMP 
(cGMP) levels (Wu et al., 2012). Thus, the increase in [Ca2+]i subsequent to application 
of kainate in this study could be via a kainate-induced increase in cGMP levels in the cells 
leading to inhibition of KATP to induce [Ca
2+]i. Studies have shown that application of 
kainate or glutamate results in a dose-dependent increase in cGMP levels in rat cerebellar 
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tissue (Briley et al., 1979; Oh and McCaslin, 1996) and isolated mouse pancreatic β-cells 
(Wu et al., 2012).  Activation of AMPAR, one of the iGluR subtypes have also been 
shown to increase the concentration of cGMP and subsequent increase in [Ca2+]i (Wu et 
al., 2012). 
The kainate-induced increase in [Ca2+]i was shown to be significantly higher in the 
presence of 30 mM glucose compared to 3 mM glucose (Figure 2.18). This is suggestive 
that the effect of kainate on [Ca2+]i is dependent in part on the concentration of glucose. 
Several studies have shown that in pancreatic β-cells and in islets of both rodent and 
human, glucose metabolism leads to increased concentration of intracellular glutamate 
(Otter and Lammert, 2016; Maechler and Wollheim, 1999). In another study, glutamate 
was the only amino acid out of twelve to increase upon glucose stimulation (Maechler 
and Wollheim, 1999). Thus, cells exposed to high concentration (30 mM) of glucose will 
have a higher concentration of intracellular glutamate compared to cells exposed to low 
glucose (3 mM). Glutamate generated as result of glucose metabolism in β-cells is 
imported into insulin-containing vesicles via vesicular glutamate transporter (VGLUT)1 
and VGLUT3 (Otter and Lammert, 2016; Gheni et al., 2014) and then exported out of the 
secretory granules to the outside of the cell via excitatory amino acid transporter 2 
(EAAT2) (Gammelsaeter et al., 2011). Transport of glutamate to the outside of the cells 
could lead to increased extracellular concentration of glutamate which could make more 
glutamate available to bind GluRs including KARs on β-cells to initiate depolarisation 
and eventual influx of calcium.    
2.6.3b. Kainate-induced increase in [Ca2+]i is attenuated by NBQX but not Gyki-52466  
In previous studies, 100 µM of kainate activated both kainate and AMPA receptors in 
neurons while lower concentrations (10-30 µM) preferentially activated KARs (Muller et 
al., 2003; Lee et al., 2004; Palacios-Filardo and Lerma, 2014). Though 25 µM of kainate 
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was used in this current study, it was important to block AMPARs to establish that the 
increase in [Ca2+]i was induced by activation of KARs. Gyki-52466 is a selective non-
competitive antagonist of AMPA (IC50: 10-20 µM), kainate (IC50: 450 µM) and NMDA 
(IC50: 50 µM) receptors (Rogawski et al., 2013; Donevan and Rogawski, 1993). The IC50 
value represents the concentration of an inhibitor where the response (or binding) to an 
agonist is reduced by half (Matute, 2011; Donevan and Rogawski, 1993). Thus, based on 
these IC50, 100 µM of Gyki-52466 will inhibit AMPA and NMDA receptors but not 
KARs. In the presence of 3 mM or 30 mM glucose, pre-incubation of the cells with 100 
µM Gyki-52466 did not affect the kainate-induced increase in [Ca2+]i (Figures 2.19-2.20). 
This observation indicates that in this current study, kainate bound to β-cell KARs but 
not AMPAR/NMDAR to elicit a transient increase in [Ca2+]i. 
Furthermore, incubation of the cells with 30 µM NBQX prior to application of kainate 
resulted in significantly reduced influx of Ca2+ (Figures 2.21-2.22). Studies have shown 
that 10-100 µM NBQX inhibits both native and recombinant kainate and AMPA receptors 
in clonal cell lines, isolated neurons, brain slices and rodents (Matute, 2011; Jane et al., 
2009; Dohare et al., 2016; Park et al., 2015). This study is the first to report of β-cell KAR 
inhibition by NBQX. The results indicate that inhibition of β-cell KARs results in 
reduction or attenuation of mechanisms which trigger kainate-induced increase in [Ca2+]i.  
 
2.6.3c. Kainate-induced change in [Ca2+]i is potentiated by the selective group I mGlu 
receptor agonist DHPG. 
In the presence of 3 mM or 30 mM glucose, incubation of MIN6 β-cells with DHPG prior 
to application of kainate induced an increase in [Ca2+]i which was significantly higher 
than the increase observed when only kainate was applied (Figures 2.23-2.24). This is the 
first study to report of KAR potentiation by group I mGluR activation in pancreatic β-
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cells. Isoforms of mGluRs including group I mGluRs (mGluR1 and mGluR5) have been 
shown to be present in MIN6 and other β-cell lines as well as in isolated β-cells and islets 
of rodent and human (Brice et al., 2002; Storto et al., 2006) (Chapter one, tables 1.6-1.8). 
Potentiation of kainate-induced increase in [Ca2+]i in MIN6 β-cells by DHPG is in 
agreement with a previous study (Cho et al., 2003; Rojas et al., 2013). In these studies, 
co-application of amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl) propanoic acid (ATPA); 
a KAR agonist and DHPG resulted in significant increase in [Ca2+]i. This increase in 
[Ca2+]i was significantly higher than the increase induced by ATPA alone. Furthermore, 
co-localisation of KAR subunits (GluK4 and GluK5) with group I mGluR has been 
reported in rat hippocampus and in cultured rat cortex (Rojas et al., 2013). In the study, 
activation of group I mGluRs with 50 µM DHPG enhanced KAR-induced calcium 
signals. The potentiation of KARs by group I mGluRs was observed only in heteromeric 
GluK2/GluK5 or GluK2/GluK4 subunit assembly but not in homomeric receptor 
combinations (Rojas et al, 2013).  
The potentiation of β-cell KARs group 1 mGluRs may be via a number of mechanisms. 
The first mechanism could be via an mGluR-mediated increase in protein kinase C (PKC). 
Previous studies have shown that mGluR-mediated enhancement of KAR signalling in 
neurons is attenuated by the inhibition of PKC (Cho et al., 2003; Rojas et al., 2013) while 
modulation of KAR signalling by PKC has also been reported in previous studies (Cho et 
al., 2003; Melyan et al., 2002). PKC has been shown to induce phosphorylation of key 
residues in the C-terminal domain of KARs which leads to enhanced response of KAR 
subunits to agonists including glutamate and kainate (Cho et al., 2003; Rojas et al., 2013).  
In conclusion, kainate binds to and activate β-cell KARs to cause transient increase in 
[Ca2+]i which was significantly higher in the presence of stimulatory glucose 
concentrations compared to non-stimulatory concentrations. The transient increase in 
 Chapter Two                                                                                                      2.6 Discussion 183 
 
[Ca2+]i could be due to direct permeation of Ca
2+ through calcium-permeable KAR 
channels or through activation of voltage-dependent calcium channels. The transient 
increase in [Ca2+]i  is attenuated by NBQX but not Gyki-52466 thus one of the effect of 
kainate on [Ca2+]i is through activation of KARs. Furthermore, activation of group I 
mGluRs potentiated the kainate-induced transient increase in [Ca2+]i.  
These observations indicate that similar to mechanisms in cells of the CNS, kainate binds 
to β-cell KARs with resultant increase in [Ca2+]i. Exocytosis of insulin granules from β-
cells is primarily dependent on the intracellular calcium concentration ([Ca2+]i) (Pedersen 
et al., 2011; Hou et al., 2009). Thus, the observations that activation of β-cell KARs 
results in increased [Ca2+]i indicate that these receptors play significant roles in 
modulating one of the most important processes and mechanisms of the pancreatic β-cell; 
calcium influx.   
 
 
 
 
 
2.6.4. Kainate potentiates glucose-stimulated insulin secretion in MIN6 and INS-1 
pancreatic β-cells 
The effect of kainate on insulin secretion from β-cells was investigated in MIN6 mouse 
and INS-1 rat clonal β-cells. In both MIN6 and INS-1 β-cells, kainate enhanced glucose-
stimulated insulin secretion in the presence of 3 mM or 30 mM glucose. Insulin secretion 
induced by kainate in the presence of 3 mM or 30 mM glucose was significantly higher 
than insulin secretion induced by glucose only (Figures 2.28-2.31). Previous studies have 
investigated GSIS in MIN6 and INS-1 β-cells in the presence of glucose concentrations 
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ranging from 3 mM to 28 mM (Reinhardt et al., 2016; Suzuki et al., 2015; Nakatsu et al., 
2015) and both MIN6 and INS-1 β-cells are cultured in high glucose medium (25 Mm for 
MIN6 and 11.1 for INS-1) (Suzuki et al., 2015; Reinhardt et al., 2016). Thus, the 
concentrations of glucose used in investigation of how kainate modulate GSIS in this 
current study is within the range used by previous studies and also fall into the 
physiological glucose concentrations in which these cells are cultured. The kainate-
induced increase in GSIS is consistent with a previous study (Gonoi et al., 1994). 
However, in this previous study (Gonoi et al., 1994), 0.5 mM of kainate was used to 
stimulate GSIS. The use of 0.5 mM kainate to induce GSIS has a limitation because 
kainate concentrations of 0.1 mM and above have been shown to activate both kainate 
and AMPA receptors in neurons (Muller et al., 2003; Lee et al., 2004). The use of 0.025 
mM in this current study is consistent with previous studies where 0.01-0.05 mM kainate 
has been shown to preferentially activate KARs and not AMPAR (Lee et al., 2004; 
Palacios-Filardo and Lerma, 2014).  Furthermore, kainate (0.01-1 mM) has been shown 
to enhance insulin secretion from isolated rat islets of Langerhans in the presence of 8.3 
mM glucose in one study (Inagaki et al., 1995). 0.5 mM kainate did not stimulate insulin 
secretion from isolated rat islets of Langerhans in the presence of 3.3-16.7 mM glucose 
in another study (Molnar et al., 1995). Thus, in addition to using concentrations of kainate 
which could potentially activate AMPARS, previous studies have produced conflicting 
results about the effect of kainate on GSIS from pancreatic endocrine cells. Results from 
the current study has thus addressed the limitations in the previous studies by using 
kainate concentrations that preferentially activates KARs to study how KARs potentiate 
insulin secretion. The current study has also highlighted a novel observation of how 
kainate could enhance GSIS at both stimulatory and non-stimulatory glucose 
concentrations and thus there is the need to consider the effect of kainate on GSIS when 
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substances or medications which can potentially activate KARs are being prescribed or 
used.   
It has been established that exocytosis of insulin-containing secretory granules from β-
cells is principally dependent on the influx of Ca2+ (Rorsman and Braun, 2013; Cantley 
and Ashcroft, 2015; Otter and Lammert, 2016). As shown in section 2.4.3, kainate 
increases the [Ca2+]i in β-cells hence the observed increase in insulin secretion is likely to 
be the result of increased influx of Ca2+. Increased [Ca2+]i in β-cells has been shown to 
increase the docking of insulin-containing secretory granules and also stimulate 
exocytosis of these granules (Wu et al., 2012). This may be one of the mechanisms of 
kainate-induced increase in insulin secretion from pancreatic β-cells.  
In both MIN6 and INS-1 β-cells, there was no increase in insulin secretion when the cells 
were incubated with NBQX (selective and competitive KAR antagonist) prior to kainate 
incubation. Incubation of the cells with Gyki-52466 (highly selective, non-competitive 
antagonist of AMPAR/NMDAR) prior to kainate incubation resulted in increased GSIS 
which was statistically not different from insulin secretion observed after incubation with 
kainate alone. These observations indicate that the observed kainate-induced increase in 
GSIS is as a result of activation of β-cell KARs.   
In the presence of 3 mM or 30 mM glucose, incubation of MIN6 or INS-1 β-cells with 
DHPG prior to kainate incubation resulted in enhanced GSIS which was not statistically 
different from insulin secretion observed after incubation with kainate alone. DHPG has 
been shown to cause significant increase in insulin secretion from MIN6 at glucose 
concentrations of 3-10 mM but not in the presence of higher glucose (25 mM) 
concentration (Brice et al., 2002). As discussed previously (Chapter one, section 1.5.7) 
and shown in this study (section 2.6.3c), DHPG activates group I mGluRs which 
subsequently potentiates KAR signalling including increased influx of Ca2+. Thus, the 
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observation that there is no statistical difference between insulin secretions induced by 
kainate alone or kainate after pre-incubation with DHPG may be due to the biphasic 
nature of insulin secretion from β-cells. DHPG potentiates kainate-induced increase in 
[Ca2+]i which could only result in increased docking of insulin-containing secretory 
granules to the plasma membrane but not exocytosis of these granules.  
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2.6.5. Effect of prolonged exposure to glutamate and kainate on the viability of pancreatic 
α-cells and β-cells. 
Change in cell viability after chronic exposure to kainate and glutamate was investigated 
using the MTT assay. Similar to other neuronal cells, prolonged exposure to kainate (10-
50 µM) and glutamate (10-40 mM) significantly reduces viability of SH-SY5Y cells (Zhu 
et al., 2016; Cannarsa et al., 2008). Thus, this cell line was used as a positive control for 
kainate- and glutamate-induced changes in cell viability.  
 
2.6.5a. Prolonged exposure to glutamate and kainate causes reduced viability of cultured 
pancreatic α-cells and β-cells.  
Exposure to 0.1-0.5 mM of kainate resulted in significant reduction in viability of both α- 
(α-TC) and β- (INS-1) cells (Figure 2.33). Kainate is a potent neurotoxin which has been 
shown to be about thirty times more potent as a neurotoxin than glutamate (Zhang and 
Zhu, 2011). This is the first study to report of kainate-induced reduction in viability of β- 
and α-cell of the pancreas. This is also the first study to show that kainate-induced 
reduction in viability of β-cells is dose-dependent (Figure 2.34). Thus, similar to 
observations in neuronal cell lines (Cannarsa et al., 2008), kainate induced a dose-
dependent reduction in viability of INS-1 β-cells.  
Exposure of INS-1 β-cells and α-TC cells to glutamate (0.25-12.0 mM) and kainate (0.1-
0.5 mM) for 72 hours resulted in significant reduction in viability of the cells (Figure 
2.33). The observation that glutamate induces significant reduction in α-TC cells is in 
contrast to a previous study which reported that incubation of α-TC with 0.1-5 mM 
glutamate for 120 hours did not cause any significant reduction in α-TC cells (Di Cairano 
et al., 2011). This observed differences regarding the effect of glutamate on viability of 
α-TC cells may be due to a number of technical factors. First, in the previous study (Di 
 Chapter Two                                                                                                      2.6 Discussion 188 
 
Cairano et al., 2011), 8 x 103 cells were seeded compared to 2 x 104 cells in this current 
study. Also, the culture medium for the current study contained 2 mM L-glutamine while 
the previous study used media containing 0.1 mM glutamic acid supplemented with 0.7 
mM L-glutamine. The observed glutamate-induced reduction in viability of cultured β-
cells is in agreement with a previous study in which 0.1-5 mM glutamate caused 
significant reduction in viability of mouse βTC3 (Di Cairano et al., 2011). This indicates 
that glutamate-induced reduction in viability of pancreatic β-cells is not cell line-specific.  
Glutamate- and kainate-induced reduction in α- and β-cell viability could likely be the 
result of excitotoxicity. Studies have shown that cells of the endocrine pancreas including 
α- and β-cells are exposed to 50-100 µM glutamate concentration which can increase to 
about 500 µM after ingestion of glutamate-rich diet (Hawkins, 2009; Otter and Lammert, 
2016; Graham et al., 2000). Both neuronal and pancreatic β-cells have been shown to 
keep extracellular glutamate at physiologically low concentrations to prevent excessive 
or chronic activation of GluRs (Di Cairano et al., 2011; Robinson and Jackson, 2016). 
One of the most significant mechanisms of excitotoxicity involves increased influx of 
Ca2+. Calcium overload in cells triggers excitotoxic cascades including ER stress, 
mitochondrial dysfunction, depletion of ATP, activation of Ca2+-dependent enzymes 
(including nitric oxide synthase), generation of free radicals, oxidative stress and other 
mechanisms that lead to apoptosis and autophagy (Mohd Sairazi et al., 2015). Moreover, 
increased Ca2+ influx leading to apoptosis and autophagy has been shown to be the 
underlying mechanism of glutamate-induced β-cell death (Di Cairano et al., 2011). 
Administration of kainate has been shown to increase [Ca2+]i in β-cells (Figures 2.17-
2.18) whiles glutamate has been shown to activate α-cells to induce an increase in [Ca2+]i 
(Cabrera et al., 2008). Thus, the observed glutamate- and kainate-induced reduction in 
viability of α- and β-cells may the as a result of increased [Ca2+]i. Moreover, kainate- or 
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glutamate-induced death or dysfunction of α-cells in the islets of Langerhans could result 
in increased release of glutamate from the cell into the ECF (Davalli et al., 2012). This 
may increase the amount of glutamate available to bind to KARs on β-cells to cause 
sustained activation and eventual cell death. Increased concentration of plasma glucagon 
has been reported in T1DM and T2DM subjects indicating α-cell hypersecretion (Muller 
et al., 1973; Dunning et al., 2007). Since glucagon is co-secreted with glutamate (Cho et 
al, 2010; Feldmann et al., 2011), it can be inferred that glutamate levels may be high in 
diabetes. If this happens, the excess glutamate could further contribute to destruction of 
both α- and β-cells leading to exacerbation of the condition.  
Furthermore, excitotoxic-induced death of pancreatic β-cells may be a mechanism to 
remove ‘overexcited’ cells whose continuous signalling may result in excessive insulin 
secretion and eventual hypoglycaemia.  
 
2.6.5b. KAR antagonists reduces the effect of kainate on the viability of pancreatic α-cells 
and β-cells  
Pre-incubation of INS-1 β-cells and α-TC cells with NBQX (selective and competitive 
AMPA and kainate receptor antagonist) prior to chronic exposure to kainate resulted in 
significantly improved viability of the cells (Figure 2.35). This is the first study to report 
of protective properties of KAR antagonists in pancreatic endocrine cells. NBQX has 
been shown to protect neurons and other cells of the CNS from kainate-induced toxicity 
in vitro (Twele et al., 2015). In vivo studies have also shown that NBQX protects mice 
from seizure-induced excitotoxic cell death (Schauwecker, 2010; Twele et al., 2015). The 
protective effect of α- and β-cells by NBQX may be via mechanisms including reduction 
in [Ca2+]i. This is supported by results from this study, which has shown that application 
of NBQX attenuates the effect of kainate on [Ca2+]i (Figures 2.21-2.22). Moreover, 
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another KAR antagonist, CNQX has been shown to attenuate glutamate-induced increase 
in [Ca2+]i in βTC3 in previous studies (Di Cairano et al., 2011). Attenuation of kainate-
induced increase in [Ca2+]i by CNQX  has also been reported in isolated human islets of 
Langerhans (Cabrera et al., 2008). Thus, reduction in [Ca2+]i may be the primary 
mechanism by which KAR antagonists protect α- and β-cells from kainate-induced cell 
death. Protection of β-cells and α-cells from kainate-induced excitotoxicity by KAR 
antagonists may explain why anti-epileptic drugs such as topiramate which attenuates 
glutamate-induced excitotoxicity also have antidiabetic properties and preserve β-cell 
survival and function (Davalli et al., 2012; Toplak et al., 2007; Angehagen et al., 2003).  
 
2.6.5c. Dihydrokainic acid (DHK) enhances the effect of chronic exposure of glutamate 
on pancreatic α-cell and β-cell viability. 
Exposure of mouse MIN6 β-cells to glutamate did not cause significant reduction in cell 
viability (Figure 2.36). This is in agreement with a previous study which showed that 
chronic exposure to glutamate had no significant effect on the viability of MIN6 β-cells 
(Morley et al., 2000). In another study, it was observed that glutamate cause significant 
reduction in viability of mouse βTC3 β-cells (Di Cairano et al., 2011). The reasons for 
discrepancy between the effect of glutamate on these two mouse β-cell lines remains 
unclear and needs further investigations but it could be due to differences in mechanisms 
by which these cells regulate glutamate concentrations or could also be due to presence 
or absence of certain proteins or channels in these cells. Application of glutamate in the 
presence of DHK; a selective inhibitor of glial glutamate transporter-1 (GLT 1) resulted 
in significantly reduced cell viability compared to application of glutamate alone. This 
was observed in MIN6 and INS-1 β-cells and α-TC cells (Figures 2.36-2.37). This is the 
first study to show that DHK potentiates glutamate-induced reduction in viability of 
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pancreatic α-cells. Potentiation of glutamate-induced β-cell death agrees with reports 
from a previous study which observed that DHK increased extracellular concentration of 
glutamate and potentiated glutamate-induced cell death in mouse βTC3 and human β-
cells (Di Cairano et al., 2011).  
Extracellular concentration of glutamate in the CNS is kept at physiological levels by 
glutamate transporters located on plasma membrane of neuronal and astroglial cells 
(Omote et al., 2016; Raiteri and Raiteri, 2015). In the endocrine pancreas, studies have 
shown that variants of the glial glutamate transporter-1 (GLT 1) are expressed on plasma 
membrane of INS-1 and β-TC3 β-cell lines as well as in isolated mouse and human α- 
and β-cells (Di Cairano et al., 2011; Meabon et al., 2012). Thus, it can be inferred that 
application of DHK inhibited GLT 1 on the plasma membrane which resulted in inability 
of the cells to undertake clearance of extracellular glutamate. This subsequently led to 
increased glutamate concentration and chronic activation of the KARs resulting in 
excitotoxicity. 
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2.7. Conclusion 
The primary aim of this part of the study was to establish the molecular characterisation 
of KAR subunits and their auxiliary proteins in pancreatic endocrine cells. The study also 
aimed to establish the effect of these KAR subunits on the function and viability of 
pancreatic α- and β-cells. RT-PCR and immunoblotting confirmed the presence of 
functional KAR subunits that can form homomeric or heteromeric units. In addition, Neto 
1 and Neto 2 auxiliary proteins of KARs were also present in cultured α- and β-cells as 
well as in rat islets of Langerhans.  
Fura-2AM imaging of cultured MIN6 β-cells showed that activation of KARs with 
kainate increased that intracellular calcium concentration and potentiated glucose-
stimulated insulin secretion at both non-stimulatory and stimulatory glucose 
concentrations. This effect of kainate was blocked by the KAR antagonist but not by an 
AMPAR/NMDAR antagonist. Furthermore, prolonged exposure of kainate and 
glutamate reduced the viability of both cultured α- and β-cells of the pancreas. KAR 
antagonist showed significant protection of cultured α- and β-cells from kainate-induced 
cell death.  
These results indicate that functional KAR subunits are important components of 
pancreatic endocrine cells and their activation or inhibition has several implications on 
the function of survival of these cells.    
The proposed mechanisms of KAR subunit functions and their role in survival of 
pancreatic endocrine cells is illustrated in figure 2.38. 
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Figure 2.38. Proposed model for the role of kainate receptors in pancreatic α- and β-cells: In β-cells, glucose enters the cell, undergoes glycolysis to generate pyruvate which is oxidised in 
the mitochondria to yield ATP and glutamate (1). Increased ATP inhibits the ATP-sensitive potassium channel (KATP) channels leading to opening of voltage-dependent calcium channel (VDCC) 
and Ca2+ influx (2). Glutamate from glucose metabolism leaves the cell via glutamate transporter (3) or enters insulin-containing secretory granules (ISG) to potentiate release of insulin (4). 
Glutamate from circulation passes through the fenestrated endothelium of the islet vasculature (5) to bind to KARs on β-cells leading to increased influx of Ca2+ via three mechanisms: direct 
permeation through Ca2+-permeable GluK2 and GluK3 subunits (6); direct opening of VDCC by depolarising effect of GluK2/5 (7); KAR (GluK2/5; GluK2/4)-induced increase in cGMP levels 
which leads to inhibition of KATP channels and subsequent opening of VDCC (8). Neto 1 and Neto 2 modulates binding of glutamate (9) and the depolarising effect of KARs is enhanced by group 
I mGluRs (mGluR1, mGluR5) (10). KAR-induced influx of Ca2+ potentiates GSIS (11). In α-cells, extracellular glutamate binds and activates KARs (GluK2/5, GluK3/5). Activated KARs regulates 
the co-secretion of glutamate with glucagon from glucagon-containing secretory granules (GSG) (12). This mechanism may be modulated by Neto 1 and Neto 2 (13). Prolonged activation of α- 
and β-cell KARs (GluK2-5) leads to increased Ca2+ influx and cell death via mechanisms including mitochondrial dysfunction, ER stress and oxidative stress (14) (15).  
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Chapter Three 
Role of GluRs in autoimmune T1DM 
3.1. Introduction 
There is no report of a direct link between GluR antigens and the autoimmune process in 
T1DM but circumstantial evidences exist that suggest that further investigation into this 
link is justified. First, the prevalence of T1DM among autoimmune epilepsy patients is 
double the prevalence in the general population (Keezer et al., 2015). This prevalence 
was also more than double that of T2DM among these epilepsy patients. Moreover, 
significantly high titres of anti-GAD antibodies have been reported in serum of children 
suffering from refractory epilepsy and autoimmune limbic encephalitis (Abd El-Aziz and 
El-Serogy, 2013; Blanc et al, 2009). These observations indicate the existence of 
autoantibodies against both GluRs and islet autoantigen in the same condition, suggesting 
a possible linkage between these receptors and T1DM autoimmune process. These 
suggestions are enforced further by observations that GAD autoantibodies play a major 
role in both acute and chronic epilepsy (Liimatainen et al., 2012) considering that 
autoantibodies to this enzyme are implicated in T1DM. Interestingly, antidiabetic drugs 
such as exenatide (Tsunekawa et al., 2007) and glitazones (Cunha et al., 2009) which are 
known to preserve β-cell integrity and survival also possess neuroprotective properties, 
while the anti-epileptic drug topiramate which attenuates glutamate-induced 
excitotoxicity also have antidiabetic properties and preserve β-cell survival and function 
(Davalli et al., 2012). 
Even though all these observations are circumstantial, they provide significant insights 
into the possibility that GluRs may be involved in both β-cell function and death. 
Investigating the presence of antibodies against GluR subunits in serum of T1DM patients 
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is a novel study which will contribute significantly to the search for the exact trigger or 
cause of the autoimmune process in T1DM. All the well-established autoantibodies in 
T1DM are targeted against intracellular antigens involved in secretory pathways (Arvan 
et al., 2012) which implies that an extracellular or transmembrane antigen may be the 
first target of the autoimmune process resulting in the release of these intracellular 
proteins. Since GluRs are transmembrane proteins, identification of autoantibodies 
against GluR antigens in serum of T1DM patients will provide a good foundation to 
investigate the possibility of these autoantibodies in the initiation or trigger of the 
autoimmune process in T1DM.   
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3.2. Aims 
The aim of this chapter is to investigate the presence of autoantibodies against GluR 
subunits in serum of newly-diagnosed T1DM patients.  
Specific objectives for this chapter include: 
1) Isolation of GluR-rich synaptosomal plasma membrane (SPM) fraction from 
whole rat brain. 
2) Optimisation of an ELISA for detection of GluRs in SPM fractions using 
commercial GluR antibodies, T1DM and non-diabetic control serum samples. 
3) Analysis and selection of T1DM sera which react against SPM proteins in ELISA 
for further analysis. 
4) Immunoblotting of SPM proteins using commercial GluR antibodies, T1DM and 
non-diabetic control serum samples. 
5) Transient overexpression of specific GluR subunits in HEK293 cells 
6) Optimisation of immunoblotting technique for detecting antibodies against GluR 
subunits in sera of T1DM patients. 
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3.3. Materials and Method 
3.3.1. Materials 
Details of materials are supplied in Appendix 1. 
 
3.3.2. Preparation of synaptosomal plasma membrane (SPM) 
All procedures were carried out at 4oC using pre-cooled reagents and buffers. Ten 
volumes (1:10 ratio of buffer to volume of brain tissue) of HEPES-buffered sucrose 
solution (4 mM HEPES pH 7.4, 0.32 M sucrose) containing 0.1 mM PMSF and 1 mM 
sodium orthovanadate was added to one volume of rat brain and then the brain 
homogenised using a Potter-Elvehjem tissue grinder (Thermo-Fisher Scientific, Paisley, 
UK). The homogenate was centrifuged at 1000 x g at 4oC to yield a nuclear fraction pellet 
(P1). The supernatant (S1) was transferred into a fresh tube and centrifuged at 10,000 x g 
for 15 minutes to produce a crude synaptosomal pellet (P2). The resulting supernatant 
(S2) was discarded and the P2 pellet was resuspended in 10 volumes of HEPES-buffered 
sucrose and centrifuged at 10,000 x g for 15 minutes to yield a washed crude 
synaptosomal fraction (P2I). The P2I pellet was lysed by resuspending in 10 mL of ice-
cold deionised water containing 1X protease inhibitor, 0.1 mM PMSF and 1 mM sodium 
orthovanadate and then passing the suspension through a 1 mL syringe attached to a 25 x 
1 inch (0.5 x 25 mm) needle 20-25 times. The solution was quickly adjusted to 4 mM 
HEPES using 1 M HEPES (pH 7.4) stock solution and mixed constantly for 30 minutes 
in cold room (4oC) to ensure complete lysis. The lysate was then centrifuged at 25,000 x 
g for 20 minutes to yield a lysed synaptosomal membrane fraction (P3). The P3 pellet 
was resuspended in 2-5 mL of HEPES-buffered sucrose solution. Using a Pasteur pipette, 
the resuspended membrane was layered onto a discontinuous sucrose gradient (0.8 M, 1.0 
M and 1.2 M from top to bottom of the tube (supplemented with 0.1 mM PMSF and 1 
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mM sodium orthovanadate) from top to bottom respectively in an ultraclear tube. The 
gradient was centrifuged at 150,000 x g for 2 hours in a swinging bucket rotor and the 
synaptic plasma membrane in the layer between 1.0 M and 1.2 M sucrose was recovered 
by carefully puncturing the tube with a needle and withdrawing the layer with a syringe. 
The concentration of sucrose in the recovered fraction was diluted to 0.32 M by adding 
2.5 volumes of 4 mM HEPES pH 7.4 and then centrifuged at 150,000 x g for 30 minutes. 
The pellet, P5 was resuspended in 1-2 mL ice-cold HEPES buffer (50 mM pH 7.4, 2 mM 
EDTA, 0.1 mM PMSF and 1 mM sodium orthovanadate) (Hahn et al., 2009; Carlin et 
al., 1980; Cho et al., 1992; Dosemeci et al., 2006; Molnar et al., 1994). Figure 3.1 
summarises the procedure. 
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Brain 
Brain homogenised in HEPES-sucrose 
buffer 
Brain homogenate 
Homogenate was centrifuged 
at 1000 x g  
Supernatant (S1) + Nuclear fraction pellet (P1) 
Supernatant was centrifuged at 10,000 x g  
Crude synaptosomal pellet (CSP) (P2) 
CSP resuspended in HEPES 
sucrose buffer and  
centrifuged at 10,000 x g 
Washed crude synaptosomal pellet (WCSP) (P2I) 
WCSP lysed in ice-cold deionised water, adjust suspension 
to 4 mM HEPES, centrifuge at 25,000 x g 
Lysed synaptosomal fraction (LSF) (P3) 
LSF resuspended in HEPES-
sucrose, transfer into sucrose 
gradient and centrifuged at 
150,000 x g 2hrs 
Fraction between 
between 1.0 M and 
1.2 M sucrose recovered 
Fraction resuspended in 
HEPES-sucrose buffer and 
centrifuged 150,000 x g 
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Synaptosomal 
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Membrane 
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1.2 M sucrose 
 Cytosol 
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ER, Golgi, plasma 
membrane 
 Synaptosome 
 Mitochondria 
Figure 3.1. Summary of experimental procedure for preparation of synaptosomal plasma 
membrane fraction. ER: Endoplasmic reticulum; Golgi: Golgi apparatus 
Chapter Three                                                                                 3.3 Materials and Methods 200 
 
 
3.3.3. Optimisation of amount of antigen required for immobilisation  
Rat SPM fraction was diluted to concentrations of 0.25 µg, 0.5 µg, 1.0 µg, 2.0 µg and 4 
µg per 100 µL in coating buffer (13 mM Na2CO3, 35 mM NaHCO3, pH: 9.6) and then 
100 µL transferred into Nunc-Immuno™ MicroWell™ 96-well ELISA plates. The plates 
were sealed with sealing films and incubated at 4oC overnight on plate shaker at 500 rpm. 
The plates were inverted to remove unbound solution and then rinsed three times 5 
minutes each on a plate shaker using PBS-T washing buffer (1X PBS with 0.05% (v/v) 
Tween-20). After each wash, the plates were inverted and blotted firmly on paper towel 
to remove residual buffer (Miura et al., 2008; Chiodo et al., 2013; Molnar et al., 1994). 
After rinsing, the wells were blocked with 200 µL of 5% (w/v) BSA diluted in washing 
buffer for 1 hour at room temperature on plate shaker (500 rpm). The blocking solution 
was removed and the wells were rinsed with PBS-T and blotted by inverting the plates 
and tapping firmly on paper towel to remove residual liquid from the wells. 200 µL of 
anti-GluK2/3, anti-GluK5 and anti-pan-AMPAR diluted to 1:1000 in 1% (w/v) BSA were 
added to designated wells in the SPM-coated plates and sealed. The plates were then 
incubated for 2 hours at room temperature on a plate shaker (500rpm). Controls were set 
by adding 200 µL of 1% (w/v) BSA to designated coated wells. After incubation, the 
plates were inverted to remove unbound antibody and then the wells were rinsed three 
times using 400 µL of PBS-T washing buffer. HRP-conjugated anti-rabbit IgG secondary 
antibody diluted to 1:5000 in 1% BSA was added to the wells and incubated at room 
temperature for 1 hour on a plate shaker at 500 rpm. Coated wells incubated with anti-
rabbit only were also set up as controls. The antibody solution was disposed of and the 
wells were rinsed and blotted three times. After the last wash, 100 µL of enhanced K-blue 
TMB substrate was added to the wells and the plate was shaken at 500 rpm until a blue 
colour developed. The reaction was immediately stopped by adding 100 µL of 1 M HCl 
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solution and optical density was read at 450 nm using the Megallan Infinite® F50 
microplate reader (Tecan, Mannedorf, Switzerland) within 20 minutes of adding the HCl 
solution. A bar chart representing mean ± SEM of optical density (450 nm) against 
concentration of SPM for three independent experiments was plotted using Excel. 
Statistical comparisons were performed using one-way ANOVA and differences between 
means were considered statistically significant if the p value was less than 0.05.  
The amount of bound SPM protein was measured using the BCA protein quantification 
assay as follows: triplicates of 10 μL BSA standards of concentrations 0-1000 μg/mL 
were prepared in wells of the 96-well plate after which 200 μL of BCA working reagent 
(50:1; BCA reagent: copper (II) sulphate solution) was added to each of the BSA 
standards. To the immobilised SPM protein, 210 μL of the working reagent was added 
followed by incubation at 600C for 20 minutes. Absorbance at 492 nm was read with 
Megallan plate reader (Tecan, Reading, UK). A BSA standard curve of absorbance 
against concentration was plotted and used to determine the concentrations of the 
immobilised SPM proteins (da Luz et al., 2015). 
Based on the measurement of bound protein and the optical density of the reaction 
between the coated antigen and antibody, 3 µg/100 µL was selected as the optimal 
concentration of SPM for coating the plates for ELISA.  
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3.3.4. Testing for the presence of autoantibodies to GluRs subunits in sera of T1DM 
patients and aged-matched non-diabetic control subjects.  
3.3.4a. Details of T1DM patients and control subjects 
Serum samples from forty newly-diagnosed T1DM patients and forty age-matched non- 
diabetic healthy individuals were collected at the University Hospital of Wales (Wales, 
UK). Tables 3.1-3.2 show details of the T1DM patients and non-diabetic controls. 
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Table 3.1. Details and sample codes of newly-diagnosed T1DM patients and healthy 
non-diabetic controls 
T1DM patients Non-diabetic healthy controls 
Sample ID Gender Age Sample ID Gender Age 
ND603 F 39 1 F 39 
ND604 M 38 2 M 38 
ND605 M 44 3 M 44 
ND607 F 40 4 F 40 
ND609 F 47 5 F 47 
ND614 F 29 6 F 29 
ND615 F 37 7 F 37 
ND637 F 45 8 F 45 
ND638 F 43 9 F 43 
ND650 M 46 10 M 46 
ND662 F 48 11 F 48 
ND674 M 47 12 M 47 
ND675 F 38 13 F 38 
ND490 M 46 14 M 46 
ND488 F 29 15 F 29 
ND450 M 50 16 M 50 
ND419 F 50 17 F 50 
ND517 M 40 18 M 40 
ND522 F 42 19 F 42 
ND530 M 29 20 M 29 
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Table 3.2. Details and sample codes of newly-diagnosed T1DM patients and healthy 
non-diabetic controls 
T1DM patients Non-diabetic healthy controls 
Sample ID Gender Age Sample ID Gender Age 
ND534 M 35 21 M 35 
ND548 F 30 22 F 30 
ND568 M 48 23 M 48 
ND398 M 47 24 M 47 
ND358 F 42 25 F 42 
ND397 M 48 26 M 48 
ND557 M 43 27 M 43 
ND456 M 39 28 M 39 
ND455 M 45 29 M 45 
ND365 F 52 30 F 52 
ND667 M 44 31 M 44 
ND512 F 46 32 F 46 
ND596 F 42 33 F 42 
ND494 F 47 34 F 47 
ND507 M 51 35 M 51 
ND480 M 50 36 M 50 
ND533 M 42 37 M 42 
ND609 F 47 38 F 47 
ND366 F 47 39 F 47 
ND541 M 50 40 M 50 
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3.3.4b. Testing for the presence of antibodies to GluR-enriched SPM proteins in sera of 
T1DM control patients. 
Nunc-Immuno™ MicroWell™ 96-well ELISA plates were coated overnight at 4oC with 3 
µg/100 mL SPM fraction, washed and then blocked with 5% (w/v) BSA as described in 
section 3.3.3. Serum samples from T1DM patients, control patients and commercially-
acquired delipidated (free of cholesterol, triglycerides and most other lipids) human 
serum (TCS Biosciences, Buckingham, UK) were diluted to 1:1000 in 1% (w/v) BSA and 
added to the SPM-coated wells. The plates were sealed and incubated at room temperature 
for 2 hours on a shaker (500 rpm). The wells were rinsed three times and 200 µL of 
1:10,000 HRP-conjugated anti-rabbit IgG secondary antibody was added to the wells and 
incubated at room temperature for 1 hour on a plate shaker (500 rpm). The wells were 
rinsed, blotted and 100 µL of K-blue solution was added followed by 50 µL HCl as 
described in section 3.3.3. The optical density was determined at 450 nm and a bar chart 
representing mean ± SEM optical density from three independent experiments was 
plotted. Samples with mean optical density higher than mean optical density of the 
delipidated serum were selected to be used for reaction against SPM fractions in 
immunoblotting.  
 
3.3.5. Visualisation of the SPM proteins recognised by autoantibodies in serum of T1DM 
patients and non-diabetic controls  
Synaptosomal plasma membrane fraction (20 µg) was added to equal volume of 2X 
loading buffer (0.0625 M Tris-HCl, pH 6.8, 1% (w/v) SDS, 10% (v/v) bromophenol blue) 
and subjected to polyacrylamide gel electrophoresis followed by transfer onto a PVDF 
membrane (Chapter two, Section 2.3.9). The membrane was incubated with ponceau red 
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for 5 minutes at RT and then the stain was rinsed off with distilled water and TBS-T. This 
enhanced visualisation of the protein bands and enabled cutting the membranes into 
individual strips each containing a lane of separated SPM fraction. The membrane was 
then rinsed in TBS-T (50 mM Tris-HCl; pH: 7.4, 150 mM NaCl, 0.1% Tween) until the 
stained protein bands disappeared. The membranes were blocked in 5% milk for 1 hour 
and incubated overnight at 4oC with human T1DM or control sera (1 in 1000 diluted in 
5% milk), delipidated commercial human serum (1 in 1000), anti-GluK2/3 (1 in 3000) 
and anti-GluK5 (1 in 3000). The membrane was washed six times in TBS-T for 5 minutes 
each and incubated with 1:10,000 dilution of HRP-conjugated anti-human IgG secondary 
antibody for 45 minutes followed by washing the membrane six times in TBS-T for 5 
minutes each. The membrane was then incubated with 2 mL of HRP substrate for 1 
minute. Detection of immunopositive bands was performed using the enhanced 
chemiluminescence detection system and Syngene gel imaging and analysis system 
(Syngene, Cambridge, UK). (Storto et al., 2006; Whitehead et al., 2013; Diraison et al., 
2010).   
 
3.3.6. Transient transfection of HEK293 cells with plasmids encoding GluR subunits  
HEK293 cells were seeded onto 10 cm2 cell culture-treated dishes at density of 3 x 106 
cells/10 mL and cultured in DMEM (Chapter two, Section 2.3.2).  
Cells were transfected with plasmids encoding kainate (GluK2, GluK5), AMPA (GluA1) 
and NMDA (GluN1, GluN2A, GluN2B) receptors. These constructs were provided 
courtesy of Professor Elek Molnar (University of Bristol, UK). The transfection mixture 
was prepared by adding 7 µg of plasmid to 500 µL of Opti-MEM® I reduced serum media. 
The transfection reagent was prepared by adding polyethylenimine (PEI) (three and half 
times the volume of plasmid DNA required) to 500 µL of Opti-MEM® I. Both mixtures 
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were briefly vortexed and the transfection reagent mixture was added to the plamid-Opti-
MEM mixture and incubated at room temperature for 20 minutes. The mixture was then 
added to the cultured HEK293 cells and incubated under cell culture conditions for 48-72 
hours (Tom et al., 2008; Longo et al., 2013; Varadi and Rutter, 2002).  
Protein lysate was prepared using RIPA extraction method and quantified using Bradford 
assay (Chapter two, sections 2.3.5-2.3.6). 
 
3.3.7. Visualisation of overexpressed GluR subtypes recognised by the autoantibodies in 
the serum samples using immunoblotting 
Membrane lysate fraction from transiently transfected HEK293 cells (30 µg) was added 
to equal volume of 2X loading buffer and subjected to polyacrylamide gel electrophoresis 
followed by transfer onto a PVDF membrane (Chapter two, section 2.3.9). The membrane 
was blocked in 5% milk for 1 hour and incubated overnight at 4oC with human T1DM or 
control sera (1 in 250 diluted in 5% milk), anti-GluK2/3 (1 in 3000), anti-GluK5 (1 in 
3000) and anti-pan-AMPAR (1 in 1000) primary antibodies.  
The membranes were washed six times in TBS-T for 5 minutes each and incubated at RT 
for 45 minutes with HRP-conjugated anti-rabbit or anti-mouse IgG secondary antibody 
(dilution; 1:4000 in 5% milk).  
After incubation, the membrane was washed six times in TBS-T for 5 minutes each and 
incubated with 2 mL of HRP substrate for 1 minute. Detection of immunopositive bands 
was performed using the enhanced chemiluminescence detection system and Syngene gel 
imaging and analysis system (Syngene, Cambridge, UK). (Storto et al., 2006; Whitehead 
et al., 2013; Diraison et al., 2010).   
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The membranes were stripped of all bound antibodies for 35 minutes at 50oC in stripping 
buffer (2% (w/v) SDS, 0.0625 M Tris, pH 6.8, 0.11 M 2-mercaptoethanol) before 
reprobing (Varadi et al., 1996). 
3.3.8. Statistical analysis 
Data are presented as means ± SEM of at least three independent experiments with 
number of replicates stated in respective experiments. Statistical comparisons were 
performed by one-tailed Student’s t-test using Microsoft Excel or one-way ANOVA using 
Minitab data analysis software. Differences between means were considered statistically 
significant if the p value was less than 0.05.  
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3.4. Results 
3.4.1. Investigation of the presence of autoantibodies against glutamate receptor 
subunits in serum of type 1 diabetic patients. 
This current study identified functional KAR channels in pancreatic endocrine cells and 
have also established that these receptors play significant roles in β-cells including 
calcium influx and insulin secretion (Chapter two, sections 2.4.1-2.4.4). Also, these 
receptors have been shown to significantly influence the viability of pancreatic endocrine 
cells (Chapter two, section 2.4.5). Other studies have identified the other iGluR subtypes 
in pancreatic endocrine cells (Chapter one, Tables 1.6-1.8).  
Evidence linking pathogenesis of neurological conditions to GluR autoantibodies 
(Chapter one, section 1.8) as well as the potential role of glutamate and GluRs in diabetes 
mellitus have been discussed (Chapter one, section 1.10). Furthermore, circumstantial 
evidence which is indicative of a possible relationship between TIDM pathogenesis and 
GluR antigens/autoantibodies has also been discussed (section 3.1). Thus, it was 
important to investigate the presence of autoantibodies against KARs and other GluR 
subtypes in serum of T1DM patients.  
Serum samples from forty newly-diagnosed T1DM individuals as well as forty age-
matched non diabetic healthy individuals were collected at the University Hospital of 
Wales. Details of the patients and healthy non-diabetic controls are shown in section 
3.3.4, tables 3.1-3.2.   
 
 
 
Chapter Three                                                                                                          3.4 Results 210 
 
 
3.4.1a. Optimisation of the amount of synaptosomal plasma membrane (SPM) fraction 
required for the coating of ELISA wells 
To select the optimal SPM concentration required to immobilise in ELISA plates, 
different amounts (0.25-4.0 µg) of the SPM were immobilised into ELISA plates, 
incubated with primary (anti-GluK2/3, anti-GluK5, anti-pan-AMPAR) and secondary 
(horseradish peroxidase-conjugated anti-rabbit IgG) antibodies. A TMB horseradish 
peroxidase substrate was added and incubated for 20 minutes followed by addition of 1 
M HCl to stop the reaction. Optical density at 450 nm was measured immediately after 
addition of the HCl (section 3.3). A bar chart of optical density against concentration of 
the immobilised protein was plotted (Figure 3.2). From the results, coating the ELISA 
wells with 2-4 µg of SPM showed approximately the same antibody binding and 
approximately the same amount of bound protein hence 3 µg was selected as the amount 
of SPM protein to coat the wells.   
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Figure 3.2. Optimisation of the amount of SPM required for immobilisation in ELISA plates. SPM fractions were prepared from rat whole brain tissue and 
immobilised onto ELISA wells. The coated wells were incubated with anti-GluK2/3, anti-GluK5 and anti-pan-AMPAR primary antibodies and then with HRP-
conjugated anti-rabbit IgG secondary antibody. The wells were rinsed, incubated with enhanced K-blue TMB substrate and then optical density measured at 450 
nm. Results are presented as means ± SEM from three separate experiments.  
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3.4.1b. Selection of test sera that react with GluR-enriched SPM fraction proteins  
After optimising the amount of SPM fraction required to coat the wells for ELISA, the 
assay was used to select T1DM sera that react with GluR-enriched SPM proteins as 
described in section 3.3.4. Negative controls were set up by excluding the primary 
antibody incubation step. An image of a representative ELISA plate after addition of HCl 
stop solution is shown in Figure 3.3. Bar graph of optical density for 40 T1DM, 40 non-
diabetic controls and 3 delipidated (free of cholesterol, triglycerides and most other lipids) 
human serum is shown in Figure 3.4 and a bar graph comparing optical density between 
T1DM patients and their age- and gender-matched controls is shown in Figure 3.5. 
Individual value plot was used to analyse the data distribution and also to compare the 
optical densities for T1DM and non-diabetic controls (Figure 3.6). The individual plots 
indicate that there is no significant differences in immunoreactivities between serum of 
T1DM and non-diabetic controls. Also, the plots show the same data distribution between 
immunoreactivities of T1DM and controls.  
Serum of T1DM patients and non-diabetic controls with optical density above the mean 
optical density of the commercial human serum were selected for further analysis. In total, 
34 sera representing approximately 43% of the samples were selected based on this 
approach.  
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Figure 3.3. Representative ELISA for selection of sera from T1DM patients and non-diabetic controls that react with GluR-enriched SPM 
proteins. SPM proteins were immobilised in ELISA plates and incubated with serum of T1DM patients and non-diabetic controls and delipidated 
human serum followed by incubation with HRP-conjugated anti-human IgG secondary antibody. Negative control was set up by excluding the 
primary antibody step of the reaction. Image is representative of three independent experiments.  
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Figure 3.4. Selection of test sera that react with GluR-enriched SPM proteins. SPM fraction proteins were immobilised in ELISA plates and incubated 
with serum from T1DM patients and non-diabetic controls and delipidated human serum followed by incubation with HRP-conjugated anti-human IgG 
secondary antibody. Negative control (NC) was set up by excluding the primary antibody incubation step. Samples with optical densities above that of 
commercial human sera (CHS) were selected for further analysis. Results are presented as means ± SEM from three separate experiments.  
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Figure 3.5. Bar graph showing optical densities for T1DM patients and aged- and gender-matched non-diabetic controls. SPM fraction proteins 
were immobilised in ELISA wells and incubated with serum of T1DM patients and non-diabetic controls followed by incubation with HRP-conjugated 
anti-human IgG secondary antibody. TMB ELISA substrate was added and optical density measured at 450 nm. Results are presented as means ± SEM 
from three separate experiments.  
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Figure 3.6. Individual value plots of optical densities for T1DM and non-diabetic control samples. SPM fraction proteins were immobilised in ELISA 
plates and incubated with serum from T1DM patients and non-diabetic controls followed by incubation with HRP-conjugated anti-human IgG secondary 
antibody. TMB ELISA substrate was added and optical density measured at 450 nm. Results are presented as means from three separate experiments.  
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3.4.1c. Visualisation of the SPM target proteins recognised by autoantibodies in serum 
of T1DM patients and non-diabetic controls  
In addition to GluRs, several other proteins are present in synaptosomal plasma 
membrane fraction (Rodriguez-Moreno and Sihra, 2013; Biesemann et al., 2014). Thus, 
immunoblotting was used to investigate the type of SPM proteins which reacted with 
antibodies in the test samples. SPM protein (20 µg) was separated using SDS-PAGE, 
transferred onto PVDF membrane, incubated with 1:1000 dilution of serum of T1DM 
patients, non-diabetic controls and commercial human serum followed by incubation with 
HRP-conjugated anti-human IgG secondary antibody (1:10,000) as described in section 
3.35. The immunoblot results are shown in Figure 3.7.  
The results show immunopositive bands in the region between 100 and 150 kDa in some 
T1DM and non-diabetic control serum samples. This region (100-150 kDa) corresponds 
to the molecular weight range for GluR proteins. Membranes which were incubated with 
commercial human serum showed no immunopositive bands. Immunopositive bands 
were present in the region between 50 and 75 kDa for some of the membranes incubated 
with T1DM or non-diabetic control sera. Though the identity of these bands could not be 
elucidated from this technique, the method gave an indication that antibodies in the test 
sera target SPM proteins with molecular weight range between 100 and 150 kDa.  
                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                      
 
 
 
                                                                                                                                                                                                                                                                                   
 
 
 
 
 
 
 
 
 
 
Commercial 
antibodies 
Figure 3.7. Immunoblotting of SPM proteins using serum of T1DM patients, non-diabetic controls and GluK antibodies. SPM proteins were separated using 
SDS-PAGE, transferred onto PVDF membrane and incubated with serum of T1DM, non-diabetic controls, anti-GluK2/3 or anti-GluK5 antibodies followed by HRP-
conjugated anti-human/rabbit IgG secondary antibody. The region inside the yellow rectangle represents where GluR subunit proteins are expected. Figures are 
representative of two independent experiments. Sample ID and patient details are shown in tables 3.1-3.2. CHS: commercial human serum. 
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3.4.1d. Identification of sera that specifically recognise overexpressed GluR subunits in 
HEK293 cells.   
Based on the results from section 3.4.1c, using immunoblotting to detect SPM proteins 
that are bound by antibodies in the serum samples was not specific. However, the 
technique was useful in selecting serum samples that reacted with separated SPM fraction 
proteins. Based on these observations, GluR subunits (GluK2, GluK5, GluA1, GluN2A 
and GluN2B) were overexpressed in HEK293 cells as described in section 3.3.6. 
Membrane lysates were prepared from the transfected HEK293 cells and 20 μg of protein 
was separated using SDS-PAGE, transferred onto PVDF membrane and then incubated 
with serum of T1DM or non-diabetic controls as described in sections 3.3.6-3.3.7. 
Negative controls were set up by reacting test serum with proteins from non-transfected 
HEK293 cells. Positive controls were set up by reacting anti-GluK2/3, anti-GluK5 and 
ant-pan-AMPAR antibodies with proteins from GluK2-, GluK5- and GluA1-tranfected 
HEK293 cells respectively. Four serum samples (sample ID: 358, 596, 18 and 615) were 
used in this experiment. These four samples were selected because they showed 
immunoreactive bands within a region corresponding to the molecular weight range for 
GluR proteins when they were incubated with SPM proteins in immunoblotting (Figure 
3.7). However, not all the samples that showed immunoreactive bands with SPM were 
used at this stage due to time constraints.     
The reaction between the overexpressed proteins and the commercial antibodies (anti-
GluK2/3, anti-GluK5 and anti-pan-AMPAR) showed immunopositive bands in the region 
that corresponds to the molecular weights of these GluR subunit proteins (100-110 kDa) 
(Figure 3.8). This confirmed that the transfected GluK2, GluK5 and GluA1 were 
expressed in the HEK293 cells. However, due to unavailability of anti- GluN2A and anti-
GluN2B antibodies, expression of these transfected subunits could not the confirmed. 
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There were no reactions between the commercial antibodies and membrane lysates from 
non-transfected HEK293 cells (Figure 3.8).  
The reaction between membrane lysates from the transfected HEK293 and the test sera 
showed several immunopositive bands within the region which corresponds to the 
molecular weight range for GluR proteins (100-150 kDa). Some immunopositive bands 
were also outside the region that corresponds to the molecular weight range for GluR 
proteins (Figures 3.9-3.12). The presence of non-specific immunoreactive bands makes 
it difficult to conclude that the overexpressed proteins were specifically targeted by 
corresponding antibodies in the test samples.  
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Figure 3.8. Confirmation of expression of GluR subunits in transfected HEK293 cells. Proteins prepared from HEK293 cells transfected with GluK2 (A), 
GluK5 (B) and GluA1 (C) were separated using SDS-PAGE, transferred onto PVDF membranes. The membranes were labelled with corresponding antibodies 
(anti-GluK2/3, anti-GluK5 and anti-pan-AMPAR) followed by incubation with corresponding HRP-conjugated anti-rabbit IgG secondary antibody. The 
immunopositive bands were visualised using enhanced chemiluminescence. One experiment was performed.  
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Figure 3.9. Identification of serum that specifically recognise overexpressed GluR subunits in HEK293 cells. Proteins prepared from GluR subunit-
transfected HEK293 cells were separated using SDS-PAGE, transferred onto PVDF membrane. The membrane was incubated with test serum (1:200) 
followed by incubation with HRP-conjugated anti-human IgG secondary antibody. The immunopositive bands were visualised using enhanced 
chemiluminescence. The region inside the yellow rectangle represents where GluR subunit proteins are expected. Sample ID and patient details are shown 
in tables 3.1-3.2.  One experiment was performed.  
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Figure 3.10. Identification of serum that specifically recognise overexpressed GluR subunits in HEK293 cells. Proteins prepared from GluR subunit-
transfected HEK293 cells were separated using SDS-PAGE, transferred onto PVDF membrane. The membrane was incubated with test serum (1:200) followed 
by incubation with HRP-conjugated anti-human IgG secondary antibody. The immunopositive bands were visualised using enhanced chemiluminescence. The 
region inside the yellow rectangle represents where GluR subunit proteins are expected. Sample ID and patient details are shown in tables 3.1-3.2.  One 
experiment was performed.  
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Figure 3.11. Identification of serum that specifically recognise overexpressed GluR subunits in HEK293 cells. Proteins prepared from GluR subunit-
transfected HEK293 cells were separated using SDS-PAGE, transferred onto PVDF membrane. The membrane was incubated with test serum (1:200) 
followed by incubation with HRP-conjugated anti-human IgG secondary antibody. The immunopositive bands were visualised using enhanced 
chemiluminescence. The region inside the yellow rectangle represents where GluR subunit proteins are expected and the red rectangle indicates an 
immunopositive band of interest.  Sample ID and patient details are shown in tables 3.1-3.2. One experiment was performed.  
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Figure 3.12. Identification of serum that specifically recognise overexpressed GluR subunits in HEK293 cells. Proteins prepared from GluR 
subunit-transfected HEK293 cells were separated using SDS-PAGE, transferred onto PVDF membrane. The membrane was incubated with test serum 
(1:200) followed by incubation with HRP-conjugated anti-human IgG secondary antibody. The immunopositive bands were visualised using enhanced 
chemiluminescence. The region inside the yellow rectangle represents where GluR subunit proteins are expected. Sample ID and patient details are 
shown in tables 3.1-3.2.  One experiment was performed. 
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On the membrane labelled with serum with sample ID 615, an immunopositive band was 
present in the GluA1 lane (highlighted in red in Figure 3.11). This band was distinct from 
the other immunopositive bands. It was suggested from this observation that this 
immunopositive band could likely be the result of reaction between the overexpressed 
GluA1 protein and a corresponding antibody in the serum. A look at the patient details 
(Tables 3.1-3.2) showed that the serum with sample ID 615 is a T1DM patient. 
To further investigate this observation, the membrane was stripped of the antibodies by 
incubating in a stripping buffer (2% SDS, 0.0625 M Tris, pH 6.8, 0.11 M 2-
mercaptoethanol). The membrane was then reprobed with anti-pan-AMPAR antibody at 
4oC overnight followed by incubation with HRP-conjugated anti-rabbit IgG secondary 
antibody. The reprobed membrane is shown in Figure 3.13.  
A crude method of band position analysis involving measuring the distance from the top 
of the gel to the middle of the band of interest was utilised. The distances from the top of 
the gel to the protein ladder markers were also measured. The log of molecular weights 
of the protein ladder against the distance was plotted to derive an equation (Figure 3.14). 
The distance measured from the top of the gel to the middle of the band of interest (14 
mm) was used in the equation of the curve (y = -0.38ln(x) + 3.0457) to determine the log 
of molecular weight of the band of interest (2.0428). The anti-log of this figure 
(approximately 110.2) represented the approximate molecular weight of the band of 
interest. From literature, the molecular weight of GluA1 is between 100 and 105 kDa 
(Hoftberger et al., 2015). Thus it can be inferred from these observations that 
immunoblotting of overexpressed GluR proteins with T1DM serum could be used to 
identify antibodies in serum that react with these GluR proteins.  
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Figure 3.13. Reprobing of membrane of with anti-pan-AMPAR to investigate immunopositive band of interest. The membrane labelled with 
sample ID 615 (A) was incubated with stripping buffer and labelled with anti-pan-AMPAR antibody followed by incubation with HRP-conjugated anti-
rabbit IgG secondary antibody. The immunopositive bands were visualised using enhanced chemiluminescence (B). The band in the red rectangle is 
the immunopositive band of interest. One experiment was performed.  
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Figure 3.14. Determining the approximate molecular weight of an immunopositive band of interest.  The membrane was stripped and reprobed 
with anti-pan-AMPAR followed by incubation with HRP-conjugated anti-rabbit IgG secondary antibody. The distance of the molecular weight markers 
from the top of the membrane were plotted against the log of their molecular weights. The equation of the logarithmic trendline was used to calculate 
the approximate molecular weight of the band of interest. 
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3.5. Summary of results 
The aim of this chapter was to investigate the presence of autoantibodies against GluR 
subunits in serum of newly-diagnosed T1DM patients. The following is a summary of the 
results: 
 Serum from both T1DM patients and non-diabetic controls reacted with 
synaptosomal plasma membrane proteins. 
 Reaction between SPM proteins and serum samples from T1DM patients or non-
diabetic controls in ELISA was useful in selecting samples for further analysis. 
 Antibodies in serum from T1DM patients and non-diabetic controls reacted with 
SPM proteins in the region corresponding to the molecular weight range for GluR 
proteins. However, this reaction was not specific since other SPM proteins with 
molecular weights outside the molecular weight range for GluRs were also bound 
by antibodies in the test serum. 
 GluR subunits (GluK2, GluK5, GluA1, GluN1, GluN2A and GluN2B) were 
expressed when transfected into HEK293 cells. 
 Antibodies in serum from T1DM patients and non-diabetic controls reacted with 
proteins extracted from GluR-transfected HEK293 cells in the region 
corresponding to the molecular weight range for GluR proteins. However, this 
reaction was not specific since other immunoreactive bands were present in 
regions outside the molecular weight range for GluRs. 
 The methods used in this chapter (ELISA and immunoblotting) could be further 
optimised and used in the identification of autoantibodies against GluR proteins.  
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3.6. Discussion 
As discussed previously (Chapter one, section 1.10), there is no existing data to establish 
a direct link between T1DM and GluR subunit antigens or antibodies (Chapter one, 
section 1.10). However, previous studies have suggested indirect links between 
glutamate, GluRs and pathogenesis of T1DM (Chapter one, section 1.10). The 
investigation of anti-GluR autoantibodies in T1DM patients is essential considering that 
use of previously-identified T1DM autoantibodies has helped with prediction of the 
disease but has not helped significantly with prevention (Atkinson et al., 2014). 
Moreover, the well-established autoantigens in T1DM are involved in the secretory 
pathways and are predominantly located in β-cells hence these autoantigens could not 
likely be the first to be targeted by the autoimmune process in T1DM (Arvan et al., 2012). 
GluRs on the other hand are transmembrane proteins which could be targeted to initiate 
an autoimmune process (Willard and Koochekpour, 2013; Lodge, 2009). Thus 
investigation of autoantibodies to GluRs in T1DM could contribute to our understanding 
of the autoimmune process in T1DM and also provide significant information about the 
multifactorial nature of T1DM. Furthermore, results from this current study have shown 
that functional KAR subunits are present and modulate the functions and survival of 
pancreatic endocrine cells (Chapter two). Thus, an investigation into possible roles of 
GluR antigens and autoantibodies in the pathogenesis of T1DM was essential. Thus, this 
chapter investigated the presence of autoantibodies against KAR and other GluR subunits 
antigens in serum of newly-diagnosed T1DM patients and also in serum of age-matched 
non-diabetic controls.  
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3.6.1. Reaction between serum from T1DM/controls and GluR-enriched SPM proteins in 
ELISA can be used to select samples from T1DM and controls for further analysis.  
Reaction between serum of T1DM patients or non-diabetic controls with SPM fraction 
showed that some serum from both T1DM and control serum reacted with proteins in the 
synaptosome fraction (Figure 3.3).  
SPM fraction was used at this stage because studies have established that this fraction is 
rich in glutamatergic synaptic proteins including GluRs (Rodriguez-Moreno and Sihra, 
2013; Biesemann et al., 2014). Synaptosomal preparations have also been used in several 
studies involving GluRs including identification and control of neurotransmitter release 
and role of GluRs in calcium ion influx (Rodriguez-Moreno and Sihra, 2013; Sumioka et 
al., 2011; Evans, 2015; Molnar et al., 1994).  
Moreover, reactions between serum/CSF and crude preparations containing neuronal 
components has been used in previous studies to select samples that react against neuronal 
components for further analysis (Nibber et al., 2015; Gleichman et al., 2014; Fujita et al., 
2012). For instance, in studies investigating autoantibodies to AMPARs, serum from 
Rasmussen’s encephalitis and anti-AMPAR encephalitis were reacted against primary 
neuronal cultures to select samples that react against GluRs on the surface of these 
neurons for further investigations (Nibber et al., 2015; Gleichman et al., 2014). Another 
study used reaction between serum of Creutzfeldt–Jakob disease patients and rat 
hippocampal preparations to select samples which react against neuronal components in 
the preparation for further investigations to detect autoantibodies against NMDARs in the 
patients (Fujita et al., 2012). Thus, reaction between antibodies in the patient/control 
samples and glutamatergic synaptic proteins in SPM was useful selecting samples for 
further analysis in the current study. 
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Negative control which excluded primary antibody incubation confirmed that the 
secondary antibody (anti-human) alone did not bind to the SPM proteins. Furthermore, 
commercially-acquired delipidated human sera reacted with the SPM proteins implying 
that serum from both diabetic and non-diabetic controls may contain antibodies that react 
against SPM proteins. This observation does not necessarily indicate that the method used 
is not specific. In a previous study using ELISA, it was observed that serum from both 
diabetic patients and some non-diabetic healthy controls show strong immunopositivity 
with purified pancreatic duodenal homeobox protein 1 (Pdx1), a protein suggested to be 
a β-cell-specific autoantigen in T1DM (Li et al., 2010). Other studies have also shown 
the presence of autoantibodies against GluR antigens in serum of patients and healthy 
control individuals. In one study, autoantibodies against GluA3 were present in serum of 
both Rasmussen’s encephalitis patients and health controls (Mantegazza et al., 2002). 
From these observations, it could be concluded that use of GluR-enriched SPM proteins 
in ELISA can be used to select samples from T1DM and controls for further analysis. 
However, as a limitation, this method of reacting serum samples and GluR-enriched SPM 
proteins is not specific for identification of autoantibodies in T1DM.  
 
3.6.2. Visualisation of the SPM target proteins recognised by the autoantibodies in serum 
of T1DM patients and non-diabetic controls  
To determine the specific SPM proteins that are targets for antibodies in the serum 
samples, SPM proteins were separated on a gel and then reacted against human serum in 
immunoblotting. The results indicate immunopositive bands that corresponds to the 
molecular weight range for glutamatergic proteins (100-150 kDa). In addition to this, 
there were bands with molecular weights outside the range of GluR proteins. This was 
observed in reactions between SPM proteins and both T1DM and non-diabetic controls 
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(Figure 3.6). This method has been used to detect serum autoantibodies in experimental 
autoimmune encephalomyelitis rats against myelin proteins in SPM fractions (Degano et 
al., 2004; Pedraza et al., 2006). Other studies have used immunoblotting of crude 
membrane fraction from mouse primary hippocampal neurons with serum to detect 
NMDA receptor antibodies in herpes simplex encephalitis patients (Pruss et al., 2013).  
Another study used crude homogenates of human basal ganglia to detect anti-basal 
ganglia antibodies in serum of individuals suffering from idiopathic movement disorders 
(Church et al., 2004). It can be concluded from the results that labelling SPM proteins 
with serum of T1DM or controls in immunoblot gives information about the nature of the 
proteins that are targeted by antibodies in the serum samples. Also, information derived 
from these reactions enabled the selection of serum samples which reacted against SPM 
proteins in the expected molecular weight range. A limitation of this method is that the 
immunopositive bands were not specific since in some of the samples, other 
immunopositive bands were present in regions outside the expected molecular weight 
range. However, this method was   useful in screening and selecting serum samples for 
further analysis.  
 
3.6.3. T1DM and control serum samples react with and recognise overexpressed GluR 
subunits in HEK293 cells.   
This approach was aimed at increasing the sensitivity and specificity of the reaction 
between GluR antigens and corresponding autoantibodies in the serum of T1DM and 
control subjects. Immunopositive bands were present in the expected molecular weight 
range of 100-150kDa (Figures 3.9-3.12). However, there were other bands with molecular 
weights below or above the expected range which may be indicative non-specific binding. 
The presence of immunopositive band in the reactions between proteins from GluK2, 
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GluK5, GluA1 and their corresponding specific antibodies indicates that expression of 
these three GluR subunits in HEK293 cells was successful. Also, there were no 
immunopositive bands when proteins from non-transfected HEK293 cells were labelled 
with these specific antibodies indicating that HEK293 cells do not express native GluR 
subunits. However, unavailability of antibodies against GluN1, GluN2A and GluN2B in 
our laboratory meant that we could not verify if these subunits were expressed in HEK293 
cells after transfections. Membranes which were incubated with T1DM sera showed more 
distinct immunopositive bands compared to membranes which were incubated with non-
diabetic control serum (Figures 3.9-3.12). This observation may not be representative, 
since only one control serum was used in the immunoblotting compared to three T1DM 
sera. A similar method has been used in previous studies in which proteins from GluA1- 
and GluA2-transfected HEK293 cells were used in immunoblotting to detect 
autoantibodies in serum of anti-AMPAR encephalitis human patients (Gleichman et al., 
2014). Another study used protein lysates from GluN1- and GluN2-transfected HEK293 
cells to detect autoantibodies to these NMDAR subunits in serum of herpes simplex 
encephalitis patients using immunoblotting (Pruss et al., 2013). Similarly, in a study 
detect autoantibodies against Pdx1 proteins in serum of T1DM patients, proteins prepared 
from Pdx1-transfetced cells was separated using SDS-PAGE, transferred onto 
nitrocellulose membrane and labelled with serum of T1DM and controls (Li et al., 2010).  
However, in contrast to the current study, all three previous studies (Gleichman et al., 
2014; Pruss et al., 2013; Li et al., 2010) purified the overexpressed proteins and also 
purified IgG from the patient serum for the immunoblotting. Thus, the non-specific 
immunopositive bands observed in this current study may be as result of using non-
purified GluR subunit proteins or labelling the proteins with whole serum instead of 
purified IgG. In spite of these differences, it can be concluded that labelling overexpressed 
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GluR proteins with test serum can potentially help to determine if autoantibodies against 
GluRs are present in serum of T1DM and non-diabetic healthy controls provided that 
steps are taken to reduce non-specific reactions.  
The membrane labelled with sample with ID 615 showed a distinct band in the GluA1 
lane and was within the expected range of molecular weight for GluRs (Figure 3.11). The 
lane protein from non-transfected HEK293 cells did not show immunopositive band 
indicating that the observed immunopositive band in the GluA1-transfected lane could 
likely be as result of reaction between antibodies in the serum sample and GluA1. Re-
probing of the membrane with anti-pan-AMPAR antibody showed that the 
immunopositive band was very distinct and within the expected molecular weight range 
for GluA1 protein (100-105) (Figure 3.13). Using a crude method of molecular weight 
analysis, the molecular weight of the band was estimated to be approximately 109.8 kDa. 
From literature, the molecular weight of GluA1 is between 100 and 105 kDa (Hoftberger 
et al., 2015). Based on the information available, serum sample 615 is from a 37-year old 
newly diagnosed T1DM female. Though this could be an indication of the presence of 
autoantibodies against GluA1 subunit protein in serum of this T1DM patient, no specific 
or direct conclusions can be made regarding this observation for two reasons. First, 
another method of detection including radioimmunoassay (Nibber et al., 2015), ELISA 
(Lai et al., 2009), immunohistochemistry (Barry et al, 2015) and immunofluorescence 
(Lauvsnes et al., 2014) could be used to confirm or verify that the immunopositive band 
is the result of reaction between GluA1 protein and corresponding autoantibody in the 
T1DM patient’s serum. Secondly, autoantibodies against GluA1 subunit protein has been 
detected in serum of individuals suffering from anti-AMPAR encephalitis (Gleichman et 
al., 2014; Lai et al., 2009). Thus, detection of autoantibody against GluA1 antigen in the 
serum of the T1DM patient could potentially be as a result of T1DM and anti-AMPAR 
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encephalitis comorbidity. The likelihood of this comorbidity could not be investigated 
since there was not sufficient clinical information or medical history available for the 
T1DM patients whose sera were used in this study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.7. Conclusion 
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The primary aim of this part of the study was to determine if autoantibodies against KAR 
and other GluR subunits are present in serum of T1DM patients. By using SPM fractions 
and proteins from HEK293 cells transfected with GluR subunits as antigen targets, some 
of the serum samples from both T1DM and non-diabetic controls were shown to react 
against these antigen targets. Though some technical challenges including non-specific 
binding between antibodies and the target proteins were identified, the methods of 
autoantibody identification used in this study were useful in selecting test samples that 
reacted against proteins in SPM preparations as well as showing potential for detection 
of autoantibodies against over-expressed GluR subunits in HEK293 cell lines. Due to 
time-constraints, only four out of the selected thirty-four test samples were tested for 
presence of autoantibodies to overexpressed GluR subunits. Thus, there is the need for 
further optimisation of the techniques and for more samples to be tested.  
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Chapter Four 
Thesis Discussion 
4.1. Discussion 
This study addressed three main areas; first, the identification of KAR subunits in 
pancreatic endocrine cells. The study identified four KAR subunits (GluK2, GluK3, 
GluK4, GluK5) in α- and β-cells and all five subunits (GluK1-5) in islets of Langerhans. 
In addition, the study showed that Neto 1 and Neto 2 auxiliary proteins are present in α- 
and β-cells and rat primary islets of Langerhans. Furthermore, this is the first study to 
show a preferential expression of Neto 1 for α-cells and Neto 2 for β-cells of the pancreas. 
Few studies have reported of KARs in the endocrine pancreas (Molnar et al., 1995; 
Inagaki et al., 1995; Gonoi et al, 1994; Cabrera et al., 2008; Weaver et al., 1996). In 
addition to contrasting observations from these previous studies, many questions 
remained unresolved about the specific molecular characterisation of these receptors. For 
instance, only GluK5 protein has previously been identified in pancreatic β-cells (Molnar 
et al., 1995). Thus, results from this current study has provided sufficient information to 
address these unresolved questions about KARs in pancreatic endocrine cells and has also 
show that functional homomeric or heteromeric units of KARs could assemble in α- and 
β-cells of the pancreas. The successful identification of KAR subunits and auxiliary 
proteins in pancreatic endocrine cells supports previous suggestions of similarities 
between cells of the endocrine pancreas and the CNS (Del Rosario et al., 2015; Marquard 
et al., 2015; Di Cairano et al., 2011; Cheng et al., 2015; Hanson et al., 2015) and also 
provide new insights into non-neuronal expression of KARs.  
The second area which was addressed by this current study is the role of KARs in 
regulation of the [Ca2+]i and GSIS in β-cells as well as the effect of KAR agonists on the 
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viability of α- and β-cells. The results show that activation of KARs by kainate results in 
increased [Ca2+]i and GSIS in β-cells. Results from previous studies were inconclusive 
regarding how KAR activation affect [Ca2+]i and GSIS in β-cells (Molnar et al., 1995; 
Inagaki et al., 1995; Gonoi et al, 1994) due to contrasting observations. Thus, results from 
this current study provides significant evidence for the important role of KARs pancreatic 
β-cell physiology. Furthermore, this study is the first to observe that prolonged exposure 
of α- and β-cells to kainate significantly reduce viability of these cells. The observation 
that prolonged activation of KARs by glutamate significantly reduces viability of β-cells 
supports previous observations (Di Cairano et al., 2011). However, the observation that 
prolonged exposure to glutamate causes significant reduction in viability of α-cells is in 
contrast to previous reports (Di Cairano et al., 2011). Thus results from this current study 
provides significant evidence to show that similar to neurons and other cells of the CNS, 
pancreatic endocrine cells are vulnerable to prolonged exposure to glutamate and other 
agonists of KARs.  
In conclusion, results from previous studies have remained inconclusive regarding the 
molecular characterisation and function of KAR subunits in pancreatic cells. However, 
based on the confirmatory and novel observations from this current study, it can be 
concluded that functional homomeric and heteromeric units of KARs are present and can 
assemble in pancreatic endocrine cells. In addition, it can be concluded that similar to 
observations in the CNS, KARs play significant role in the function and survival of 
pancreatic endocrine cells. Thus, the presence of β-cell KARs should be considered when 
therapies are being developed to target neuronal KARs with the aim of managing 
neurological conditions since these therapies could potentially have beneficial or 
deleterious effects on pancreatic endocrine cells. Moreover, results from this study has 
contributed to understanding why antidiabetic drugs such as exenatide and glitazones 
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possess neuroprotective properties (Cunha et al., 2009; Tsunekawa et al., 2007) or why 
anti-epileptic drugs such as topiramate which attenuates glutamate-induced excitotoxicity 
also have antidiabetic properties and preserve β-cell survival and function (Davalli et al., 
2012; Toplak et al., 2007; Angehagen et al., 2003). Thus, β-cell KARs could be 
considered as potential targets in the management or treatment of diabetes mellitus. In the 
same vein, it can be concluded based on novel results from this current study that 
significant considerations must be taken regarding the consumption of glutamate-rich 
food supplements and other salts of glutamate since these products have the potential to 
increase blood glutamate concentration resulting in exposure α- and β-cell KARs to 
increased plasma glutamate with potentially deleterious effects.  
GluRs have been shown to be autoantibody targets in a number of autoimmune 
neurological conditions (Nibber et al., 2016; Lancaster, 2016). Thus, the third part of this 
study investigated the role of GluR antigens as potential targets of the autoimmune 
process in T1DM. Several procedures and techniques for the detection of anti-GluR 
autoantibodies in serum was used in this study and different techniques were optimised 
to identify autoantibodies in serum of T1DM patients and non-diabetic controls.  The 
results showed indications that ELISA and immunoblotting using SPM proteins and 
overexpressed GluR proteins could be used to detect serum autoantibodies that react 
against GluR subunits in serum of patients.  Thus, this is an area of further research.  
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4.2. Future work 
4.2.1. KARs in pancreatic endocrine cells 
Previous studies have shown that in isolated neurons and mouse models, Neto 1 and Neto 
2 enhances the expression of GluK2 and GluK5 subunits (Sheng et al., 2015; Copits et 
al., 2011). Thus, in future studies, the amount of KAR subunit mRNA and proteins can 
be measured in α- and β-cells after Neto 1 and Neto 2 genes have been silenced. This will 
help to assess how auxiliary subunits proteins affect the surface expression of KARs in 
pancreatic endocrine cells. The presence of GluK1 mRNA and protein in pancreatic δ-
cells and PP cells could also be investigated in future works to understand why GluK1 is 
expressed in the islets of Langerhans but not in α- cells or β-cells.  
 
4.2.2. Calcium imaging and glucose-stimulated insulin secretion  
In the current study, kainate was applied to MIN6 β-cells for two minutes and there was 
sustained rise in [Ca2+]i. In previous studies (Inagaki et al., 1995; Gonoi et al, 1994), 
kainate was applied to MIN6 β-cells for 40 seconds and then for 10-15 minutes. In both 
applications, there was sustained rise in [Ca2+]i. Sustained rise in [Ca
2+]i subsequent to 
application of kainate for a relatively long period could be due to sustained KAR 
activation and slow onset of desensitisation. Previous studies have suggested that KAR 
desensitisation is dependent on several factors including physicochemical properties of 
bound ligands as well as receptor internalisation (Dawe et al., 2013).  Neto 1 and Neto 2 
have been shown to enhances the surface expression of KARs particularly GluK2 (Sheng 
et al., 2015; Zhang et al., 2009) while Neto 2 slows onset of KAR desensitisation (Griffith 
and Swanson, 2015; Straub et al., 2011b; Zhang et al., 2009). Thus future studies could 
explore how silencing Neto 1 and Neto 2 could affect the response of β-cells or islets of 
Langerhans to sustained application of kainate. The idea behind this will be to determine 
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if Neto 1 and Neto 2 in β-cells play specific roles in agonist binding, onset of 
desensitisation or recovery from desensitisation of β-cell KARs. This could be determined 
by silencing Neto 1 and Neto 2 and then investigating how application of kainate for a 
relatively prolonged period (5-15 minutes) affect [Ca2+]i and GSIS. The results from this 
study would provide more insights into mechanisms underlying the role of KARs and its 
auxiliary proteins in pancreatic β-cells.  
 
4.2.3. Detection of anti-GluR autoantibodies in serum of T1DM patients 
The serum samples used in this current study were from newly-diagnosed T1DM. In a 
previous study investigating the presence of autoantibodies against Pdx1 proteins in 
serum of T1DM patients and non-obese diabetic mice (Li et al., 2010), it was observed 
that levels of anti-Pdx1 autoantibodies in NOD mice were higher before onset of diabetes 
but reduced significantly or became undetectable after disease onset. The titres of other 
autoantibodies implicated in T1DM (IA-2, GAD65, insulin and ZnT8) have been shown 
to fluctuate before and after the onset of diabetes (Bonifacio, 2015; Mannering et al., 
2015; Morran et al., 2015). Thus, it could be suggested that the presence and titres of 
autoantibodies against GluR antigens in serum of T1DM patients could be dependent on 
the stage of the disease. Thus, in addition to samples from newly-diagnosed T1DM 
patients, future work could include serum samples from individuals at different stages on 
T1DM as well as from individuals who are genetically at risk of developing T1DM.   
To reduce background noise and increase sensitivity of the immunoblotting, GluR subunit 
proteins prepared from transfected HEK293 cells could be purified using protein tags 
such polyhistidine or FLAG-tags. This technique has been used to purify AMPAR 
proteins from transiently-transfected HEK293 cells in studies investigating presence of 
anti-AMPAR antibodies in CSF and serum (Gill and Madden, 2008; Shanks et al., 2014). 
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Furthermore, antibody purification methods could be used to enrich and concentrate 
antibodies from serum of T1DM and control subjects and used in both ELISA and 
immunoblotting. Though this method will require significantly large sample volume, this 
could potentially increase sensitivity of the technique and reduce background noise. 
Antibody purification methods have been used in previous studies where autoantibodies 
to GluR subunit proteins were investigated in serum and CSF of patients suffering from 
anti-NMDAR and anti-AMPAR encephalitis (Manto et al., 2010; Gleichman et al., 2014; 
Hughes et al., 2010). These methods enabled the use of several different methods to detect 
GluR subunit proteins.  
Furthermore, in previous studies investigating autoantibodies against AMPAR subunits 
in patients with Rasmussen's Encephalitis (RE), there was no reactivity between RE 
serum samples and HEK293 cells which had been singly-transfected with AMPAR 
subunits (GluA1, GluA2, GluA3) (Nibber et al., 2015). However, there was reactivity 
between some of the RE serum samples and HEK293 cells co-transfected with GluA2 
and GluA3 (Nibber et al., 2015). This implies that the antigenic epitope targeted by the 
autoantibodies is formed by contributions of the two AMPAR subunits (GluA2 and 
GluA3). Thus, a similar phenomenon or mechanism could be present in reactivity 
between autoantibodies in T1DM and GluR subunits whereby the antigenic epitope is 
formed or made stable as result of contribution of two or more subunits. For future works, 
HEK293 cells could be co-transfected with receptor combinations (GluK2/GluK5 for 
instance) and then reacted against the T1DM serum samples.  
In addition, in future studies, immunopositive bands from the reaction between GluR 
subunit proteins and serum could be investigated further using mass spectroscopy to 
confirm if these bands contain sequences of the expected GluR subunit. This approach 
has been used to confirm autoantibodies to AMPAR in serum of patients suffering from 
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limbic encephalitis (Lai et al., 2009) and anti-NMDAR encephalitis (Gleichman et al., 
2012). However, confirmation of immunopositive bands could only be done after the 
immunoblotting technique has been optimised. 
  
Several issues remain unresolved with regards to the nature and mechanism of 
autoimmune T1DM. Mechanisms by which immune tolerance to β-cell antigens is 
compromised remain unclear. Moreover, the observation that all the autoantigen 
candidates in T1DM are intracellular present suggest that further studies are required to 
determine if a surface antigen is first targeted in the initial stages of the disease before the 
intracellular antigens are exposed to the immune system. This is essential to understand 
fully the autoimmune mechanisms of the disease and develop potential therapeutic and 
preventative strategies for T1DM.  
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2-mercaptoethanol Sigma M6250 
Advanced DMEM Thermo-Fisher 12491-015 
Agarose Sigma A9539 
BCA Protein Assay Reagent kit Thermo-Fisher 23227 
BIOTAQ DNA polymerase  Bioline  BIO-21040 
BSA Sigma A9418 
cDNA synthesis kit Bioline BIO-65043  
Chloroform Sigma 288306 
DEPC-treated water Sigma 95284  
DHPG Tocris 0805 
DMEM 25 mM Glucose Sigma D5671 
DMEM no Glucose  Thermo-Fisher 11966-025 
DMSO SigmaD8418 
EDTA Sigma E9884 
Enhanced K-Blue® TMB substrate Oxford Biosystems 308177  
EZ-Link™ Sulfo-NHS-SS-Biotin Thermo-Fisher 21331 
FBS Thermo-Fisher 16000-044 
FURA-2AM Thermo-Fisher F-1221 
Glycine Sigma G8898 
Gyki-52466 Tocris 1454 
HRP substrate Millipore WBKLS0500 
HRP-conjugated anti-mouse antibody Sigma A9044 
HRP-conjugated anti-rabbit antibody  Sigma A0545  
Human Serum Stabilised - Delipidated TCS Biosciences DR750-500 
IGEPAL® or Nonidet P-40 Sigma I3021 
Kainate  Tocris 0222 
L-glutamic acid Sigma G1251 
L-glutamine solution  Sigma G7513 
Low melting point agarose Sigma A9414 
Mouse Insulin ELISA kit Diagenics 10-1247-01 
MTT powder Sigma M5655 
NBQX Tocris 0373 
Nuclease-free water  Sigma W4502 
Nunc-Immuno™ MicroWell™ 96-well 
ELISA plates 
Sigma M9410-1CS 
Opti-MEM® I Reduced Serum Media Thermo-Fisher 31985-062 
Penicillin/streptomycin Sigma P4333 
Phenol-free DMEM Thermo-Fisher 21063-029 
PMSF Sigma P7626 
Polyethylenimine (PEI) Sigma 408727 
Poly-L-lysine hydrobromide Sigma P1399 
Ponceau red Sigma P7170 
Protease inhibitor cocktail  Roche 04693116001 
Rabbit anti-GluK2/3 Millipore 07-598 
Rabbit GluK5 antibodies  Millipore 06-315 
Rat Insulin ELISA kit Diagenics 10-1250-01 
RPMI amino acid solution Sigma R7131 
RPMI-1640 Sigma R5886 
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SDS Sigma L3771 
Sodium deoxycholate Sigma D6750 
Sodium orthovanadate Sigma S6508 
Sodium pyruvate Sigma P2256 
StreptaAvidin agarose beads Thermo-Fisher 20353 
Treated cell culture dishes Thermo-Fisher 150288 
Tri reagent Sigma T9424 
Triton X-100 Sigma T8787 
Trypsin-EDTA Sigma T3924 
Wizard® SV PCR Clean-Up kit Promega A9281 
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Appendix II 
DNA Sequencing Results 
5 ng/µl of purified PCR product together with its specific forward or reverse primers 
were sent to Eurofins MWG (Ebersberg, Germany) to be sequenced.  
1.1. KAR subunit expression in MIN6 mouse β-cells 
GluK2: Reverse primer (CAGAGCAGCATCAGTCGTCA) 
Sequence of gene amplified:  
 
TGAGTCAGGTTTTGGAGGTGCCTGTAACCGTTCCATCGACCACTTCTCGATGATGGAGGA 
GACTTGGGTATTCTCTGTATTTAGTATTCTGAACCCTGTCATATTTACGCCACTGTATCT 
GTAGGGCTCCACATCAAGAGCGAAGAGGTCCAGAGTCGTAAATATATAGTGGTAGTATTC 
TGTCATCATTCCCATAGCTAATGCCTGCTTTAAAATGCCTGCTGCCATTTCATGGCTGCA 
GTCGAAGATCACGTGGAACTCCTTGCCCCTCTTCATCTCTTTCAGCAAAGGCTTTGCATC 
TTTTGTATCAGCTGGCAGCTGACGAATTTTAAGTCGAAGATTGTACCTTGATGGAGCTTT 
GATGAGCTCTTGCAAGCGAATGAGACCAGTGCTGTCGTCATACACAACTGTGACAGTTTT 
CCACTTAAAAAACTGCACCAAATCCAAGATGGCACGGCTGAGGAAAAAG 
 
GluK3: Forward primer (GGTTCCGCATACTCAACGTG) 
Sequence of gene amplified:  
CTAGCATTGTGGAGAGTGGGCCATGGAGCGACTGCAGGCAGCTCCCCGGGCAGAGTCAGG 
CCTGCTGGATGGTGTGATGATGACGGATGCTGCCCTGCTCTATGACGCGGTCCACATTGT 
GTCTGTGTGCTACCAGCGAGCGCCACAGATGACCGTGAACTCCCTGCAGTGCCATCGGCA 
CAAGGCCTGGCGCTTTGGTGGCCGCTTCATGAACTTCATCAAGGAGGCTCAATGGGAAGG 
ATTAACTGGACGGATTGTGTTCAACAAAACCAGTGGCTTGCGGACTGATTTTGATCTGGA 
CATCATCAGCCTGAAGGAAGATGGCCTCGAGAAGGTTGGAGTATGGAGTCCAGCTGACGG 
TCTCAATATCACTGAGGTTGCCAAAGGCCGAGGTCCTAATGTCACTGACTCTCTGACCAA 
TAGGTCACTCATCGTCACCACTGTGCTGGAGGAGCCTTTTGTCATGTTCCGCAAGTCTGA 
TAGGACCCTTTATGGCAATGACCGGTTTGAGGGCTACTGCATAA 
 
GluK4: Forward primer (ATCCGGGATGACAAGACAGC) 
Sequence of gene amplified:  
CTCCATGTCGCACACCATCCTCCTGAAGGCAGCTGAACTGGGGATGGTGTCAGCCTATTA 
CACATACATCTTCACCAATCTGGAGTTCTCCCTCCAGAGAATGGACAGCCTTGTGGATGA 
TAGAGTCAACATCTTAGGATTTTCCATTTTCAACCAATCCCATGCATTCTTCCAAGAGTT 
CTCCCAGAGCCTCAACCAATCCTGGCAGGAGAACTGTGACCATGTGCCCTTCACCGGCCC 
TGCGTTGTCCTCAGCCCTGCTGTTTGACGCTGTCTATGCTGTGGTGACAGCGGTACAGGA 
ACTGAACCGGAGCCAAGAGATTGGTGTGAAGCCCCTGTCCTGTGGCTCAGCCCAGATCTG 
GCAGCATGGCACCAGCCTCATGAACTACCTTCGCATGGTAGAATTGGAAGGTCTTACCGG 
CCACATTA 
 
Appendix II                                                                                            Sequencing Results 
ii 
 
Gluk5: Reverse primer (TACCACACCCCTATCTCACG) 
Sequence of gene amplified:  
CTCTCAGGATGCGTAGTGTGTAGTTGGTCCTCTGCCCTTTGCTGTTGAACTCAACCCGCC 
CGGTCAGCCCGTCATACTCTACCATTCGAAGGTAGTTCATAAGGCTGGTCCCATGGGGCC 
AAATGTTGGCCGAAGTGCAGGCCAGTGGCTTGACGCCAATCTCCTGGCTTCGGTTCAGTT 
CTCGGACAGCGCTTACCACCACGTGCACAGCGTCAAACATCAGGGCTGCGGACAGCGCAG 
GGCCAGGATAGGTGCTGGCTTCACAGTTCTCCCTCCAGGACATGTTGAGGCTGCGCACAA 
ACTCTGGGTAGAAGGGGTGGGAGGTGTTGAACATGGAAAAGCCCAGGATGTTGGAGGAGT 
CCTCCACGATACCATCCAGATGCAGGATGGGAAAGTCCATGGTGGTGAGGATGTACTTGT 
AAAACGCTGAGGTCATTCCCAGCTCCGAAGCCTTAC 
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1.2. Neto 1 and Neto 2 expression in MIN6 mouse β-cells 
 
Neto 1: Forward primer (CACCAGTGGGACTGTCATTG) 
Sequence amplified: 
GGGATGGCTGTGATCATCCTTATTATCGTTTCTGTCATTGTACAGATCAAACAGCCTCGT 
AAAAAATACGTCCAAAGGAAGTCAGACTTTGACCAGACCGTTTTCCAGGAGGTGTTTGAG 
CCTCCCCACTATGAGTTATGTACGCTCAGAGGAACTGGAGCAACAGCCGACTTTGCAGAT 
GTGGCAGAGAACGATAATTCGGATGATCACAATGCAGGAAGTCACGCCGATGACAGTCCC 
ACTCAGGGCGCCCCCGCACTGCTGATCTATTTCTTCTACTATATACTTACCACAAGGGAC 
ATCTTCCTTCTTGATGGCCAGCCCTACATATTCAGAGTTAAAAAAATGAGGGGGTTCAG 
 
 
Neto 2: Forward primer (CACCAGTGGGACTGTCATTG) 
Sequence amplified: 
GGGTCAAACATGAGTGTATCTATATTTTGGAAGCTGCTCCTCGTCAACGAATAGAGCTGA 
CCTTTGATGAACGCTATTATATAGAGCCATCATTCGAATGTCGGTTTGATCACTTGGAAA 
TTCGAGACGGGCCATTTGGTTTTTCTCCTCTTATAGATCGTTACTGTGGCGTGAAAAGCC 
CTCCATTAAAAAGAGGGGGTTGAGTCGAAGACTGGTGGGATCCTCTGGGTTTCAAGGGCT 
CCAATAACGATCCTGCCCCCTCCTGCTCAATTTCTTGTATTTCATTCCTTCCGCGGAGAA 
CAATCTTGGCTCCCCGCAAGCCCGGCCTCCCTTCTGTTATTTATAGAAGCCCAGGGAGGG 
AAAGTGATGCCCTGTCCATCAAACAGACCCCGAGGAAAGTCTCCCCTGGGGAAGATACTT 
ATTCCTCCGACTTGTTGCC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix II                                                                                            Sequencing Results 
iv 
 
 
1.3. KAR subunit expression in INS-1 rat β-cells 
GluK2: Reverse primer (CGGTTCTTCCAAAATGGTGGT) 
Sequence of gene amplified:  
 
GTTTTTTAGTGGAACTGTCACAGTTGTGTATGACGACAGCACTGGTCTCATTCGCTTGCA 
AGAGCTCATCAAAGCTCCATCAAGGTACAATCTTCGACTTAAAATTCGTCAGCTGCCAGC 
TGATACAAAAGATGCAAAGCCTTTGCTGAAAGAGATGAAGAGGGGCAAGGAGTTCCACGT 
GATCTTCGACTGCAGCCATGAAATGGCAGCAGGCATTTTAAAGCAGGCATTAGCTATGGG 
AATGATGACAGAATACTACCACTATATATTTACGACTCTGGACCTCTTCGCTCTTGATGT 
GGAGCCCTACAGATACAGTGGCGTAAATATGACAGGGTTCAGAATACTAAATACAGAGAA 
TACCCAAGTCTCCTCCATCATCGAGAAGTGGTCGATGGAACGGTTACAGGCACCTCCAAA 
ACCTGACTCAGGTTTGCTGGATGGATTTATGACGACTGATGCTGCTCTAAT 
 
GluK3: Forward primer (CCGAGGTCCTAATGTCACCG) 
Sequence of gene amplified:  
TAGCCATTGTGGAGAGTGGTCCATGGAGCGGCTACAGGCAGCTCCCCGGGCAGAGTCAGG 
CCTGCTGGATGGAGTGATGATGACCGATGCAGCCCTGCTCTACGATGCGGTCCACATTGT 
GTCTGTGTGCTACCAGCGAGCGCCGCAGATGACTGTGAACTCCCTACAGTGCCATCGGCA 
CAAGGCCTGGCGCTTCGGTGGCCGCTTCATGAACTTCATCAAGGAGGCTCAATGGGAAGG 
ATTAACTGGACGGATTGTTTTCAACAAAACCAGTGGCTTGCGGACTGATTTTGATCTGGA 
CATCATCAGCCTCAAGGAAGATGGCCTCGAGAAGGTCGGGGTGTGGAGTCCAGCTGACGG 
TCTCAATATCACTGAGGTTGCCAAAGGCCGAGGTCCTAATGTCACCGACTCTCTGACCAA 
CAGGTCAC 
 
GluK4: Forward primer (CCAGGTTGGCTGTGTACGAT) 
Sequence of gene amplified:  
GGCCCGTGGGTATGCCGACTGAGCACACACCTTGGACCCAAAATTTGTCTTGACTATAAG 
ATGTACAGGGGTAAAAAATGGAACAGAATTTGAGGGTATGGCCAATCAATTCCTGGCCCA 
GAATGAGATCTACGAGAGAGAGCTCACCCCTGCAACTATTAATGATATTCTGATATATTT 
GAAGACAGGAGCCGAGCATAAGTGTCATCAGTGAGGTTTCACCCAGCAACTGCGGGAAAA 
TGTTGCAAAGACCCATAACCAAATCCTGTGGAATCCCTTTGGCGATTCTGTGGAAGAGGG 
GAGTTGAGGACCGAACATGGTACAAGGGTCAAGGACAACACGAGGGAAACTACATTATTG 
ATTAATCCGGGCTCAAATGGGTTTATAGTGAATCAACTG 
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Gluk5: Reverse primer (GGACTTCCCCATCCTGCATC) 
Sequence of gene amplified:  
ACGGAGCTGGGATGACCTCAGCGTTTTACAAGTACATCCTCACCACCATGGACTTTCCCA 
TCCTGCATCTGGATGGTATCGTGGAGGACTCCTCCAACATCCTGGGCTTTTCCATGTTCA 
ACACCTCCCACCCCTTCTACCCAGAGTTTGTGCGCAGCCTCAACATGTCCTGGAGGGAGA 
ACTGTGAAGCCAGCACCTATCCTGGCCCTGCGCTGTCCGCAGCCCTGATGTTTGACGCTG 
TGCACGTGGTGGTAAGCGCTGTCCGAGAACTGAACCGAAGCCAGGAGATTGGCGTCAAGC 
CACTGGCCTGCACTTCGGCCAACATTTGGCCCCATGGGACCAGCCTTATGAACTACCTTC 
GAATGGTAGAGTATGACGGGCTGACCGGGCGGGTTGAGTTCAACAGCAAAGGGCAGAGGA 
CCAACTACACACTACCCATCCTGGAGAAGTCCCGCCAGGGCCACCG 
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1.4. Neto 1 and Neto 2 expression in INS-1 rat β-cells 
Neto 1: Forward primer (CACCAGTGGGACTGTCATTG) 
Sequence amplified: 
TGATCTCCTTATTATCGTTTCTGTCATTGTACAGATCAAACAGCCTCGTAAAAAATACGT 
CCAAAGGAAGTCAGACTTTGACCAGACCGTTTTCCAGGAGGTGTTTGAGCCTCCCCACTA 
TGAGTTATGTACGCTCAGAGGAACTGGAGCAACAGCCGACTTTGCAGATGTGGCAGAA 
 
 
 
Neto 2: Forward primer (TTTGCTTCGCCAAATTATCC) 
Sequence amplified: 
AGGAGTGTATCTATATTTTGGAAGCTGCTCCTCGTCAACGAATAGAGCTGACCTTTGATG 
AACGCTATTATATAGAGCCATCATTCGAATGTCGGTTTGATCACTTGGAAATTCGAGACG 
GGCCATTTGGTTTTTCTCCTCTTATAGATCGTTACTGTGGCGTGAAAAGCCCTCCATTAA 
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1.5. KAR subunit expression in α-TC1 clone 6 mouse α-cells 
GluK2: Forward primer (GACTTCTCTTCCCTCAGCCG) 
Sequence amplified: 
GACGTCATGGTGCAGCTTTTAGTGGAACTGTCACAGTTGTGTATGACGACAGCACTGGTC 
TCATTCGCTTGCAAGAGCTCATCAAAGCTCCATCAAGGTACAATCTTCGACTTAAAATTC 
GTCAGCTGCCAGCTGATACAAAAGATGCAAAGCCTTTGCTGAAAGAGATGAAGAGGGGCA 
AGGAGTTCCACGTGATCTTCGACTGCAGCCATGAAATGGCAGCAGGCATTTTAAAGCAGG 
CATTAGCTATGGGAATGATGACAGAATACTACCACTATATATTTACGACTCTGGACCTCT 
TCGCTCTTGATGTGGAGCCCTACAGATACAGTGGCGTAAATATGACAGGGTTCAGAATAC 
TAAATACAGAGAATACCCAAGTCTCCTCCATCATCGAGAAGTGGTCGATGGAACGGTTAC 
AGGCACCTCCAAAACCTGACTCAGGTTTGCTGGATGGATTTATGACGACTGTGCCTTGCT 
CTA 
 
GluK3: Reverse primer (ATGCAGTAGCCCTCAAACCG) 
Sequence amplified: 
CACTTTATCTACCTAGGCTCTGTCAGACTTGCGGAACATGACAAAAGGCTCCTCCAGCAC 
AGTGGTGACGATGAGTGACCTATTGGTCAGAGAGTCAGTGACATTAGGACCTCGGCCTTT 
GGCAACCTCAGTGATATTGAGACCGTCAGCTGGACTCCATACTCCAACCTTCTCGAGGCC 
ATCTTCCTTCAGGCTGATGATGTCCAGATCAAAATCAGTCCGCAAGCCACTGGTTTTGTT 
GAACACAATCCGTCCAGTTAATCCTTCCCATTGAGCCTCCTTGATGAAGTTCATGAAGCG 
GCCACCAAAGCGCCAGGCCTTGTGCCGATGGCACTGCAGGGAGTTCACGGTCATCTGTGG 
CGCTCGCTGGTAGCACACAGACACAATGTGGACCGCGTCATAGAGCAGGGCAGCATCCGT 
CATCATCACACCATCCAGCAGGCCTGACTCTGCCCGGGGAGCTGCCTGCAGTCGCTCCAT 
GGCCCACTTCTCCACAATGGCTGAGACATGGGGATTGTCCACGTTGAGTATGCGGAACCA 
ACT 
 
GluK4: Forward primer (ATCCGGGATGACAAGACAGC) 
Sequence amplified: 
CCAAATTTTTTGTAATTTATTATGCTGGTGCGATCCTGCTGACCTATCTCTGACTCACCC 
GACAGACACTTCCTTCCATCTCTTGCTTGCGTCTCGTTTCCTGCCCGGATGTCTGCAACC 
CATACATAGACTCCAACAAACAGCCTGACTAAAGACCACGCCCGGTGAAGGAAAGATGCA 
TGCACTTCTCTCGCCTGGCTTGATTGATTGACTGTCTGAAATATTTCTTGAAAGAATGGA 
TGTGATTGAATGAAAATGATCCATCCATGTATGTTCTCTCTTTCATCCAGCTGGCTGTTC 
TTTCTCTGGAGAAATACCTATTGATTGATAAGTATGTGTAAGAAATTGACTCACTCCCTC 
CCCCATTTGCCTTCCTTAAGAAGGAGGGCGAGCTACATGCATTGGTTGGCATGAATAATG 
AAACTGTCTTGCTTGCCCTCATAGATA 
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GluK5: Forward primer (TGATGCCAATGCGTCCATCT) 
Sequence amplified: 
AAAGTCCTCGTAGCTTCGGAGCTGGGATGACCTCAGCGTTTTACAAGTACATCCTCACCA 
CCATGGACTTTCCCATCCTGCATCTGGATGGTATCGTGGAGGACTCCTCCAACATCCTGG 
GCTTTTCCATGTTCAACACCTCCCACCCCTTCTACCCAGAGTTTGTGCGCAGCCTCAACA 
TGTCCTGGAGGGAGAACTGTGAAGCCAGCACCTATCCTGGCCCTGCGCTGTCCGCAGCCC 
TGATGTTTGACGCTGTGCACGTGGTGGTAAGCGCTGTCCGAGAACTGAACCGAAGCCAGG 
AGATTGGCGTCAAGCCACTGGCCTGCACTTCGGCCAACATTTGGCCCCATGGGACCAGCC 
TTATGAACTACCTTCGAATGGTAGAGTATGACGGGCTGACCGGGCGGGTTGAGTTCAACA 
GCAAAGGGCAGAGGACCAACTACACACTACGCATCCTGGAGAAGTCCCGCCAGGGCCACC 
GTGAGATAGGGGTGTGGTAA 
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1.6. Neto 1 and Neto 2 expression in α-TC1 clone 6 mouse α-cells 
Neto 1: Forward primer (CACCAGTGGGACTGTCATTG) 
Sequence amplified: 
GGGTGCATGTGATATCCTTATTATCGTTTCTGTCATTGTACAGATCAAACAGCCTCGTAA 
AAAATACGTCCAAAGGAAGTCAGACTTTGACCAGACCGTTTTCCAGGAGGTGTTTGAGCC 
TCCCCACTATGAGTTATGTACGCTCAGAGGAACTGGAGCAACAGCCGACTTTGCAGATGT 
GGCAGAAACGATAATACGGCTGCTGCCATGCCGGATCCCGCCGCTGTCAGACCCAAGCGC 
GCTCCTCCACCCTGCTGATCTATTTCTTGTCCTATATCCCTACGACTCGGGTCCTCTTCG 
CTCTCGCTGTGGAGCCTTACATTATCTATGGTTTGAGGCCCAGGGGGTGAAGAGATGTAA 
ACACTCGAATACCCCCTCATCCTGCCTCCGCTAGAAATATTCGATGGTTCCGGTACTGGC 
CCATCCCAGACCTGACTCTTGCCCCTTGGACGAAATACGACGACCGTACGTGCTATGCA 
 
Neto 2: Forward primer (CACCAGTGGGACTGTCATTG) 
Sequence amplified: 
GAGTCCAAACATGAGTGTATCTATATTTTGGAGCTGCTCCTCGTCAACGAATAGAGCTGA 
CCTTTGATGAACGCTATTATATAGAGCCATCATTCGAATGTCGGTTTGATCACTTGGAAA 
TTCGAGACGGGCCATTTGGTTTTTCTCCTCTTATAGATCGTTACTGTGGCGTGAAAAGCC 
CTCCATTAACAAGTCTGGATGGCGGCCTCGCTGGGCGGGCCCGCTTTTCTCAAGGCGTTT 
CACAACCCTCCTCCCCCCTCCTGCTCCCTTTCTTGTATCTCTTGCCTTCCGCGAAGTACC 
ATCTCCCTGCTCGGCAGCCTTACCTAACCTCCGTAATTAAATCCCTCAGGGGATGAAATG 
ATGCTTTGATTGCAACCAGACCCGTATGCTACCGTCCCTGAGTAGATTCTATTCCTCCAC 
CATTCACAGCACCTGACTCAACTCCTTCCCCTGCGTAAACAAATCGACACTGCTATTTGC 
TCCAAAATAAAGAA 
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1.7. KAR subunit expression in rat islets of Langerhans 
GluK1: Forward primer (GGAAGGAACTGAAAAGATTGGG) 
Sequence amplified: 
ACGTGGGCTGACATGACGGATGGCAACAGAGACAGGTCCAACAATATCACGGACTCGCTG 
GCTAACCGCACACTCATTGTCACCACTATTCTGGAAGAGCCCTACGTGATGTACAGGAAA 
TCCGATAAGCCCTTGTATGGAAACGACAGGTTTGAAGGATATTGCCTGGATCTGCTGAAA 
GAACTGTCCAATATCCTGGGTTTTCTTTACGATGTTAAACTGGTTCCTGATGGCAAATAT 
GGAGCACAGAATGACAAAGGGGAATGGAATGGGATGGTAAAAGAACTCATCGACCACAGA 
GCTGACCTGGCAGTGGCCCCTCTCACCATCACATACGTACGGGAGAAAGTCATTGACTTC 
TCCAAGCCCTTCATGACCCTGGGCATTAGCATCCTTTACCGGAAGCCCAATGGACACATT 
CT 
 
GluK2: Forward primer (CTTGACGTGGAGCCCTACAG) 
Sequence amplified: 
GATTCAGGATACTAAATACAGAGAATACCCAAGTCTCCTCCATCATCGAAAAGTGGTCTA 
TGGAACGGTTACAGGCGCCTCCAAAACCTGACTCAGGTTTGCTGGATGGATTTATGACGA 
CTGATGCTGCTCTGATGTATGATGCAGTGCACGTTGTGTCTGTGGCTGTCCAACAGTTTC 
CCCAGATGACAGTCAGCTCCTTGCAATGCAATCGACACAAACCCTGGCGCTTTGGGACCC 
GCTTCATGAGTCTAATTAAAGAGGCTCACTGGGAAGGTCTCACAGGCAGAATAACATTTA 
ACAAAACCAATGGATTACGGACAGATTTTGATTTGGATGTGATCAGTCTCAAGGAAGAAG 
GTCTGGAGAAGATTGGAACTTGGGATCCAGCCAGTGGCCTGAATATGACAGAAAGTCAGA 
AAGGAAAGCCAGCAAATATCACAGACTCATTGTCTAATCGTTCTTTGATTGTTACCACCA 
TTTTGGAAGAACCGACAGAAATC 
 
 
GluK3: Forward primer (CCGAGGTCCTAATGTCACCG) 
Sequence amplified: 
CTCATCGTCACCACTCTGCTGGAGGAGCCTTTTGTCATGTTCCGCAAGTCTGATAGGACC 
CTTTACGGCAATGACCGGTTCGAGGGCTACTGCATCGACTTGCTCAAGGAGCTGGCGCAC 
ATCCTGGGCTTCTCCTACGAGATCCGGCTGGTGGAAGACGGCAAGTACGGGGCACAGGAC 
GACAAGGGCCAGTGGAACGGCATGGTCAAGGAACTCATTGACCACAAAGCAGATCTGGCT 
GTGGCTCCCCTGACCATCACCCATGTCCGAGAGAAGGCCATTGACTTCTCTAAGCCTTTT 
ATGACCCTCGGAGTGAGCATCTTATATCGAAAACCCAATGGCACCAACCCCAGTGTCTTC 
TCCTTCCTCAACCCCCTGTCCCCAGACATCTGGATGTACGTGCTACTCGCCTACCTGGGT 
GTCAGCTGTGTCCTCTTCGTCATTGCCAGTTTCAG 
 
GluK4: Forward primer (CCACCATCCTGGAAAACCCA) 
Sequence amplified: 
GGACATGGAAGGCAATGACCGGTACGAGGGATTCTGCGTGGACATGCTCAAGGAGTTGGC 
TGAGATCCTACGGTTCAACTACAAGATCCGCCTCGTTGGGGATGGTGTTTACGGCGTACC 
TGAGGCCAACGGCACCTGGACGGGCATGGTTGGGGAGCTGATCGCTCGGAAAGCAGATCT 
GGCTGTGGCGGGCCTCACCATCACAGCTGAACGTGAGAAAGTGATTGATTTCTCCAAGCC 
GTTCATGACGCTGGGAATTAGTATTCTTTACAGAGTTCATATGGGCC 
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GluK5: Reverse primer (TGATGCCAATGCGTCCATCT) 
Sequence amplified: 
TCTCCACATCTTGGGCTTTTCCATGTTCAACACCTCCCATCCCTTCTACCCGGAGTTTGT 
GCGCAGCCTCAACATGTCCTGGAGGGAGAACTGCGAAGCCAGCACCTACCCTGGCCCTGC 
GCTGTCGGCAGCCCTGATGTTTGATGCCGTGCATGTGGTGGTAAGCGCTGTCCGAGAGCT 
GAACCGGAGCCAGGAGATTGGTGTCAAGCCACTGGCTTGCACTTCGGCCAACATCTGGCC 
CCATGGGACCAGCCTCATGAACTACCTGCGCATGGTAGAGTATGACGGGCTGACTGGGCG 
GGTTGAGTTCAACAGCAAAGGGCAGAGGACCAACTACACACTGCGCATCCTGGAGAAGTC 
CCGCCAGGGCCACCGTGAGATAGGGGTGTGGACTTCATT 
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1.8. Neto 1 and Neto 2 expression in rat islets of Langerhans 
Neto 1: Reverse primer (TCTGCCACATCTGCAAAGTC) 
Sequence amplified: 
CTTGGCATTCTATGCTCTGAGCGTGCATACTCATAGTGAGGAGGCTCAAACACCTCCTGG 
AAAACGGTCTGGTCAAAGTCTGACTTCCTTTGGACGTATTTTTTACGAGGCTGTTTGATC 
TGTACAATGACAGAAACGATATTAAGGAAGATCACAATGCAGGAAGTCACGCCAATGACA 
GTCCCACTGGTGATAAAAACAGTCTGGTTGATTATCTACTTTTTCCGTTCCCCGCCTCCC 
CAAGGCGTTTAAAATGCCTCCCCCCCTCTCCTCCTCCATTTCTTATATTTCTTGCCTTCT 
CCGCGGTACCTTCTTCGTCCCTGCCCGGTCTGGCCCATCTTCCCTAAGGTTATTCCCTCG 
GGGGGTGAAATGATGCCCTGGCACCAAATACCTCCCTTCGCTCCTGCTCCTGGGCATATT 
GGGAAGTTCCGCCTTGTT 
 
 
Neto 1: Forward primer (CACCAGTGGGACTGTCATTG) 
Sequence amplified: 
CTGGACTGCAACATGAGTGTATCTATATTTTGGAAGCTGCTCCTCGTCAACGGATAGAGC 
TGACCTTTGATGAACGATATTATATAGAGCCATCATTTGAATGCCGGTTTGATCACTTGG 
AAGTTCGAGACGGGCCATTTGGCTTCTCTCCTCTTATAGATCGTTACTGTGGCGTGAAAA 
GCCCTCCATTAAGAAGATGGGGACTGTAGCCTTGTTCTGGCCCTGGGCGTTTTAAAGCCC 
GCATTAGCTCTCCTACCCCCGCCTCCATACTTTCTTGTATATATTGCCTACTGCAGACAA 
CTATGCTCTTGCAGTGTAGCCTTACCTATATTCTGTAATTATATGAGCCAAGGGCAATGA 
ACTAAGCCACAGAATCGCCAAGTTTCCTCCCTTGCCGTCCCTGGGTATATGAAATTCTTA 
AGGGCACCCCCAAAATCTGACTCAACTTCTCCCCCTGGATTCGTGACGTTAGCACTCCTT 
TGTGCTTTAATTAATG 
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Sequence: GluK 2 B_GluK-2-R Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
469
10
478
57.12
Samples:
Bases:
Average spacing:
13659
486
29.0
Average quality >= 10: 9, 20: 7, 30: 452
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
A A T C C G C A C T
10
G A G T CA G G T T
20
T T G G A G G T G C
30
C T G T A A C C G T
40
T C C A T C G A C C
50
A C T T C T C G A T
60
G A T G G A G G A G
70
A C T T G G G T A
T
80
T C T C T G T A T T
90
T A G T A T T C T G
100
A A C C C T G T C A
110
T A T T T A C G C C
120
A C T G T A T C T G
130
T A G G G C T C C A
140
C A T C A A G A G C
150
G A A G A G G T C C
160
A G A
G T C G T A A
170
A T A T A T A G T G
180
G T A G T A T T C T
190
G T C A T C A T T C
200
C C A T A G C T A A
210
T G C C T G C T T T
220
A A A A T G C C T G
230
C T G C C A T T T C
240
A T G G C T
G C A G
250
T C G A A G A T C A
260
C G T G G A A C T C
270
C T T G C C C C T C
280
T T C A T C T C T T
290
T C A G C A A A G G
300
C T T T G C A T C T
310
T T T G T A T C A G
320
C T G G C A G C T G
330
A C G A A T T T T A
340
A G T C G A A G A T
350
T G T A C C T T G A
360
T G G A G C T T T G
370
A T G A G C T C T T
380
G C A A G C G A A T
390
G A G A C C A G T G
400
C T G T C G T C A T
410
A C A
C A A C T G T
420
G A C A G T T T T C
430
C A C T T A A A A A
440
A C T G C A C C A A
450
A T C C A A G A T G
460
G C A C G G C T G A
470
G G A A A A A G A A
480
A G T C A
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Sequence: GluK 3 A_GluK-3-F Clipped length:
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Right clip:
Avg. qual. in clip.:
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Samples:
Bases:
Average spacing:
13400
533
26.0
Average quality >= 10: 5, 20: 6, 30: 505
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
G A A T C A A T T C
10
T A G C A T T G T G
20
G A G A G T G G G C
30
C A T G G A G C G A
40
C T G C A G G C A G
50
C T C C C C G G G C
60
A G A G T C A G G C
70
C T G C T G G A T G
80
G T G T G A T G A T
90
G A C G G A T G C T
100
G C C C T G C T C T
110
A T G A C G C G G T
120
C C A C A T T G T G
130
T C T G T G T G C T
140
A C C A G C G A G C
150
G C C A C A G A T G
160
A C C G T
G A A C T
170
C C C T G C A G T G
180
C C A T C G G C A C
190
A A G G C C T G G C
200
G C T T T G G T G G
210
C C G C T T C A T G
220
A A C T T C A T C A
230
A G G A G G C T C A
240
A T G G G A A G
G A
250
T T A A C T G G A C
260
G G A T T G T G T T
270
C A A C A A A A C C
280
A G T G G C T T G C
290
G G A C T G A T T T
300
T G A T C T G G A C
310
A T C A T C A G C C
320
T G A A G G A A G A
330
T G
G C C T C G A G
340
A A G G T T G G A G
350
T A T G G A G T C C
360
A G C T G A C G G T
370
C T C A A T A T C A
380
C T G A G G T T G C
390
C A A A G G C C G A
400
G G T C C T A A T G
410
T C A C T G
A C T C
420
T C T G A C C A A T
430
A G G T C A C T C A
440
T C G T C A C C A C
450
T G T G C T G G A G
460
G A G C C T T T T G
470
T C A T G T T C C G
480
C A A G T C T G A T
490
A G G A C C C T T
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T
500
A T G G C A A T G A
510
C C G G T T T G A G
520
G G C T A C T G C A
530
T A
Page: 3 / 3
16.02.2013
Sequence: GluK 3 A_GluK-3-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
524
10
533
58.7
Samples:
Bases:
Average spacing:
13400
533
26.0
Average quality >= 10: 5, 20: 6, 30: 505
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
Page: 1 / 3
16.02.2013
Sequence: GluK 4 A_GluK-4-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
428
18
445
56.97
Samples:
Bases:
Average spacing:
13360
449
30.0
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A C A A T C T A A G
10
G C C A C G C C T C
20
C A T G T C G C A C
30
A C C A T C C T C C
40
T G A A G G C A G C
50
T G A A C T G G G G
60
A T G G T G T C A G
70
C C T A T T A C A C
80
A T A
C A T C T T C
90
A C C A A T C T G G
100
A G T T C T C C C T
110
C C A G A G A A T G
120
G A C A G C C T T G
130
T G G A T G A T A G
140
A G T C A A C A T C
150
T T A G G A T T T T
160
C C A T T T T
C A A
170
C C A A T C C C A T
180
G C A T T C T T C C
190
A A G A G T T C T C
200
C C A G A G C C T C
210
A A C C A A T C C T
220
G G C A G G A G A A
230
C T G T G A C C A T
240
G T G C C C T T C A
250
C
C G G C C C T G C
260
G T T G T C C T C A
270
G C C C T G C T G T
280
T T G A C G C T G T
290
C T A T G C T G T G
300
G T G A C A G C G G
310
T A C A G G A A C T
320
G A A C C G G A G C
330
C A A G
A G A T T G
340
G T G T G A A G C C
350
C C T G T C C T G T
360
G G C T C A G C C C
370
A G A T C T G G C A
380
G C A T G G C A C C
390
A G C C T C A T G A
400
A C T A C C T T C G
410
C A T G G T A
G A A
420
T T G G A A G G T C
430
T T A C C G G C C A
440
C A T T A A C A
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Sequence: GluK 5 B_GluK-5-R Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
456
8
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Clip. 1 BQ 20 WL 10 Quality: 0 - 9
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20 - 29
>= 30
G T G C T A G C T C
10
T C A G G A T G C G
20
T A G T G T G T A G
30
T T G G T C C T C T
40
G C C C T T T G C T
50
G T T G A A C T C A
60
A C C C G C C C G G
70
T C A G C C C
G T C
80
A T A C T C T A C C
90
A T T C G A A G G T
100
A G T T C A T A A G
110
G C T G G T C C C A
120
T G G G G C C A A A
130
T G T T G G C C G A
140
A G T G C A G G C C
150
A G T G G C T T G A
160
C
G C C A A T C T C
170
C T G G C T T C G G
180
T T C A G T T C T C
190
G G A C A G C G C T
200
T A C C A C C A C G
210
T G C A C A G C G T
220
C A A A C A T C A G
230
G G C T G C G G A C
240
A G C G C
A G G G C
250
C A G G A T A G G T
260
G C T G G C T T C A
270
C A G T T C T C C C
280
T C C A G G A C A T
290
G T T G A G G C T G
300
C G C A C A A A C T
310
C T G G G T A G A A
320
G G G G T G G G
A G
330
G T G T T G A A C A
340
T G G A A A A G C C
350
C A G G A T G T T G
360
G A G G A G T C C T
370
C C A C G A T A C C
380
A T C C A G A T G C
390
A G G A T G G G A A
400
A G T C C A T G G T
410
G G
T G A G G A T G
420
T A C T T G T A A A
430
A C G C T G A G G T
440
C A T T C C C A G C
450
T C C G A A G C C T
460
T A
Page: 2 / 3
16.02.2013
Sequence: GluK 5 B_GluK-5-R Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
456
8
463
53.97
Samples:
Bases:
Average spacing:
13514
463
30.0
Average quality >= 10: 8, 20: 7, 30: 438
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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16.02.2013
Sequence: GluK 5 B_GluK-5-R Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
456
8
463
53.97
Samples:
Bases:
Average spacing:
13514
463
30.0
Average quality >= 10: 8, 20: 7, 30: 438
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
Page: 1 / 3
22.06.2013
Sequence: MIN6 NETO 1_NETO-1-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
180
15
194
51.46
Samples:
Bases:
Average spacing:
14340
359
40.0
Average quality >= 10: 119, 20: 33, 30: 178
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
G G G AT GG C T G
10
T G AT CA T C C T
20
T A T T A T C G T T
30
T C T G T C A T T G
40
T A C A G A T C A A
50
A C A G C C T C G T
60
A A A A A A T A C G
70
T C C A A A G G A A
80
G T
C A G A C T T T
90
G A C C A G A C C G
100
T T T T C C A G G A
110
G G T G T T T G A G
120
C C T C C C C A C T
130
A T G A G T T A T G
140
T A C G C T C A G A
150
G G A A C T G G A G
160
C A A C A G
C C G A
170
C T T T G C A G A T
180
G T G G C A G A GA
190
A C G A T A A T T C
200
G G A T G A T C A C
210
A A T G C A G G A A
220
G T C A C G C C G A
230
T G A C A G T C C C
240
A C T C A G G G C
G
250
C C C C C G C A C T
260
G C T G A T C T A T
270
T T C T T C T A C T
280
A T A T A C T T A C
290
C A C A A G G G A C
300
A T C T T C C T T C
310
T T G A T G G C C A
320
G C C C T A C A T A
330
T T C
A G A G T T A
340
A A A A A A T G A G
350
G G G G T T C A
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22.06.2013
Sequence: MIN6 NETO 1_NETO-1-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
180
15
194
51.46
Samples:
Bases:
Average spacing:
14340
359
40.0
Average quality >= 10: 119, 20: 33, 30: 178
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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22.06.2013
Sequence: MIN6 NETO 1_NETO-1-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
180
15
194
51.46
Samples:
Bases:
Average spacing:
14340
359
40.0
Average quality >= 10: 119, 20: 33, 30: 178
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
Page: 1 / 3
22.06.2013
Sequence: MIN6 NETO 2_NETO-2-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
189
11
199
53.3
Samples:
Bases:
Average spacing:
16300
439
38.0
Average quality >= 10: 196, 20: 34, 30: 178
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
G G G T C A A A C A
10
T G A G T G T A T C
20
T A T A T T T T G G
30
A A G C T G C T C C
40
T C G T C A A C G A
50
A T A G A G C T G A
60
C C T T T G A T G A
70
A C G C T A T T A T
80
A T A G A G C C A T
90
C A T T C G A A T G
100
T C G G T T T G A T
110
C A C T T G G A A A
120
T T C G A G A C G G
130
G C C A T T T G G T
140
T T T T C T C C T C
150
T T A T A G A T C G
160
T T A C
T G T G G C
170
G T G A A A A G C C
180
C T C C A T T A A A
190
A A G A G G G G G T
200
T G A G T C G A A G
210
A C T G G T G G G A
220
T C C T C T G G G T
230
T T C A A G G G C T
240
C C A A T A
A C G A
250
T C C T G C C C C C
260
T C C T G C T C A A
270
T T T C T T G T A T
280
T T C A T T C C T T
290
C C G C G G A G A A
300
C A A T C T T G G C
310
T C C C C G C A A G
320
C C C G G C C T C C
330
C T T C T G T T A T
340
T T A T A G A A G C
350
C C A G G G A G G G
360
A A A G T G A T G C
370
C C T G T C C A T C
380
A A A C A G A C C C
390
C G A G G A A A G T
400
C T C C C C T G G G
410
G A A G
A T A C T T
420
A T T C C T C C G A
430
C T T G T T G C
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22.06.2013
Sequence: MIN6 NETO 2_NETO-2-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
189
11
199
53.3
Samples:
Bases:
Average spacing:
16300
439
38.0
Average quality >= 10: 196, 20: 34, 30: 178
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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22.06.2013
Sequence: MIN6 NETO 2_NETO-2-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
189
11
199
53.3
Samples:
Bases:
Average spacing:
16300
439
38.0
Average quality >= 10: 196, 20: 34, 30: 178
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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29.07.2014
Sequence: INS1 GluK2_GluK2-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
471
15
485
56.26
Samples:
Bases:
Average spacing:
16164
494
33.0
Average quality >= 10: 13, 20: 10, 30: 447
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
C G G C C C G T AT
10
G T G A G T T T T T
20
T A G T G G A A C T
30
G T C A C A G T T G
40
T G T A T G A C G A
50
C A G C A C T G G T
60
C T C A T T C G C T
70
T G C A A G A G C
T
80
C A T C A A A G C T
90
C C A T C A A G G T
100
A C A A T C T T C G
110
A C T T A A A A T T
120
C G T C A G C T G C
130
C A G C T G A T A C
140
A A A A G A T G C A
150
A A G C C T T T G C
160
T G A
A A G A G A T
170
G A A G A G G G G C
180
A A G G A G T T C C
190
A C G T G A T C T T
200
C G A C T G C A G C
210
C A T G A A A T G G
220
C A G C A G G C A T
230
T T T A A A G C A G
240
G C A T T A G
C T A
250
T G G G A A T G A T
260
G A C A G A A T A C
270
T A C C A C T A T A
280
T A T T T A C G A C
290
T C T G G A C C T C
300
T T C G C T C T T G
310
A T G T G G A G C C
320
C T A C A G A T A C
330
A G T G G C G T A A
340
A T A T G A C A G G
350
G T T C A G A A T A
360
C T A A A T A C A G
370
A G A A T A C C C A
380
A G T C T C C T C C
390
A T C A T C G A G A
400
A G T G G T C G A T
410
G G A A
C G G T T A
420
C A G G C A C C T C
430
C A A A A C C T G A
440
C T C A G G T T T G
450
C T G G A T G G A T
460
T T A T G A C G A C
470
T G A T G C T G C T
480
C T A A T G A A A A
490
A T T
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29.07.2014
Sequence: INS1 GluK2_GluK2-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
471
15
485
56.26
Samples:
Bases:
Average spacing:
16164
494
33.0
Average quality >= 10: 13, 20: 10, 30: 447
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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29.07.2014
Sequence: INS1 GluK2_GluK2-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
471
15
485
56.26
Samples:
Bases:
Average spacing:
16164
494
33.0
Average quality >= 10: 13, 20: 10, 30: 447
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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26.07.2014
Sequence: INS1 Gluk3_GluK3-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
428
11
438
55.28
Samples:
Bases:
Average spacing:
12297
537
23.0
Average quality >= 10: 18, 20: 35, 30: 455
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
A C C A A A G T T C
10
T A G C C A T T G T
20
G G A G A G T G G T
30
C C A T G G A G C G
40
G C T A C A G G C A
50
G C T C C C C G G G
60
C A G A G T C A G G
70
C C T G C T G G A T
80
G G
A G T G A T G A
90
T G A C C G A T G C
100
A G C C C T G C T C
110
T A C G A T G C G G
120
T C C A C A T T G T
130
G T C T G T G T G C
140
T A C C A G C G A G
150
C G C C G C A G A T
160
G A C T G T G
A A C
170
T C C C T A C A G T
180
G C C A T C G G C A
190
C A A G G C C T G G
200
C G C T T C G G T G
210
G C C G C T T C A T
220
G A A C T T C A T C
230
A A G G A G G C T C
240
A A T G G G A A G G
250
A
T T A A C T G G A
260
C G G A T T G T T T
270
T C A A C A A A A C
280
C A G T G G C T T G
290
C G G A C T G A T T
300
T T G A T C T G G A
310
C A T C A T C A G C
320
C T C A A G G A A G
330
A T G G
C C T C G A
340
G A A G G T C G G G
350
G T G T G G A G T C
360
C A G C T G A C G G
370
T C T C A A T A T C
380
A C T G A G G T T G
390
C C A A A G G C C G
400
A G G T C C T A A T
410
G T C A C C G A
C T
420
C T C T G A C C A A
430
C A G G T C A C T C
440
A T C G T C A C C A
450
C T C T G C T G G A
460
G G A G C C T T T T
470
G T C A T G T T C C
480
G C A A G T C T G A
490
T A G G A C C C T T
500
T
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26.07.2014
Sequence: INS1 Gluk3_GluK3-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
428
11
438
55.28
Samples:
Bases:
Average spacing:
12297
537
23.0
Average quality >= 10: 18, 20: 35, 30: 455
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
A C G G C A A T G
510
A C C G G T T T G A
520
G G G C T A C T G C
530
A T C C C A
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26.07.2014
Sequence: INS1 Gluk3_GluK3-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
428
11
438
55.28
Samples:
Bases:
Average spacing:
12297
537
23.0
Average quality >= 10: 18, 20: 35, 30: 455
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
Page: 1 / 3
18.10.2014
Sequence: RatGluk42_Rat-GluK4R Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
38
55
92
27.31
Samples:
Bases:
Average spacing:
12961
248
53.0
Average quality >= 10: 103, 20: 49, 30: 31
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
T G T T T C C T T T
10
A T T T T G C C C C
20
C T T T A C A C C A
30
C T T G A C G C A G
40
C G T T G T G G A C
50
A A A G C C C G C G
60
G G G C G A T G G T
70
G G A G C C T T G C
80
T G C A T G A A G C
90
C T C C C A C T G T
100
A A A C T A G A G G
110
C T G T T G C C C A
120
T A G A G T A C T G
130
G T T G A C T C G G
140
A C A T T C T A T C
150
T G C C C T G T G C
160
A C A A T T A T G T
170
G G A C
T G T A C T
180
A C T C A T A A T G
190
A G T T A T T G A G
200
C C C C T T A G A T
210
G A T G A A A T A A
220
T T T G A C T T C C
230
A G A T C A T C T T
240
G C T G C T T
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18.10.2014
Sequence: RatGluk42_Rat-GluK4R Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
38
55
92
27.31
Samples:
Bases:
Average spacing:
12961
248
53.0
Average quality >= 10: 103, 20: 49, 30: 31
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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18.10.2014
Sequence: RatGluk42_Rat-GluK4R Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
38
55
92
27.31
Samples:
Bases:
Average spacing:
12961
248
53.0
Average quality >= 10: 103, 20: 49, 30: 31
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
Page: 1 / 3
26.07.2014
Sequence: INS1 GluK5_GluK5-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
471
23
493
35.3
Samples:
Bases:
Average spacing:
12702
503
26.0
Average quality >= 10: 52, 20: 81, 30: 347
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
A C C T T T T C T C
10
G T A T T G C T T C
20
G G A G C T G G G A
30
T G A C C T C A G C
40
G T T T T A C A A G
50
T A C A T C C T C A
60
C C A C C A T G G A
70
C T T T C C C A T C
80
C T G
C A T C T G G
90
A T G G T A T C G T
100
G G A G G A C T C C
110
T C C A A C A T C C
120
T G G G C T T T T C
130
C A T G T T C A A C
140
A C C T C C C A C C
150
C C T T C T A C C C
160
A G A G T T T G
T G
170
C G C A G C C T C A
180
A C A T G T C C T G
190
G A G G G A G A A C
200
T G T G A A G C C A
210
G C A C C T A T C C
220
T G G C C C T G C G
230
C T G T C C G C A G
240
C C C T G A T G T T
250
T
G A C G C T G T G
260
C A C G T G G T G G
270
T A A G C G C T G T
280
C C G A G A A C T G
290
A A C C G A A G C C
300
A G G A G A T T G G
310
C G T C A A G C C A
320
C T G G C C T G C A
330
C T T C
G G C C A A
340
C A T T T G G C C C
350
C A T G G G A C C A
360
G C C T T A T G A A
370
C T A C C T T C G A
380
A T G G T A T A G T
390
A T G A C G G G C T
400
G A C C G G G C G G
410
G T T G A G T
T C A
420
A C A G C A A A G G
430
G C A G A G G A C C
440
A A C T A C A C A C
450
T A C G C A T C C T
460
G G A G A A G T C C
470
C G C C A G G C C C
480
A C C G T G A G A T
490
A G G G G T G T G G
500
T
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26.07.2014
Sequence: INS1 GluK5_GluK5-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
471
23
493
35.3
Samples:
Bases:
Average spacing:
12702
503
26.0
Average quality >= 10: 52, 20: 81, 30: 347
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
A
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26.07.2014
Sequence: INS1 GluK5_GluK5-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
471
23
493
35.3
Samples:
Bases:
Average spacing:
12702
503
26.0
Average quality >= 10: 52, 20: 81, 30: 347
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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26.07.2014
Sequence: INS1 Neto1o_Neto1-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
178
12
189
53.16
Samples:
Bases:
Average spacing:
12177
189
65.0
Average quality >= 10: 7, 20: 11, 30: 158
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
GT G C A C T CC T
10
G T G AT C T C C T
20
T A T T A T C G T T
30
T C T G T C A T T G
40
T A C A G A T C A A
50
A C A G C C T C G T
60
A A A A A A T A C G
70
T C C A A A G G A A
80
G
T C A G A C T T T
90
G A C C A G A C C G
100
T T T T C C A G G A
110
G G T G T T T G A G
120
C C T C C C C A C T
130
A T G A G T T A T G
140
T A C G C T C A G A
150
G G A A C T G G A G
160
C A A C
A G C C G A
170
C T T T G C A G A T
180
G T G G C A G A
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26.07.2014
Sequence: INS1 Neto1o_Neto1-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
178
12
189
53.16
Samples:
Bases:
Average spacing:
12177
189
65.0
Average quality >= 10: 7, 20: 11, 30: 158
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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26.07.2014
Sequence: INS1 Neto1o_Neto1-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
178
12
189
53.16
Samples:
Bases:
Average spacing:
12177
189
65.0
Average quality >= 10: 7, 20: 11, 30: 158
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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26.07.2014
Sequence: INS1 Neto2o_Neto2-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
180
12
191
55.78
Samples:
Bases:
Average spacing:
12159
191
64.0
Average quality >= 10: 4, 20: 1, 30: 170
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
G A A T C A C C A A
10
C A G G A G T G T A
20
T C T A T A T T T T
30
G G A A G C T G C T
40
C C T C G T C A A C
50
G A A T A G A G C T
60
G A C C T T T G A T
70
G A A C G C T A T
T
80
A T A T A G A G C C
90
A T C A T T C G A A
100
T G T C G G T T T G
110
A T C A C T T G G A
120
A A T T C G A G A C
130
G G G C C A T T T G
140
G T T T T T C T C C
150
T C T T A T A G A T
160
C
G T T A C T G T G
170
G C G T G A A A A G
180
C C C T C C A T T A
190
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26.07.2014
Sequence: INS1 Neto2o_Neto2-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
180
12
191
55.78
Samples:
Bases:
Average spacing:
12159
191
64.0
Average quality >= 10: 4, 20: 1, 30: 170
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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26.07.2014
Sequence: INS1 Neto2o_Neto2-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
180
12
191
55.78
Samples:
Bases:
Average spacing:
12159
191
64.0
Average quality >= 10: 4, 20: 1, 30: 170
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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22.06.2013
Sequence: ALPHA GLUK2_mGLUK2-FClipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
458
19
476
58.65
Samples:
Bases:
Average spacing:
12073
483
25.0
Average quality >= 10: 14, 20: 5, 30: 442
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
G A C G T C A T G G
10
TG CA G C T T T T
20
A G T G G A A C T G
30
T C A C A G T T G T
40
G T A T G A C G A C
50
A G C A C T G G T C
60
T C A T T C G C T T
70
G C A A
G A G C T C
80
A T C A A A G C T C
90
C A T C A A G G T A
100
C A A T C T T C G A
110
C T T A A A A T T C
120
G T C A G C T G C C
130
A G C T G A T A C A
140
A A A G A T G C A A
150
A G C C T T
T G C T
160
G A A A G A G A T G
170
A A G A G G G G C A
180
A G G A G T T C C A
190
C G T G A T C T T C
200
G A C T G C A G C C
210
A T G A A A T G G C
220
A G C A G G C A T T
230
T T A A A G C A G G
240
C A T T A G C T A T
250
G G G A A T G A T G
260
A C A G A A T A C T
270
A C C A C T A T A T
280
A T T T A C G A C T
290
C T G G A C C T C T
300
T C G C T C T T G A
310
T G T G G A G C C C
320
T A C A G
A T A C A
330
G T G G C G T A A A
340
T A T G A C A G G G
350
T T C A G A A T A C
360
T A A A T A C A G A
370
G A A T A C C C A A
380
G T C T C C T C C A
390
T C A T C G A G A A
400
G T G G T C G A T G
410
G A
A C G G T T A C
420
A G G C A C C T C C
430
A A A A C C T G A C
440
T C A G G T T T G C
450
T G G A T G G A T T
460
T A T G A C G A C T
470
G T G C C T T G C T
480
C T
Page: 2 / 3
22.06.2013
Sequence: ALPHA GLUK2_mGLUK2-FClipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
458
19
476
58.65
Samples:
Bases:
Average spacing:
12073
483
25.0
Average quality >= 10: 14, 20: 5, 30: 442
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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22.06.2013
Sequence: ALPHA GLUK2_mGLUK2-FClipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
458
19
476
58.65
Samples:
Bases:
Average spacing:
12073
483
25.0
Average quality >= 10: 14, 20: 5, 30: 442
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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22.06.2013
Sequence: ALPHA GLUK3_mGLUK3-RClipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
514
30
543
42.03
Samples:
Bases:
Average spacing:
13737
543
26.0
Average quality >= 10: 33, 20: 56, 30: 425
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
C A C T T T A T C T
10
A C C T A G G C T C
20
T G T C A G A C T T
30
G C G G AA C A T G
40
A C A A A A G G C T
50
C C T C C A G C A C
60
A G T G G T G A C G
70
A T G A G T G A C C
80
T A T T
G G T C A G
90
A G A G T C A G T G
100
A C A T T A G G A C
110
C T C G G C C T T T
120
G G C A A C C T C A
130
G T G A T A T T G A
140
G A C C G T C A G C
150
T G G A C T C C A T
160
A C T C C A A C
C T
170
T C T C G A G G C C
180
A T C T T C C T T C
190
A G G C T G A T G A
200
T G T C C A G A T C
210
A A A A T C A G T C
220
C G C A A G C C A C
230
T G G T T T T G T T
240
G A A C A C A A T C
250
C G
T C C A G T T A
260
A T C C T T C C C A
270
T T G A G C C T C C
280
T T G A T G A A G T
290
T C A T G A A G C G
300
G C C A C C A A A G
310
C G C C A G G C C T
320
T G T G C C G A T G
330
G C A C T G
C A G G
340
G A G T T C A C G G
350
T C A T C T G T G G
360
C G C T C G C T G G
370
T A G C A C A C A G
380
A C A C A A T G T G
390
G A C C G C G T C A
400
T A G A G C A G G G
410
C A G C A T C C G
T
420
C A T C A T C A C A
430
C C A T C C A G C A
440
G G C C T G A C T C
450
T G C C C G G G G A
460
G C T G C C T G C A
470
G T C G C T C C A T
480
G G C C C A C T T C
490
T C C A C A A T G G
500
C T
Page: 2 / 3
22.06.2013
Sequence: ALPHA GLUK3_mGLUK3-RClipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
514
30
543
42.03
Samples:
Bases:
Average spacing:
13737
543
26.0
Average quality >= 10: 33, 20: 56, 30: 425
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
G A G A C A T G
510
G G G A T T G T C C
520
A C G T T G A G T A
530
T G C G G A A C C A
540
A C
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Sequence: ALPHA GLUK3_mGLUK3-RClipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
514
30
543
42.03
Samples:
Bases:
Average spacing:
13737
543
26.0
Average quality >= 10: 33, 20: 56, 30: 425
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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13.07.2013
Sequence: alpha GluK 4 R_GluK-4-R Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
266
179
444
37.48
Samples:
Bases:
Average spacing:
15889
453
36.0
Average quality >= 10: 54, 20: 67, 30: 303
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
T C C T A C G T G G
10
C G A A T G T T A A
20
T T C T G A G C G C
30
T G G T G C C A T G
40
C T G C C A G A T C
50
T G G G C T G A G C
60
C A C A G G A C A G
70
G G G C T T C A C A
80
C C A A T C
T C T T
90
G G C T C C G G T T
100
C A G T T C C T G T
110
A C C G C T G T C A
120
C C A C A G C A T A
130
G A C A G C G T C A
140
A A C A G C A G G G
150
C T G A G G A C A A
160
C G C A G G G C C G
170
G T G A A G G G C A
180
C A T G G T C A C A
190
G T T C T C C T G C
200
C A G G A T T G G T
210
T G A G G C T C T G
220
G G A G A A C T C T
230
T G G A A G A A T G
240
C A T G G G A T T G
250
G T T
G A A A A T G
260
G A A A A T C C T A
270
A G A T G T T G A C
280
T C T A T C A T C C
290
A C A A G G C T G T
300
C C A T T C T C T G
310
G A G G G A G A A C
320
T C C A G A T T G G
330
T G A A G A T
G T A
340
T G T G T A A T A G
350
G C T G A C A C C A
360
T C C C C A G T T C
370
A G C T G C C T T C
380
A T G A G G A T G G
390
T G T G C G A C A T
400
G G A G G C G T T G
410
G C G T G G A T G A
420
T
G A T A G T A G C
430
T G T C T T G T C A
440
T C C C G G A T T T
450
T T
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Sequence: alpha GluK 4 R_GluK-4-R Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
266
179
444
37.48
Samples:
Bases:
Average spacing:
15889
453
36.0
Average quality >= 10: 54, 20: 67, 30: 303
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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13.07.2013
Sequence: alpha GluK 4 R_GluK-4-R Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
266
179
444
37.48
Samples:
Bases:
Average spacing:
15889
453
36.0
Average quality >= 10: 54, 20: 67, 30: 303
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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22.06.2013
Sequence: ALPHA GLUK5_mGLUK5-FClipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
488
13
500
48.41
Samples:
Bases:
Average spacing:
13938
500
28.0
Average quality >= 10: 13, 20: 22, 30: 450
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
A AA G T CC TC G
10
T A G C T T C G G A
20
G C T G G G A T G A
30
C C T C A G C G T T
40
T T A C A A G T A C
50
A T C C T C A C C A
60
C C A T G G A C T T
70
T C C C A T C C T G
80
C A T C T G G A T G
90
G T A T C G T G G A
100
G G A C T C C T C C
110
A A C A T C C T G G
120
G C T T T T C C A T
130
G T T C A A C A C C
140
T C C C A C C C C T
150
T C T A C C C A G A
160
G T T T
G T G C G C
170
A G C C T C A A C A
180
T G T C C T G G A G
190
G G A G A A C T G T
200
G A A G C C A G C A
210
C C T A T C C T G G
220
C C C T G C G C T G
230
T C C G C A G C C C
240
T G A T G T T
T G A
250
C G C T G T G C A C
260
G T G G T G G T A A
270
G C G C T G T C C G
280
A G A A C T G A A C
290
C G A A G C C A G G
300
A G A T T G G C G T
310
C A A G C C A C T G
320
G C C T G C A C T T
330
C
G G C C A A C A T
340
T T G G C C C C A T
350
G G G A C C A G C C
360
T T A T G A A C T A
370
C C T T C G A A T G
380
G T A G A G T A T G
390
A C G G G C T G A C
400
C G G G C G G G T T
410
G A G T
T C A A C A
420
G C A A A G G G C A
430
G A G G A C C A A C
440
T A C A C A C T A C
450
G C A T C C T G G A
460
G A A G T C C C G C
470
C A G G G C C A C C
480
G T G A G A T A G G
490
G G T G T G G
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Sequence: ALPHA GLUK5_mGLUK5-FClipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
488
13
500
48.41
Samples:
Bases:
Average spacing:
13938
500
28.0
Average quality >= 10: 13, 20: 22, 30: 450
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
T A
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22.06.2013
Sequence: ALPHA GLUK5_mGLUK5-FClipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
488
13
500
48.41
Samples:
Bases:
Average spacing:
13938
500
28.0
Average quality >= 10: 13, 20: 22, 30: 450
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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22.06.2013
Sequence: ALPHA NETO 1_NETO-1-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
179
13
191
51.9
Samples:
Bases:
Average spacing:
14835
479
31.0
Average quality >= 10: 212, 20: 39, 30: 158
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
G G G T G C A T G T
10
G AT A T C C T T A
20
T T A T C G T T T C
30
T G T C A T T G T A
40
C A G A T C A A A C
50
A G C C T C G T A A
60
A A A A T A C G T C
70
C A A A G G A A G T
80
C
A G A C T T T G A
90
C C A G A C C G T T
100
T T C C A G G A G G
110
T G T T T G A G C C
120
T C C C C A C T A T
130
G A G T T A T G T A
140
C G C T C A G A G G
150
A A C T G G A G C A
160
A C A G C
C G A C T
170
T T G C A G A T G T
180
G G C A G A A A C G
190
A T A A T A C G G C
200
T G C T G C C A T G
210
C C G G A T C C C G
220
C C G C T G T C A G
230
A C C C A A G C G C
240
G C T
C C T C C A C
250
C C T G C T G A T C
260
T A T T T C T T G T
270
C C T A T A T C C C
280
T A C G A C T C G G
290
G T C C T C T T C G
300
C T C T C G C T G T
310
G G A G C C T T A C
320
A T T A T C
T A T G
330
G T T T G A G G C C
340
C A G G G G G T G A
350
A G A G A T G T A A
360
A C A C T C G A A T
370
A C C C C C T C A T
380
C C T G C C T C C G
390
C T A G A A A T A T
400
T C G A T G G
T T C
410
C G G T A C T G G C
420
C C A T C C C A G A
430
C C T G A C T C T T
440
G C C C C T T G G A
450
C G A A A T A C G A
460
C G A C C G T A C G
470
T G C T A T G C
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Sequence: ALPHA NETO 1_NETO-1-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
179
13
191
51.9
Samples:
Bases:
Average spacing:
14835
479
31.0
Average quality >= 10: 212, 20: 39, 30: 158
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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22.06.2013
Sequence: ALPHA NETO 1_NETO-1-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
179
13
191
51.9
Samples:
Bases:
Average spacing:
14835
479
31.0
Average quality >= 10: 212, 20: 39, 30: 158
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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22.06.2013
Sequence: ALPHA NETO 2_NETO-2-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
185
11
195
53.98
Samples:
Bases:
Average spacing:
16280
494
33.0
Average quality >= 10: 228, 20: 30, 30: 163
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
G A GT C C A AA C
10
A T G A G T G T A T
20
C T A T A T T T T G
30
G A G C T G C T C C
40
T C G T C A A C G A
50
A T A G A G C T G A
60
C C T T T G A T G A
70
A C G C T A T T A T
80
A T A G A G C C A T
90
C A T T C G A A T G
100
T C G G T T T G A T
110
C A C T T G G A A A
120
T T C G A G A C G G
130
G C C A T T T G G T
140
T T T T C T C C T C
150
T T A T A G A T C G
160
T T A C
T G T G G C
170
G T G A A A A G C C
180
C T C C A T T A A C
190
A A G T C T G G A T
200
G G C G G C C T C G
210
C T G G G C G G G C
220
C C G C T T T T C T
230
C A A G G C G T T T
240
C A C A A
C C C T C
250
C T C C C C C C T C
260
C T G C T C C C T T
270
T C T T G T A T C T
280
C T T G C C T T C C
290
G C G A A G T A C C
300
A T C T C C C T G C
310
T C G G C A G C C T
320
T A C C T A A C C
T
330
C C G T A A T T A A
340
A T C C C T C A G G
350
G G A T G A A A T G
360
A T G C T T T G A T
370
T G C A A C C A G A
380
C C C G T A T G C T
390
A C C G T C C C T G
400
A G T A G A T
T C T
410
A T T C C T C C A C
420
C A T T C A C A G C
430
A C C T G A C T C A
440
A C T C C T T C C C
450
C T G C G T A A A C
460
A A A T C G A C A C
470
T G C T A T T T G C
480
T C C A A
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Sequence: ALPHA NETO 2_NETO-2-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
185
11
195
53.98
Samples:
Bases:
Average spacing:
16280
494
33.0
Average quality >= 10: 228, 20: 30, 30: 163
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
A A T A A
490
A G A
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22.06.2013
Sequence: ALPHA NETO 2_NETO-2-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
185
11
195
53.98
Samples:
Bases:
Average spacing:
16280
494
33.0
Average quality >= 10: 228, 20: 30, 30: 163
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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25.04.2013
Sequence: Rat Islet GluK1_RK1-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
422
9
430
57.22
Samples:
Bases:
Average spacing:
13340
663
21.0
Average quality >= 10: 170, 20: 26, 30: 398
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
G C T G A C T C A C
10
G T G G G C T G A C
20
A T G A C G G A T G
30
G C AA C A G A G A
40
C A G G T C C A A C
50
A A T A T C A C G G
60
A C T C G C T G G C
70
T A A C C G C A C A
80
C T C A T T G T C A
90
C C A C T A T T C T
100
G G A A G A G C C C
110
T A C G T G A T G T
120
A C A G G A A A T C
130
C G A T A A G C C C
140
T T G T A T G G A A
150
A C G A C A G G T T
160
T G A A
G G A T A T
170
T G C C T G G A T C
180
T G C T G A A A G A
190
A C T G T C C A A T
200
A T C C T G G G T T
210
T T C T T T A C G A
220
T G T T A A A C T G
230
G T T C C T G A T G
240
G C A A A T A
T G G
250
A G C A C A G A A T
260
G A C A A A G G G G
270
A A T G G A A T G G
280
G A T G G T A A A A
290
G A A C T C A T C G
300
A C C A C A G A G C
310
T G A C C T G G C A
320
G T G G C C C C T C
330
T C A C C A T C A C
340
A T A C G T A C G G
350
G A G A A A G T C A
360
T T G A C T T C T C
370
C A A G C C C T T C
380
A T G A C C C T G G
390
G C A T T A G C A T
400
C C T T T A C C G G
410
A A G C
C C A A T G
420
G A C A C A T T C T
430
T G C A T G T C T C
440
C A T G T C T C C C
450
G T A A T C C A A A
460
A G A T C A G A A G
470
T A C A A G C C C G
480
T G C C C C C C C C
490
A T
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25.04.2013
Sequence: Rat Islet GluK1_RK1-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
422
9
430
57.22
Samples:
Bases:
Average spacing:
13340
663
21.0
Average quality >= 10: 170, 20: 26, 30: 398
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
T C C T T G C T
500
G C C T G T T T T C
510
T T T T T C T C C T
520
T G A T C T A G T T
530
C T C T A G A T A T
540
C T G T G T A A A A
550
T T G G A C C T A T
560
T A A T A G A C T C
570
C T G T
G T A C A G
580
A A G C G C G T C G
590
T G G A T G T T T T
600
T C T T C C G T A C
610
T G T C G G C C T T
620
A T T C G C T A C C
630
G C T T A G C T C A
640
A T C C T C C T C T
650
T T
C T G A C A C C
660
A G
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25.04.2013
Sequence: Rat Islet GluK1_RK1-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
422
9
430
57.22
Samples:
Bases:
Average spacing:
13340
663
21.0
Average quality >= 10: 170, 20: 26, 30: 398
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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25.04.2013
Sequence: Rat Islet GluK2_RK2-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
503
18
520
57.0
Samples:
Bases:
Average spacing:
13516
910
15.0
Average quality >= 10: 276, 20: 76, 30: 474
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
G T A C GT A G TA
10
A T G A CA G G A T
20
T CA G G A T A C T
30
A A A T A C A G A G
40
A A T A C C C A A G
50
T C T C C T C C A T
60
C A T C G A A A A G
70
T G G T C T A T G G
80
A A C
G G T T A C A
90
G G C G C C T C C A
100
A A A C C T G A C T
110
C A G G T T T G C T
120
G G A T G G A T T T
130
A T G A C G A C T G
140
A T G C T G C T C T
150
G A T G T A T G A T
160
G C A G T G C A
C G
170
T T G T G T C T G T
180
G G C T G T C C A A
190
C A G T T T C C C C
200
A G A T G A C A G T
210
C A G C T C C T T G
220
C A A T G C A A T C
230
G A C A C A A A C C
240
C T G G C G C T T T
250
G
G G A C C C G C T
260
T C A T G A G T C T
270
A A T T A A A G A G
280
G C T C A C T G G G
290
A A G G T C T C A C
300
A G G C A G A A T A
310
A C A T T T A A C A
320
A A A C C A A T G G
330
A T T A C
G G A C A
340
G A T T T T G A T T
350
T G G A T G T G A T
360
C A G T C T C A A G
370
G A A G A A G G T C
380
T G G A G A A G A T
390
T G G A A C T T G G
400
G A T C C A G C C A
410
G T G G C C T G
A A
420
T A T G A C A G A A
430
A G T C A G A A A G
440
G A A A G C C A G C
450
A A A T A T C A C A
460
G A C T C A T T G T
470
C T A A T C G T T C
480
T T T G A T T G T T
490
A C C A C C A T T T
500
T G
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Sequence: Rat Islet GluK2_RK2-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
503
18
520
57.0
Samples:
Bases:
Average spacing:
13516
910
15.0
Average quality >= 10: 276, 20: 76, 30: 474
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
G A A G A A C C
510
G A C A G A A A T C
520
T T C C C C C A A T
530
G A A G T C A C T C
540
T G C T C T G T G T
550
C A T C C A T G T C
560
T T C T A C C C T C
570
G A G A C C T G T G
580
A G
T G G T T T G T
590
A A A G A A G A T T
600
T C A G C C C G C T
610
C T A C G C A G G T
620
G T G T A T A C C A
630
C T T C A C C C T C
640
C A T T C C C C T T
650
A A C C G T T G G T
660
C C G C
T G C C G G
670
C A T C T A T C T G
680
A C C A T G A C C C
690
C C T G A A C T G T
700
G G A A T C C C A C
710
C A C A G C T A C A
720
A C T G C C A C T T
730
C A C G C A T G A C
740
G A G A G C A
T C G
750
T C A A C A C C A C
760
T G T G G T C C C T
770
A C A G A A T G T T
780
T A A A A G G A T C
790
C A C C G A C A T C
800
C A C T T T G G A G
810
A A A A A A C G G A
820
A T T T T A T T
T C
830
A T T G C A A A A G
840
G T G G A G G A A T
850
T T T C T G T G T C
860
T C T T C A C T C G
870
C A C A G A C T G A
880
C C G A A T G C C A
890
A T C T T T A G G C
900
C A A G T G T
C T
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Sequence: Rat Islet GluK2_RK2-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
503
18
520
57.0
Samples:
Bases:
Average spacing:
13516
910
15.0
Average quality >= 10: 276, 20: 76, 30: 474
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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25.04.2013
Sequence: Rat Islet GluK3_RK3-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
455
12
466
57.0
Samples:
Bases:
Average spacing:
13428
704
20.0
Average quality >= 10: 173, 20: 29, 30: 443
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
A C T G A CA G G T
10
C C T CA T C G T C
20
A C C A C T C T G C
30
T G G A G G A G C C
40
T T T T G T C A T G
50
T T C C G C A A G T
60
C T G A T A G G A C
70
C C T T T A C G G C
80
A A T G A C C G G T
90
T C G A G G G C T A
100
C T G C A T C G A C
110
T T G C T C A A G G
120
A G C T G G C G C A
130
C A T C C T G G G C
140
T T C T C C T A C G
150
A G A T C C G G C T
160
G G T G
G A A G A C
170
G G C A A G T A C G
180
G G G C A C A G G A
190
C G A C A A G G G C
200
C A G T G G A A C G
210
G C A T G G T C A A
220
G G A A C T C A T T
230
G A C C A C A A A G
240
C A G A T C T G
G C
250
T G T G G C T C C C
260
C T G A C C A T C A
270
C C C A T G T C C G
280
A G A G A A G G C C
290
A T T G A C T T C T
300
C T A A G C C T T T
310
T A T G A C C C T C
320
G G A G T G A G C A
330
T C
T T A T A T C G
340
A A A A C C C A A T
350
G G C A C C A A C C
360
C C A G T G T C T T
370
C T C C T T C C T C
380
A A C C C C C T G T
390
C C C C A G A C A T
400
C T G G A T G T A C
410
G T G C T
A C T C G
420
C C T A C C T G G G
430
T G T C A G C T G T
440
G T C C T C T T C G
450
T C A T T G C C A G
460
T T T C A G C C C T
470
C A G T C G A T G T
480
G T A G C C C T C G
490
A A C C G G
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25.04.2013
Sequence: Rat Islet GluK3_RK3-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
455
12
466
57.0
Samples:
Bases:
Average spacing:
13428
704
20.0
Average quality >= 10: 173, 20: 29, 30: 443
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
T G T T
500
G C C G T A T A G G
510
G T C C T A C C A G
520
A C A T G T G G G A
530
C G C G A A A T A T
540
C T T T C T A T A A
550
T T G G A T T G T C
560
A G T A G T T C C G
570
T G T A T A
C A C A
580
T A C C T T T C C T
590
T G A T G A T T T G
600
C T T T G A T G T G
610
T A T T G T C A G G
620
G C A C C C T T A T
630
C T A T A A C A A T
640
C T G C C T C G G G
650
G A C T
C G A G A T
660
A A C A C T T C A C
670
C G C G G T A T T T
680
G T G C T C T A T T
690
T A T C A T A G T A
700
G T T
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25.04.2013
Sequence: Rat Islet GluK3_RK3-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
455
12
466
57.0
Samples:
Bases:
Average spacing:
13428
704
20.0
Average quality >= 10: 173, 20: 29, 30: 443
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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26.04.2013
Sequence: Rat Islet GluK4_RK4-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
287
22
308
45.25
Samples:
Bases:
Average spacing:
16304
360
46.0
Average quality >= 10: 49, 20: 44, 30: 236
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
G G A G C C C C C G
10
A T G A C A C A C C
20
A G G A C A T G G A
30
A G G C A A T G A C
40
C G G T A C G A G G
50
G A T T C T G C G T
60
G G A C A T G C T C
70
A A G G A G T T G G
80
C T
G A G A T C C T
90
A C G G T T C A A C
100
T A C A A G A T C C
110
G C C T C G T T G G
120
G G A T G G T G T T
130
T A C G G C G T A C
140
C T G A G G C C A A
150
C G G C A C C T G G
160
A C G G G C A
T G G
170
T T G G G G A G C T
180
G A T C G C T C G G
190
A A A G C A G A T C
200
T G G C T G T G G C
210
G G G C C T C A C C
220
A T C A C A G C T G
230
A A C G T G A G A A
240
A G T G A T T G A T
250
T T C T C C A A G C
260
C G T T C A T G A C
270
G C T G G G A A T T
280
A G T A T T C T T T
290
A C A G A G T T C A
300
T A T G G G C C G C
310
A T A C C G G G C T
320
A T T T C T C C T T
330
T C T
G G A C C C C
340
T T T T C T C C T G
350
G A G T C T G G T
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26.04.2013
Sequence: Rat Islet GluK4_RK4-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
287
22
308
45.25
Samples:
Bases:
Average spacing:
16304
360
46.0
Average quality >= 10: 49, 20: 44, 30: 236
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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26.04.2013
Sequence: Rat Islet GluK4_RK4-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
287
22
308
45.25
Samples:
Bases:
Average spacing:
16304
360
46.0
Average quality >= 10: 49, 20: 44, 30: 236
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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25.04.2013
Sequence: Rat Islet GluK5_RK5-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
399
12
410
56.03
Samples:
Bases:
Average spacing:
13713
515
27.0
Average quality >= 10: 87, 20: 12, 30: 374
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
T A G C C CA A A G
10
A T C T C C A C A T
20
C T T G G G C T T T
30
T C C A T G T T C A
40
A C A C C T C C C A
50
T C C C T T C T A C
60
C C G G A G T T T G
70
T G C G C A G C C
T
80
C A A C A T G T C C
90
T G G A G G G A G A
100
A C T G C G A A G C
110
C A G C A C C T A C
120
C C T G G C C C T G
130
C G C T G T C G G C
140
A G C C C T G A T G
150
T T T G A T G C C G
160
T G C
A T G T G G T
170
G G T A A G C G C T
180
G T C C G A G A G C
190
T G A A C C G G A G
200
C C A G G A G A T T
210
G G T G T C A A G C
220
C A C T G G C T T G
230
C A C T T C G G C C
240
A A C A T C T
G G C
250
C C C A T G G G A C
260
C A G C C T C A T G
270
A A C T A C C T G C
280
G C A T G G T A G A
290
G T A T G A C G G G
300
C T G A C T G G G C
310
G G G T T G A G T T
320
C A A C A G C A A A
330
G G G C A G A G G A
340
C C A A C T A C A C
350
A C T G C G C A T C
360
C T G G A G A A G T
370
C C C G C C A G G G
380
C C A C C G T G A G
390
A T A G G G G T G T
400
G G A C T T C A T T
410
T
C A T T C T A C T
420
G G A T T G C T T C
430
G G G T A T T T T G
440
T C C T A C T C C T
450
T T G C T T T T A A
460
A A T A T G G T T T
470
C A A T C C A C T C
480
C A T A A C T T C A
490
C C A T
Page: 2 / 3
25.04.2013
Sequence: Rat Islet GluK5_RK5-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
399
12
410
56.03
Samples:
Bases:
Average spacing:
13713
515
27.0
Average quality >= 10: 87, 20: 12, 30: 374
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
A G T T T C
500
A T T T T C G A A C
510
A G T T
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25.04.2013
Sequence: Rat Islet GluK5_RK5-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
399
12
410
56.03
Samples:
Bases:
Average spacing:
13713
515
27.0
Average quality >= 10: 87, 20: 12, 30: 374
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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25.01.2014
Sequence: RI Neto 1 A_Neto-1-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
172
20
191
38.43
Samples:
Bases:
Average spacing:
12348
191
65.0
Average quality >= 10: 17, 20: 32, 30: 124
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
T AC A T C G CA T
10
T G T G A T A T C C
20
T T A T T A T C G T
30
T T C T G T C A T T
40
G T A C A G A TG C
50
A A A C A G C C T C
60
G T A A A A A A T A
70
C G T C C A A A G G
80
A A G T
C A G A C T
90
T T G A C C A G A C
100
C G T T T T C C A G
110
G A G G T G T T T G
120
A G C C T C C T C A
130
C T A T G A G T T A
140
T G C A C G C T C A
150
G A G G A A C C G G
160
A G C A A C A G
C T
170
G A C T T T G C A G
180
A T G T G G C A G A
190
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25.01.2014
Sequence: RI Neto 1 A_Neto-1-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
172
20
191
38.43
Samples:
Bases:
Average spacing:
12348
191
65.0
Average quality >= 10: 17, 20: 32, 30: 124
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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25.01.2014
Sequence: RI Neto 1 A_Neto-1-F Clipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
172
20
191
38.43
Samples:
Bases:
Average spacing:
12348
191
65.0
Average quality >= 10: 17, 20: 32, 30: 124
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
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22.06.2013
Sequence: RAT ISLET NETO 2_NETO-2-FClipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
183
15
197
53.79
Samples:
Bases:
Average spacing:
15510
496
32.0
Average quality >= 10: 231, 20: 28, 30: 169
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
C T G G A C T G C A
10
A C A T G A G T G T
20
A T C T A T A T T T
30
T G G A A G C T G C
40
T C C T C G T C A A
50
C G G A T A G A G C
60
T G A C C T T T G A
70
T G A A C G A T A T
80
T
A T A T A G A G C
90
C A T C A T T T G A
100
A T G C C G G T T T
110
G A T C A C T T G G
120
A A G T T C G A G A
130
C G G G C C A T T T
140
G G C T T C T C T C
150
C T C T T A T A G A
160
T C G T T
A C T G T
170
G G C G T G A A A A
180
G C C C T C C A T T
190
A A G A A G A T G G
200
G G A C T G T A G C
210
C T T G T T C T G G
220
C C C T G G G C G T
230
T T T A A A G C C C
240
G C A T T A
G C T C
250
T C C T A C C C C C
260
G C C T C C A T A C
270
T T T C T T G T A T
280
A T A T T G C C T A
290
C T G C A G A C A A
300
C T A T G C T C T T
310
G C A G T G T A G C
320
C T T A C C T A T A
330
T
T C T G T A A T T
340
A T A T G A G C C A
350
A G G G C A A T G A
360
A C T A A G C C A C
370
A G A A T C G C C A
380
A G T T T C C T C C
390
C T T G C C G T C C
400
C T G G G T A T A T
410
G
A A A T T C T T A
420
A G G G C A C C C C
430
C A A A A T C T G A
440
C T C A A C T T C T
450
C C C C C T G G A T
460
T C G T G A C G T T
470
A G C A C T C C T T
480
T G T G C T T T A A
490
T
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22.06.2013
Sequence: RAT ISLET NETO 2_NETO-2-FClipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
183
15
197
53.79
Samples:
Bases:
Average spacing:
15510
496
32.0
Average quality >= 10: 231, 20: 28, 30: 169
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
T A A T
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22.06.2013
Sequence: RAT ISLET NETO 2_NETO-2-FClipped length:
Left clip:
Right clip:
Avg. qual. in clip.:
183
15
197
53.79
Samples:
Bases:
Average spacing:
15510
496
32.0
Average quality >= 10: 231, 20: 28, 30: 169
Clip. 1 BQ 20 WL 10 Quality: 0 - 9
10 - 19
20 - 29
>= 30
